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A b s t r a c t
Current pressures of cost and speed to market are driving the need for more effective 
means of assessing the value and risks of drug portfolios. This thesis presents 
research to generate a prototype computer-aided tool to predict the process and 
business outcomes for portfolios of biopharmaceutical drugs proceeding through the 
development pathway. The tool was built using a discrete-event simulation package, 
thus facilitating the dynamic nature of drug development decisions to be captured. 
The framework uses a hierarchical approach to incorporate the interactions between 
drug development activities, the available resources and databases of information. In 
addition to the business and process issues, the risks involved in the process of drug 
development have also been incorporated into the tool.
The application of the tool for assessing drug portfolios under uncertainty is 
demonstrated via case studies. In the first, the tool was used to perform sensitivity 
and scenario analysis on the portfolio net present value (NPV). Contour plots were 
generated that provide the ability to plan for a range of contingencies including 
uncertainties in manufacturing efficiencies, product demand and the market share 
captured. The second case study was used to assess the impact of different 
manufacturing strategies on the portfolio NPV under uncertainty. This example was 
based on a biopharmaceutical company considering whether to risk building a 
facility for the commercial manufacture of its antibodies and if so, when to start 
building, or whether to rely on a contract manufacturer throughout the development 
cycle and market manufacture. The effects of uncertainties were analysed using 
Monte Carlo simulation methods. The study highlighted the benefits of incorporating 
uncertainties when ranking different strategies. The third case study looked at the 
selection of drug candidates for a drug portfolio. The risk and reward of different 
portfolios were computed using Monte Carlo simulations. The ‘Efficient Frontier’ 
method was used to select an optimal portfolio.
The thesis illustrate the benefits of using such a tool to investigate the uncertainty 
and value of different development strategies and to assist in the process of decision­
making in the context of both business and process aspects.
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C h a p t e r  1 
Sc o p e  a n d  b a c k g r o u n d
1.1 In t r o d u c t io n
The rapid growth of the biotechnology industry as a provider of high technology, 
highly specific and effective new medicinal therapies has been profound. The ability 
to modify genetically living organisms to produce a range of medicines has 
contributed to a plethora of biopharmaceuticals being developed. The biotechnology 
industry as we know it today was borne with the founding of Genentech in 1976 and 
from that early and singular beginning, the number of companies focussing 
exclusively on biological products and processes has increased globally to more than 
5,500 today (Sager, 2001). In 2000, 28 major protein-based products generated $13.3 
billion of sales and in 2002 there were 99 protein-based therapeutics in Phase II and 
Phase III clinical development (Ginsberg et al., 2002).
The biopharmaceutical industry faces mounting competitive pressures of cost 
reduction whilst increasing speed to market (Pisano and Wheelwright, 1995). The 
process of bringing these products to the market is a costly and risky one. On average 
it takes 7.7 years to bring a pharmaceutical product to market (Foo et al., 2001) and 
costs over USS 800 million (DiMasi et al., 2003). This cost of research and 
development (R&D) for new drugs has been on the rise for the past two decades 
(DiMasi et al., 2003; Halliday, 1996). Speed to market and pressure to reduce costs 
are critical factors driving the need for more effective means of assessing the value 
and risks of such drug portfolios.
In order to aid decision-making, the management that is in charge of designing and 
implementing development plans has to be able to compute the reward and risk of 
different options and routes of drug development. By reference various methods are 
used by the pharmaceutical industry for product portfolio management. Popular 
financial models used by companies include net present value, decision trees, option
17
SCOPE AND BACKGROUND
models and computer simulations (Soegaard, 2003). To address the question of 
managing biopharmaceutical drug development more effectively, a closer integration 
of the drug development activities and business process modelling is vital. The 
application of computer-aided design tools can help to achieve the objectives of 
accelerated drug development, reduce costs and ensure minimum investment loss due 
to drug candidate failure during the drug development process. This thesis 
investigates the possibility of developing a prototype software tool that accomplishes 
this integration and then explores the utility of such a tool in decision-support.
The purpose of this chapter is to review the management of the drug development 
process and the new product portfolio management of biopharmaceuticals. This 
introductory material provides an overview of biopharmaceutical drug development 
and reports on the current status of drug portfolio management. Section 1.2 provides 
a brief introduction into the key drivers and pressures in biopharmaceutical drug 
development. Section 1.3 introduces the portfolio management process deployed 
within the industry to manage drug portfolios and assist in decision-making 
regarding drug development activities. The methods used in executing portfolio 
management are discussed in Section 1.4. The process and challenges of modelling 
drug development are presented in Section 1.5. Methods of performing risk analysis 
are discussed in Section 1.6. Finally the aims and organisation of the thesis are 
presented.
1.2 B io p h a r m a c e u t ic a l  d r u g  d e v e l o p m e n t
A comprehensive description of the biopharmaceutical drug development process is 
presented in Chapter 2 of this thesis. The objective of this section is to provide a brief 
overview of the lengthy and costly process of drug development in order to 
emphasise the importance of decision-making and portfolio management during the 
drug development process. The world market for protein drugs was estimated at 
US$ 41 billion at the end of 2002 (Ernst and Young, 2003). By 2010 the worldwide 
biopharmaceutical market is expected to capture 50% of the pharmaceutical market 
(Savage, 2000). At the end of 2002 there were 130 such products (therapeutic as 
well as diagnostic) in the market and over 350 at different stages in clinical 
development (Burrill and Company, 2004a).
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This very positive image has to be considered against the harsh commercial realities. 
Over the past three decades, pressures from international markets and tough 
government policies have created difficult business conditions for the pharmaceutical 
industry (Gatica, 2003; Partington, 2000). Traditionally, the drug development 
process has been a lengthy and expensive series of non-clinical and clinical 
evaluations followed by regulatory reviews (Clemento, 1999). Every drug in a 
pharmaceutical product portfolio undergoes a well-defined development process 
(Figure 2.1). During this process of development, candidates fail due to safety, 
efficacy or commercial reasons. For every approved drug, roughly 10,000 molecules 
have started development and have been abandoned along the way (Carr, 1998).
The financial value of pharmaceutical drug developmental projects is difficult to 
assess because they are subject to considerable uncertainty (Rogers et al., 2002). This 
uncertainty lies in both the technical and market aspects of the project. The technical 
uncertainty refers to the aforesaid toxicity, efficacy, dosage and the manufacturing 
process. Market uncertainty concerns the volatility of the market as forecasted during 
the early research and development stages. Quelin (2000) provides a description of 
the technical and market uncertainties in the area of new product development in 
general. Tiggeman et al. (1998) provides a further breakdown of the uncertainty in 
product development in the pharmaceutical industry into four categories, which are 
interrelated. These are customer, technological, competitive and resource 
uncertainty.
The management of pharmaceutical research and development has become 
increasingly difficult in recent years and the need for more effective strategies and 
management practices has become greater (Halliday, 1996). Pharmaceutical 
companies are constantly faced with the question of how best to use the limited 
resources available to obtain the highest possible profit and the decisions involved 
are usually taken in the presence of significant uncertainty (Levis and Papageorgiou, 
2004). Late investment decisions could cause the pharmaceutical company a 
significant loss of revenue due to loss of patent time. Therefore the luxury of waiting 
for research and development work to be completed in order to make well-informed 
decisions is not afforded to the pharmaceutical companies.
19
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The typical decisions that a pharmaceutical company has to make during the process 
of the lengthy uncertain drug development process are:
• Which drug candidates are to be developed and which ones are to be dropped 
from the portfolio or be held back for future development
• Which candidates receive prioritisation in resource allocation
• How should resources be allocated for development work
• What manufacturing strategy should be employed in order to have material 
ready for clinical trials and consequently for the market.
The rewards and risks of drug development have to be quantified in order to make 
the best decisions. Investment into R&D activities alone does not guarantee success, 
as shown by the high failure rate of products and services that do not make it through 
to commercialisation. A robust process for decision-making should exist within an 
organisation in order to make strategically the best decisions that will add value to 
the product portfolio and help to contain the risk. However, most organisations view 
decision-making as an event and not a process (Sharpe and Keelin, 1998). R&D 
portfolio management should be an integral part of corporate culture and business 
processes of pharmaceutical companies (Tiggeman et al., 1998). The next section 
describes the process of portfolio management deployed in order for proper decision­
making in the pharmaceutical industry to be achieved.
1.3 P o r t f o l io  m a n a g e m e n t
High quality decisions about long-term business strategy often require the explicit 
analysis of uncertainty. Portfolio management is an established business process that 
is linked with other business processes including strategic planning and budgeting. 
Through portfolio management, decision-making and resource allocation are 
measurably improved. Keelin and Shew (2003) state that portfolio management is 
justified by a one-hundredfold return on investment.
Research and development (R&D) management, by its very nature, is characterised 
by uncertainty since effective R&D requires a complex interaction of variables 
(Doctor et al., 2001). It is important to balance strategic management (allocate 
resources and do the right R&D) with operational management (execution of 
projects) and at the same time take into account issues of people management
20
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(leadership, motivation, organisation and teamwork) (Menke, 1994). Portfolio 
management has progressed through three generations in the biopharmaceutical 
industry, ranging from early management science tools in the 1980s, through 
resources allocation techniques in the early 1990s, to the high-powered, value-adding 
business processes that some companies are using currently (Keelin and Shew, 
2003). The authors describe the evolution of portfolio management in the 
biopharmaceutical industry (Table 1.1).
An exploratory investigation into portfolio management practices found that one 
main goal of R&D portfolios is to achieve the right balance and mix of projects 
(Cooper et al., 1997). By diversifying the therapeutic areas, disease states and 
discovery platforms in research and development, a company can reduce its risk 
(Tiggemann et al., 1998).
As a vital part of portfolio management, companies identify potentially profit- 
making products on an ongoing basis seeking to maximise return on investment 
(Soegard, 2003). Tiggemann et al. (1998) identify four key areas, safety, efficacy, 
patient convenience and economics, in which some advantage must be found in order 
to justify a new strategy. Sharpe and Keelin (1998) describe how SmithKline 
Beecham increased the value of its portfolio by 30% through a new decision-making 
process without increasing its spending on R&D. This outlines the contribution of a 
proper decision-making strategy to increasing a company’s value both in the long 
and short term.
Loch (2000) details a study into whether general best practices in decision-making in 
new product development can be applied to a specific company and concludes that 
there is no such best practice and each company should develop a unique new 
product portfolio management strategy. Portfolio management applies to all areas of 
drug development. During the drug discovery stages the targets and mechanisms that 
are to be pursued have to be decided in line with the company’s strategy. In the 
clinical development stages one of the key issues would be to decide the 
prioritisation of products for allocating limited levels of resources. Manufacturing 
capacities and sales strategies have to be decided and applied at the front end of the 
drug development pathway.
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Table 1.1 Comparison of three generations of portfolio management (Keelin and 
Shew, 2003)
First generation Second generation Third generation
Solve problems 
Minimise cost
Purpose
Perspective
Impact on 
decision-making
Value added 
Role of staff
Line
management 
engagement 
Business process
Era (for most)
Learn
Experiment
None
None
Isolated
Not visible to line 
management
None
1980s through 
mid-1990s
Very little for most 
companies
Rarely measurable 
Mixed perceptions
Provide useful inputs
Not totally involved
Established, feeds 
budgeting
Mid-1990s to 
present
Create new value 
Maximise return on 
investment 
Significant, 
identifiable 
directional changes 
Real, measurable 
Sustained 
advantage 
Lead decision­
making process 
Fully engage key 
players
All key players 
committed
Well interlinked 
with business and 
TA strategies, 
budgeting 
Now emerging
High quality valuation methods have to be applied to capture the risks and rewards 
implicit in applying different options in R&D projects. By being able to compute and 
then compare the array of possible outcomes and key sources of uncertainty, 
management is provided with a key tool to manage and balance the portfolio. 
Effective portfolio analysis can identify the optimal portfolio in terms of value 
creation for any given set of constraints. Soegaard (2003) in outlining the challenges 
faced in drug portfolio management points out that integrating information from 
marketing and R&D is a major challenge facing the task of portfolio management.
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The author further states that the integral challenge of comparing projects at different 
development stages and difficulties of quantifying uncertainties in development are 
likely to remain major challenges in the near future. One of the most acute challenges 
inherent in decision analysis is the actual measurement of uncertainty in historical 
data (Soegard, 2003). For example Senn (1998) in describing the statistical issues in 
project prioritisation cites the task of predicting project failure rates as one of the 
biggest practical problems faced in applying decision analysis. Research into failure 
rates of pharmaceuticals is reviewed in Section 2.4.3. The models chosen for 
application in decision analysis influence both the final outcome as well as a 
company’s perception of the options and uncertainties that confront them (Soegaard, 
2003).
1.4 M e t h o d s  u se d  f o r  p o r t f o l io  m a n a g e m e n t
Strategic project management is a complex, value-creating process to assure long­
term corporate success, and hence there is a need for techniques to act as value 
creation facilitators (Asrilhant et al., 2004). Traditional portfolio evaluation models 
often rely on qualitative and semi-quantitative tools. New quantitative methods have 
been developed that compute directly how much value decisions add to an R&D 
portfolio (Keelin and Shew, 2003).
Strategic decision-making and portfolio management is applied right through many 
industries. This is reflected in the literature. Gittins (1996) reviews the quantitative 
methods in the planning of pharmaceutical research. Asrilhant et al. (2003) describes 
the best practices in decision-making in strategic project management, as applied to 
the upstream oil and gas sector. Raz et al. (2002) presents the results of an empirical 
study into risk management tools and techniques across many industries. The authors 
focus on the relationship between the project types and the application of risk 
management practices.
The methods used in portfolio management are a combination of mathematical, 
managerial and financial approaches. Over two hundred qualitative and quantitative 
models exist in the literature for R&D project selection; including financial models, 
checklist models, decision theory models, consensus models and portfolio models 
(Coffin and Taylor, 1996). A wide range of literature exists in decision-making in
23
SCOPE AND BACKGROUND
new product development. Doctor et al. (2001) provides a review of the financial 
methods used in the industry for managing uncertainty in research and development. 
Chien (2002) provides an extensive literature review of some of the early methods 
used in portfolio selection. The author divides the portfolio attributes into 
independent and interrelated categories. Independent portfolio attributes are those to 
which the contribution of each project is independent of the other projects. 
Interrelated portfolio attributes are those to which the contributions of the projects 
are interrelated. Kengpol and Brien (2001) describe the development of a decision 
support tool to assess the value of investing in Time Compression Technologies 
(TCTs) to achieve rapid product development. Time compression technology refers 
to any technology that can improve a design and manufacturing process to achieve 
better quality in a shorter period, such as rapid prototyping. The authors propose a 
decision support tool that integrates a cost/benefit analysis model, a decision-making 
effectiveness model and a common criteria model in order to select the most 
appropriate time compression technology for an organisation.
Next the different methods applied in portfolio management are reviewed. Most of 
these methods use the net present value (NPV) as the main indicator of profitability. 
The methods comprise of quantitative as well as qualitative approaches.
1.4.1 Checklists, scorecards and indices
The simplest and most widely used project selection techniques are check lists and 
project profiles which are sometimes extended by scoring systems to provide overall 
scores, giving a ranking between projects (Gittins, 1996; Tiggemann et al., 1998). 
These qualitative scoring systems are used to provide an overall score, which is then 
used to rank projects. Senn (1998) reviews the various aspects of portfolio 
management within the pharmaceutical industry and describes the use of a risk- 
reward grid for comparing different projects. Profitability indices, for example, by 
dividing expected revenue by expected cost, in principle are not the right criteria 
(Tiggemann et al., 1998). This is because the profitability indices have the property 
that a portfolio, which is made up of projects with larger indices than those of the 
possible projects that have been rejected, produces the highest possible income for a 
given expenditure expressed in terms of total expected cost (Gittins, 1996).
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1.4.2 Balanced scorecard
Introduced by Kaplan and Norton (1992) the Balanced Scorecard is an organizational 
framework for implementing and managing strategy at all levels of an enterprise by 
linking objectives, initiatives, and measures to an organization’s strategy. The 
scorecard provides an enterprise view of an organization’s overall performance. It 
integrates financial measures with other key performance indicators around customer 
perspectives, internal business processes, and organizational growth, learning, and 
innovation. Bremser and Barsky (2004) conclude that the balance scorecard method 
provides a basis for linking financial and non-fmancial performance measure for 
managing R&D activity. The authors discuss the usefulness of the balance scorecard 
method for seven performance measures and conclude that the balanced scorecard 
method could be used effectively by professionals in all functional areas.
1.4.3 Decision trees
Decision trees are mentioned in the literature to help understanding the project path, 
the probabilities of success, developing project gates and facilitating the calculation 
of revised probabilities of success as the project progresses (Doctor et al., 2001). One 
of the main disadvantages of decision trees is the inability to capture processes that 
are occurring in parallel in a meaningful way. Sharpe and Keelin (1998) used 
decision trees to address the resource allocation issues at SmithKline Beecham by 
proposing to seek alternatives to current projects. The alternatives included scaling 
up as well as scaling down the current status of the project. The authors claim that by 
explicitly modelling the alternatives and involving all the staff in the decision­
making process the company managed to increase the value of the portfolio by 30%.
1.4.4 Reviews
Organisational ability and capability has been cited as a key area for improving the 
management and planning of R&D activities. Islei et al. (1991) presents a detailed 
application of R&D portfolio modelling in the pharmaceutical industry through a 
judgmental model that allows detailed performance appraisal of project managers. 
Lilly and Porter (2003) presents research examining how organisations can use 
improvement reviews to enhance learning from product development experiences. 
The authors conclude that through reviews people-related problems could be reduced 
and it provides an insight into improving the best practices in product development.
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Thamhain (2003) reviews the management of innovative R&D teams and attempts to 
provide an insight into the type of organisational environment and managerial 
leadership that is conductive to innovative R&D team performance.
Gerson et al. (1998) describes a management tool developed by Wyeth-Lederle 
Vaccines and Pediatrics to increase the success rate of transfer of new biological 
processes from research and development to manufacture. The tool was designed to 
streamline the technology transfer through better communication and documentation. 
The outlined decision-support system provides the basis for monitoring the 
progression of the projects. Each aspect of the business process beginning with the 
discovery of a new drug to the launch of the new product is dissected into a 
hierarchical sequence of business unit operations and each of them analysed 
separately. The combined set of analyses provides, in effect, a dynamic model of the 
business showing the sequence of events and the rates and routes of flow of materials 
and information.
1.4.5 Financial methods
Markowitz (1952, 1991) proposed the portfolio theory, which was mostly aimed at 
the financial portfolio of stocks and securities. This method is explained further in 
detail in Chapter 6.
Osawa and Murakami (2002) proposed a new methodology of evaluating industrial 
R&D projects to assess the effectiveness of future R&D in terms of financial 
credibility, to prioritise them efficiently by clear criteria to reduce the time and 
burden consumed by both project leaders and management staff. Three quantitative 
criteria, sales, profit and R&D efficiency are used along with three qualitative 
criteria, strategic importance, technological effect and probability of realisation. The 
authors demonstrated the method through a case study in the electronics industry.
1.4.6 Optimisation methods for scheduling R&D
Many mathematical methods for new product selection and resource allocation can 
be found in the chemical engineering literature. However these usually result in 
complex mathematical methods where a high level of knowledge is required for 
application. Such methods have been applied mostly to chemical entities and agro­
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chemicals. By contrast little attention has been paid to biopharmaceuticals. Shah 
(2004) discussed the key issues and strategies for optimising the pharmaceutical 
supply chain as a whole. The author describes the life cycle of pharmaceutical and 
outlines the different decisions that have to be made at each stage. This is followed 
by an extensive review of the literature of recent work carried out in this area of 
optimisation.
A numerical method, where multiple criteria were used for R&D project selection 
was presented by Coffin and Taylor (1996). Schmidt (1996) presented a stochastic 
optimisation model to improve production planning and R&D resource allocation in 
biopharmaceutical production processes. The proposed model was a Markov 
decision process model that combined the features of engineering design models and 
aggregate production planning models to obtain a hybrid model that links biological 
and engineering parameters to optimise operations performance.
The task of scheduling R&D tests and the manufacturing process through the 
scheduling of batch processes are also covered within this field. Schmidt and 
Grossman (1996) addressed the problem of optimising the schedule of testing tasks 
without resource constraints or task success uncertainty in the process of new 
product development. This was limited to a single project. The problem was 
formulated as a mixed integer linear program (MILP) problem and allowed up to 19 
tasks to be scheduled and when solved maximised the net present value (NPV) of the 
project. The authors stated that each optimised project would add up to an optimised 
portfolio. It was suggested that a two level hierarchical approach be made to project 
selection. At the top level resources are allocated to different projects and then on the 
next level the testing tasks are scheduled to stay within the allocated resources.
Honkomp (1998) addressed both project selection and project scheduling with task 
success uncertainty to estimate a throughput of the R&D pipeline capacity. Here a 
mixed integer linear programming model based on discrete time representation was 
developed and a fixed sequence of tasks was addressed. However it could not handle 
a continuous time domain.
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Jain and Grossman (1999) addressed the problem of scheduling the testing tasks for a 
fixed and predetermined portfolio of projects with resource constraints and task 
uncertainty. Two MILP models that perform the sequencing and scheduling of 
testing tasks for new product development under resource constraint were presented 
in this paper. The option for out sourcing at a higher cost was included in the model 
for the first time. All three of the approaches above use deterministic mathematical 
approaches. Blau et al. (2000) presented a simulation network model for risk 
management in the new product development process. Technical success factors and 
the degree of difficulty to accommodate the resource constraint were used to plot a 
graph of mean reward/risk ratio versus the probability of success to compare 
different candidates. The simulation model presented was designed to carry out tasks 
as fast as possible and provide the management an insight into the new product 
development portfolio, for example to show where resource constraints occur.
Subramanian et al. (2000) developed a computational architecture ‘simulation- 
optimisation’ to address uncertainty issues by combining discrete event stochastic 
simulation and deterministic optimisation. The R&D pipeline management problem 
was viewed as the control problem of a performance-oriented resource constrained, 
stochastic, discrete event, and dynamic system. The model has two modules. The 
simulation module simulates and the optimiser module solves mathematical 
problems and makes decisions. Initially a portfolio is built by solving a resource over 
booked optimisation program similar to that of Honkomp (1998). Then three types of 
regulatory and supervisory control are used to solve the initially prepared portfolio.
The focus of the above literature, however, is the new product development process, 
and not the design and planning of manufacturing facilities. Decisions regarding 
manufacturing of material are of importance as it will affect the time to market and 
the market share captured by the new drug. In most of the literature it is assumed, for 
instance, that there are no capacity limitations, or that the production levels of other 
products do not affect the production level of a new product. Rotstein et al. (1999) 
considered the problem where the manufacturing capacities for three products that 
are in clinical trials are to be determined. The authors used a scenario tree to capture 
the outcomes of the clinical trials.
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Papageorgiou et al. (2001) describe an optimisation-based approach to selecting both 
a capacity planning and investment strategy in the pharmaceutical industry. The 
problem is formulated as a MILP model, takes into consideration the scale-up, 
qualification and product lifetime in getting to the market, and includes a campaign 
planning strategy with a portfolio or products that are at different stages of 
development. As the resulting model size is prohibitively large, the authors suggest 
that alternative solution approaches are investigated. However even this model does 
not take into consideration the task of performing clinical trials in biopharmaceutical 
development and is a deterministic model only.
Grossman and Maravelias (2003) proposed a MILP model that addresses three 
issues: the handling of resource allocation as a decision variable; handling of cost 
and duration of tests as functions of the type, and, the amount of resources assigned 
to each test and the installation of new resources during the course of testing. The 
authors state that allocating more resources to some testing can reduce time and 
allows more flexible schedules to be constructed. This model is closer to the real 
world more than the previous ones
Grossman and Maravelias (2001) studied the simultaneous optimization of resource- 
constrained scheduling of testing tasks in new product development, and 
design/planning of batch manufacturing facilities. Their model is a large scale MILP 
that predicts from a portfolio of new products, which products should be tested, the 
detailed testing schedule, design decisions for the process network and production 
profiles of new and existing products. It is assumed that the costs, durations and 
chances of success are known for each test. Indeed this assumption is made for all 
the methods reviewed so far. Further, in all of the above literature little or no 
attention is paid to the market uncertainty with more emphasis being placed on 
technical uncertainty. The financial metric used as a measure of profitability in all 
the above methods is the net present value (NPV).
Gatica et al. (2003) presented a mixed integer linear programming method for 
capacity planning under uncertainty for the pharmaceutical industry in which the 
optimisation based approach selects the final product portfolio and the production 
planning and investment strategy simultaneously subject to the uncertainty of the
29
SCOPE AND BACKGROUND
outcomes of the clinical trials for each potential drug. Levis and Papageorgiou (2004) 
outlined a mathematical approach programming approach for long-term, multi-site 
capacity planning under uncertainty in the pharmaceutical industry. Here the 
approach used was to select the optimum portfolio from a given set of candidates and 
planning of the manufacturing schedules under constraints.
Maravelias and Grossman (2004) proposed a mixed integer linear programming 
model for scheduling of tests for pharmaceuticals and agrochemicals. The model 
takes into account the uncertainty of the resources available and the demand on the 
resources by the tests.
1.4.7 Real options method
Rogers et al. (2002) presented a novel method where a stochastic optimisation model 
(OptFolio) of pharmaceutical research and development portfolio management using 
a real options valuation instead of the NPV approach as the financial indicator for 
making optimal project selection decisions. This paper takes into consideration the 
market uncertainties brought about by the fluctuations in demand and competition. 
This is an analogue of the Black-Scholes (1973) options pricing method and was first 
suggested by Myers (1984) when he classified research and development investment 
opportunities as real options best captured with the options analysis.
The stochastic framework suggested by Rogers et al. (2002) provides a road map for 
future decisions by making decisions of abandonment over time and calculating the 
minimum market value above which the development is continued under changing 
resource constraints. In a following paper Rogers et al. (2003) applied a Monte Carlo 
simulation procedure to the OptFolio model. This framework provided a sensitivity 
analysis of candidate drug valuations and a risk management analysis for balancing 
risk versus reward tradeoffs. The next section of the chapter provides a review of the 
modelling and simulation of biopharmaceutical drug development activities.
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1.5 M o d e l l in g  a n d  s im u l a t in g  b io p h a r m c e u t ic a l  d r u g  d e v e l o p m e n t
1.5.1 C h a l l e n g e s  o f  m o d e l l in g  t h e  d r u g  d e v e l o p m e n t  p r o c e s s
Simulation technology is used to understand complex systems and products prior to 
these ideas being prototyped, scaled up and put into full production (Johnson, 1998). 
Usefulness of models has been demonstrated in describing, designing and analysing 
systems (Banks, 1998).When modelling biopharmaceutical drug development the 
challenge is to model effectively the many different activities involved in taking a 
drug through the phases of drug development, which increase in complexity and 
duration as the drug approaches market launch. The company-and drug-specific 
business and process characteristics all have to be captured successfully and the 
resulting model should be able to evaluate operational and financial metrics such as 
the time-to-market, cost, revenue and the risk, which all feature in the decision­
making process in drug development. The business process models have to be 
combined successfully with the models of the drug development activities. The 
pharmaceutical industry is far behind other industries in examining the usefulness of 
simulation technology for its R&D process (Johnson, 1998).
Bank (1998) points out that modelling a complex, large-scale system is usually more 
difficult than modelling a strictly physical system for one or more of the following 
reasons:
1. Few fundamental laws are available
2. Many procedural elements are involved which are difficult to describe and 
represent
3. Policy inputs are required which are hard to quantify
4. Random components are significant elements
5. Human decision-making is an integral part of such systems.
A model of the drug development process could be described as a discrete, dynamic 
and stochastic one. Discrete event simulation concerns the modelling of a system as 
it evolves over time by a representation in which the state variables change 
instantaneously at separate points in time (Law and Kelton, 1991). The system state 
is updated at each event, along with capturing and freeing of resources that may 
occur at that time. Given the high level of uncertainty inherent in the drug 
development process, point estimations made for simulations would not be useful in
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decision-making. Therefore suitable distributions have to be assigned for the inputs 
in any model of the drug development process. Industrial collaboration would be 
required in the process of modelling the drug development activities, as realistic 
inputs in the form of assumptions and distributions would have to come from 
industrial experts.
Modelling has been applied in the field of bio processing in many ways. The 
mathematical modelling carried out for portfolio management in the pharmaceutical 
industry was discussed in Section 1.4. Luehrman (1994) describes a model 
configured to assess the risks and returns of new projects in the pharmaceutical 
industry using an options analysis approach with Monte Carlo simulations. Myers 
and Howe (1997) presented a life cycle financial model of pharmaceutical R&D. The 
authors present the estimates of the cost of capital based on analysis of the risk 
characteristics of pharmaceuticals and biotech stocks. Their approach was to 
investigate the different financial characteristics of the drug development process 
such as cost of capital and financial ratios of pharmaceutical companies.
Karri et al. (2001) presented a hierarchical framework to assist decision-making in 
the biopharmaceutical industry which considered the effect of planning of process 
development and allocation of resources to the overall value of the project. 
Stonebraker (2002) presented a model of a single project aimed at evaluating its 
commercial worthiness. This model took the different tasks of drug development into 
consideration. These included process development, manufacture, clinical trials and 
marketing, but the model was limited to the assessment of a single project. The 
power of modelling and simulation is not just in simulating potential outcomes, but 
also in allowing one to examine the impacts of the assumptions that inherently exist 
in the clinical development stage.
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MODEL
CONCEPTUALISATION
PROBLEM
FORMULATION
DATA COLLECTION
DOCUMENTATION & 
REPORTING
MODEL TRANSLATION 
INTO SOFTWARE
SIMULATION RUNS & 
ANALYSIS
DECISION-MAKING
DESIGN OF SIMULATION 
SCENARIOS
VERIFICATION & 
VALIDATION
Figure 1.1 Steps in a simulation study (adapted from Banks, 1998).
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Process modelling has traditionally been carried out for manufacturing operations, 
attempting to characterise mathematically the performance of unit operations in a 
manufacturing process. Coates and Kuhl (2003) describes the use of simulation 
software to solve engineering economy problems using three different examples. 
Gritsis and Titchener-Hooker (1989) demonstrated the use of SPEEDUP to model a 
train of three downstream unit operations, namely ultra filtration, precipitation and 
centrifugation so as to determine the minimum processing time. Petrides (1994) 
published a report that described the architecture and the important features of 
BioPro Designer, a bioprocess tool.
Zhou et al. (1997) illustrated the use of simulations in exploring the nature of and the 
impact of interactions that exist in a typical bioprocess for the recovery of an 
intracellular protein. Rouf et al. (2001a) demonstrated the use of two bioprocess
T X 4  t \ i
simulators, Aspen BPS and SuperPro Designer , to simulate and compare the 
economics of using serum and serum-free medium for the production of tissue 
plasminogen activator (t-PA) from Chinese hamster ovary cells. Rouf et al. (2001b) 
reported a case study of using Bioprocess Simulator (Aspen Technology Inc., 
Cambridge, Massachusetts, USA) to study the economics of fed-batch operation. 
Bioprocess modelling has been used to explore different process routes from both a 
process and a business perspective with much success (Farid et al., 2001; Mustafa et 
al, 2004; Lim et al., 2004). Shanklin et al. (2001) evaluates two commercially 
available software packages (Aspen Batch Plus vl.2, Aspen Technology, Inc., 
Cambridge, Massachusetts and Intelligent SuperPro v3.0, INTELLIGEN, INC., 
Scotch Plains, New Jersey) for modelling industrial biotechnology processes. Novais 
et al. (2001) presented a costing model used for economic comparison between 
conventional and disposable-based technology for the production of 
biopharmaceuticals.
Thomas (2003) discussed a design approach to biotech process simulations, with step 
by step descriptions and the challenges of such simulation projects. Most importantly 
the author emphasises that no specialist knowledge is needed for the development of 
simulations of bioprocesses and can be carried out by anyone who is computer 
literate. Baker and Wheelwright (2004) describe a financially based model of 
recovery process alternatives in biopharmaceutical manufacturing with a case study.
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The authors conclude that having an empirical model to assess the financial impact 
of process improvement alternatives provides a clear basis for comparison and hence 
aid decision-making.
1.6 R is k  a n a l y s is
Risk is defined as the adverse consequences of exposure to uncertainty (Blau et al.,
2000). The trade-off between risk and reward has been the basis of virtually every 
investment decision (Stambaugh, 1996). Decisions made during the drug 
development process are made in an uncertain environment characterised by 
technical and market-related risks. For example, common uncertainties in drug 
development include costs, development lengths, the efficacy and toxicity of the drug 
as well as patient population and drug price (Stonebraker, 2002).
Various approaches for identifying and measuring the uncertainty associated with a 
project appraisal have been advocated in the literature. The simplest method is to 
conduct a sensitivity analysis of each of the principle variables; the impact of ± x% 
changes in each variable on the key output measures is observed. This provides a 
result for a given change, but it does not consider the likelihood of this change 
occurring (Farid, 2001).
High-risk environments often require the need to understand better the possible range 
of outcomes and simulation modelling is an attempt to understand the range of 
possible outcomes from a given situation (Doctor et al., 2001). In Monte Carlo 
simulations, probability distributions are used as inputs in order to determine the 
probability distributions for the outputs. Through this method values will be found 
most frequently near the most likely outcome and less frequently for values further 
removed from that value. As a result, Monte Carlo simulation analysis has become 
established as a financial tool to help in risk analysis, particularly in investment 
decision-making (Doctor et al., 2001). The use of Monte Carlo simulation is 
highlighted in the literature (Blau et al., 2000; Brastow and Rice, 2003; Farid et al.,
2001). In addition commercial software packages for Monte Carlo simulation have 
been introduced that are relatively easy to use and inexpensive; examples include the 
spreadsheet add-ons @RISK (Palisade Corporation, Newfield, NY, USA) and 
Crystal Ball (Decisioneering, London, UK). Determining the probability distributions
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of the key uncertain inputs is usually based on historical data or subjective estimates 
from industrial experts.
1 .7  AIM S AND ORGANISATION OF THESIS
The preceding sections have provided a description of the uncertainty within the drug 
development process. The decision-making processes currently being applied in 
managing new product development has been reviewed. The current position of 
process and business simulation within the biopharmaceutical industry has also been 
highlighted. The literature survey highlights that at present no package allows both 
modelling the drug development process and effective decision-support that relates 
management decisions to the following strategic business issues: resource 
management, costing and risk.
The aim of this thesis is to investigate the possibility of capturing both the technical 
and business perspectives of the biopharmaceutical drug development process in a 
single and consistent framework. This can facilitate more informed decision-making 
when evaluating alternative management strategies for the drug development process 
and permit risk analysis. In order to achieve this aim a set of objectives was 
identified and forms the basis of each of the following chapters.
Chapter 2 presents an investigation of the drug development process, highlighting the 
different tasks that are involved in taking a drug candidate into the market. The 
process development, manufacture and the clinical trials are described in detail. The 
regulation process that is being applied to biopharmaceuticals is highlighted. The 
business of biopharmaceutical drug development is presented outlining the cost, time 
to market and the failure of drugs during the development process. This analysis 
helps to understand the risk and uncertainty inherent in the drug development 
process.
In Chapter 3, the conceptual framework and the implementation of the software tool 
is presented. The main characteristics of the biopharmaceutical drug development 
problem domain are identified early in the chapter, as well as the scope of the 
modelling effort. The approach taken to represent the key activities in a drug 
development process is introduced. Its key features and parameters that satisfy both
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drug development task and business applications are discussed. The implementation 
of the conceptual framework into a simulation-based decision tool for modelling the 
drug development process is then described.
Chapter 4 discusses the use of the tool to model the drug development process. The 
different applications the tool could be used for are introduced at the beginning of the 
chapter. This is followed by a discussion on the simulation process and the key 
decision points in the model. Graphical user interfaces are presented to familiarise 
the user with the tool. Next, the key inputs and outputs of the simulation tool are 
identified. Finally, the data collected as default values for the simulation are 
presented along with the assumptions made.
The application of the tool to model the drug development process and compute cost 
of development and time to market are presented in Chapter 5. A sensitivity analysis 
to identify the key parameters in drug development is carried out next. A 
hypothetical case study is set up to assess three different strategies for manufacturing 
material during the clinical trials and for the market. The Monte Carlo simulation 
technique is used to highlight the benefits of incorporating technical and market- 
related uncertainties when evaluating development strategies.
In Chapter 6, the simulation tool developed is applied to select a portfolio of drugs 
under different levels of resources. Again a hypothetical case study is used in which 
different project portfolios are generated by the tool for different resource levels. 
Next, the reward and risk values for the different portfolios are calculated. An 
efficient frontier is then constructed for the different resource levels to select the 
most optimum portfolio.
Chapter 7 provides a summary of the main contribution of this work and provides 
suggestions for future work. The extra data that was used for the case study in 
Chapter 6 is presented in Appendix A and a paper by the author, published through 
the course of this work, is attached in Appendix B.
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C h a p t e r  2
B io p h a r m a c e u t ic a l  d r u g
DEVELOPMENT
2.1 In t r o d u c t io n
The pharmaceutical industry can be defined as a complex of processes, operations, 
and organisations involved in the discovery, development and manufacture of drugs 
and medications (Shah, 2004). Biologically-derived compounds can be produced 
efficiently, are generally more specific in their action and provide an alternative 
method of treatment to chemically-derived compounds. The biotechnology industry 
is in the growth phase of its industry cycle and this phase will be marked by rapid 
sales growth due to a bevy of new products entering the market place over the next 
several years (Ginsberg et al., 2002). In 2002 there were over 350 biotechnology 
medicines in development in the US by 144 companies and the National Cancer 
Institute for nearly 200 diseases (Holmer, 2002; Burrill and Company, 2004a). These 
include 178 medicines for cancer, 47 for infectious diseases, 26 for autoimmune 
diseases and 21 for AIDS/HIV and related conditions (Holmer, 2002). Greener 
(2001) includes the discovery stage and states that there are almost 1200 biotech 
products in different stages of development.
The impressive financial rewards that can be reaped by a company by successfully 
bringing a biopharmaceutical product to the market have led to tremendous pressure 
to reduce time to market for products in the development pipeline. The world market 
for protein drugs was estimated at US$ 41 billion at the end of 2002 (Ernest and 
Young, 2003). However launching these products into the market is costly, risky and 
time consuming. On average it takes over 12 years to bring in a new pharmaceutical 
product to the market (Burrill and Company, 2004b). Worldwide there were 600 
publicly traded biotech companies in 2002, which made a combined loss of more 
than US$ 12 billion (Ernst and Young, 2004).
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This chapter initially provides a general introduction to biopharmaceuticals and their 
application as therapeutics in Section 2.2. In Section 2.3 the tasks, costs and risks of 
biopharmaceutical drug development are investigated and the economics of 
biopharmaceuticals in the marketplace are highlighted in Section 2.4. Finally the 
future of drug development is discussed in Section 2.5. The chapter ends with a 
summary of the findings.
2.2  B io p h a r m a c e u t ic a l s
Until recently, the vast majority of biopharmaceutical products were protein based 
(Table 2.1). However, during the 1990s, nucleic acid-based biopharmaceuticals also 
come to prominence, being employed in gene therapy and antisense technology 
(Walsh, 1998). Biological therapeutic products generally refer to any virus, protein, 
therapeutic serum, vaccine, blood component or gene transfer product destined for 
therapy. An understanding at the molecular level of how the body functions in health 
and the deviations which characterise the development of disease often render 
potential strategies likely to cure or control that disease. This understanding is used 
as the base for the discovery of biopharmaceuticals. The cause of disease is normally 
due to the lack of a single regulatory molecule, usually a protein. Other deceases 
such as inflammation and cancer however could be due to many factors and are 
hence more complex to treat. Biopharmaceuticals differ from chemical-based drugs 
by the way they are produced as well as regulated. However in some instances, 
categorising pharmaceuticals as products of biotechnology or chemical synthesis 
becomes somewhat artificial. For example, certain semi-synthetic antibiotics are 
produced by chemical modification of natural antibiotics derived initially by 
fermentation technology (Walsh, 1998).
T a b le  2.1 Some protein types that are being used as therapeutics
Blood clotting factors Monoclonal antibodies
Colony stimulating factors Neurotrophic factors
Enzymes Polypeptide anticoagulants
Growth factors Polypeptide hormones
Interferons Thrombolytic agents
Interleukins Vaccines
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2.3  B io p h a r m a c e u t ic a l  d r u g  d e v e l o p m e n t
Linkages between product and process technology differ substantially across the 
industries (Utterback, 1994). Pisano (1996) states that these differences influence the 
nature of both the technical and organisational challenges of process development. 
As an example, the author points out that in many types of assembled goods 
industries (automobiles, personal computers, consumer electronics), product 
functionality and features are not severely constrained or heavily impacted by the 
process design. At the other end of the spectrum are industries such as 
pharmaceuticals, chemicals, semiconductors, and advanced materials, where product 
and process designs are highly interdependent and changes in process technology can 
have a significant impact on product characteristics. Biopharmaceuticals and the 
process of manufacture clearly fit in this latter category.
In this section the many different complex activities involved in taking a 
biopharmaceutical drug candidate to the market from the point at which it has been 
identified as a potential therapeutic agent are described. The average process of drug 
development costs over US$ 400 million and takes an average 10 years (DiMasi et 
al, 2003). In addition, the complexity of drug development and clinical testing 
procedures has increased significantly over the past years (Kleinberg and Wanke, 
1995).
The first step involved in drug development would be the process of drug discovery, 
where thousands of molecules are screened for promising new therapies. 
Traditionally the knowledge of interactions at the molecular level, for regulatory 
proteins has been used to identify new drug candidates. Once these bio molecules 
have been identified and isolated, they are subjected to many trials and tests to 
ascertain efficacy and toxicity. In addition to these tests, a process to produce the 
drug in higher quantities has to be developed, tested and commissioned. These 
development activities are time-consuming, costly, and contain much uncertainty. An 
introduction to the regulatory activities involved is presented, followed by a 
description of the development process itself.
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2.3.1 Regulation of drug development
One of the major hurdles to commercialisation is achieving regulatory approval for 
the drug as well as of the manufacturing process (Humphrey, 1996). The process of 
drug development is closely scrutinised by regulatory authorities in every country. In 
the United Kingdom, it is the Medicines and Healthcare products Regulatory Agency 
(MHRA, http://www.mhra.gov.uk/). The European Union region is regulated as a 
whole by the European Agency for the Evaluation of Medicinal Products (EMEA, 
http://www.emea.eu.int/). Quality (drug stability; drug substance; dosage form), 
safety (single and repeated dose toxicity; short and long term toxicity; 
carcinogenicity; reproductive toxicology) and efficacy (therapeutical activity; clinical 
safety; dose/response trials; good clinical practice) remain the three basic criteria for 
the evaluation of the medicinal products by the EMEA (Benzi and Ceci, 1998). In 
addition the same authors describe how the value of the drug, measured by the 
quality of life added to the patients and the economic outcomes within the social 
health service are considered when assessing a drug for approval within the 
European Union. Walsh (2003) provides a description of the approval procedure 
deployed by the EMEA and presents a description of all the biopharmaceuticals 
approved in the European Union, which amount to some 88 products.
The foremost regulatory authority for medicinal products in the world is the United 
States Food and Drug Administration (FDA, http://www.fda. gov/). The Centre for 
Drug Evaluations and Research (CDER) and the Centre for Biologies Evaluation and 
Research (CBER), as part of the FDA, oversee the development and marketing 
approval process of new biopharmaceuticals. The major responsibilities of the FDA 
with regard to drugs include the following (Walsh, 1998):
• Assess pre-clinical data and decide if a potential drug is safe enough to allow 
commencement of clinical trials in humans
• Protect the interests and rights of patients participating in clinical trials
• Assess pre-clinical and clinical trial data generated by a drug and decide if 
that drug should be made available for general medical use (i.e. if it should be 
granted a marketing licence)
• Oversee the manufacture of safe effective drugs (inspect and approve drug- 
manufacturing facilities on the basis of compliance with the principles of 
good manufacturing practise as applied to pharmaceuticals)
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• Ensure the safety of the US blood supply
For most of this chapter the standards and statistics followed will be that of the FDA. 
The drug development process will now be described.
2.3.2. Drug development pathway
The progress of a candidate through the many tests and other development activities 
is recognised as the drug development process. Figure 2.1 illustrates the drug 
development pathway.
IND Application 
to the FDA
NDA Application 
to the FDA
i i
Discovery & 
Pre-Clincal Phase I Phase II Phase III
Regulatory
Review
.Development,
■Clinical Development*
Figure 2.1 A schematic representation of the drug development pathway.
Only about 1 in 10,000 molecules that enter the drug discovery phase will finally 
make it to the market (Carr, 1998). In parallel to the clinical trials, process 
development and manufacturing of the material in increasing quantities has to be 
addressed. The discovery stage of drug development is described next.
2.3.2.1 Drug discovery
The discovery of biopharmaceuticals can be attributed to the logical application of 
our ever increasing knowledge of the biochemical basis of how the body functions. 
In a simplified sense diseases are caused by the lack of a particular regulatory 
molecule, which is mostly a protein. Identifying this molecule is the first step in drug 
discovery. However, the knowledge of this regulatory molecule does not 
automatically translate into an effective therapeutic agent. The physiological 
responses displayed by a molecule in vitro or an animal model may not accurately 
predict the physiological responses seen when the product is administered to a 
human. For example, many of the most promising biopharmaceutical therapeutic 
agents (e.g. virtually all the cytokines) display multiple activities on different cell
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populations (Walsh, 1998). The availability of super-computers has spurred the 
growth of structure based or rational drug design, whereby drugs can be designed by 
analysing the structure of the molecular target and its active site (Figure 2.2).
From Body Tissue
Isolation
By Genetic 
Engineering
Bioactivity
Evaluation
Drug Design
Computer Modeling 
o f 3-D Structure
Crystallisation
Chemical Synthesis
X-ray Diffraction 
Analysis
A Drug Receptor 
or an Enzyme
Figure 2.2 Steps involved in using structure-based (rational) drug design to test and 
develop drugs based on drug-receptor interactions (Clemento, 1999).
Structure-based strategies that integrate the techniques of X-ray crystallography, 
computational chemistry and nuclear magnetic resonance spectroscopy to design 
drugs atom by atom are slowly replacing more traditional methods such as random 
screening and structural modification of existing compounds (Clemento, 1999).
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Gardner et al. (2004) describes the application of novel high throughput physical- 
chemical technologies to the pharmaceutical discovery and development process.
All the rationale drug design methods were designed for chemical entities and 
therefore the integration of biological data with chemical information poses a unique 
challenge to the biopharmaceutical industry (Shi et al., 2003). Bioinformatics refers 
to biological information, traditionally the sequence information on large molecules 
such as DNA, RNA and proteins. Chemoinformatics on the other hand deals with 
chemical information of small molecules drug. Biochemoinformatics is a new term 
being used to describe the research needs arising by the integration of bioinformatics 
and chemoinformatics (Shi et al., 2003). A comparison of the chemoinformatics and 
the bioinformatics is presented in Table 2.2.
Table 2.2 Biochemoinformatics: integrating bioinformatics with chemoinformatics 
(Shi eta l., 2003)
Bioinformatics 
(Gene/RN A/Protein)
Chemoinformatics
(Compound)
Sequence (ATGC and so on) Structure (for example SMILES)
2D structure and motif Molecular connectivity (for example
SDfile)
Active binding site Pharmacophore
Sequence homology Structure similarity
Pylogenic tree Molecular similarity and diversity
Gene ontology Chemical property
Gene function HTS and activity fingerprint
Target identification and validation Lead identification
Micro array gene expression profiling Combinatorial library design and
synthesis
Regulatory network Metabolic profile
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2.3.2.2 Pre-clinical phase
The physicochemical and other properties of any newly identified drug candidate 
have to be characterised in detail prior to clinical trials. The focus at this stage is on 
maximising the chance of identifying an ultimately unsuccessful biotechnology 
product as early as possible in the drug development pathway. A prerequisite to such 
a characterisation is initial purification of the protein to homogeneity, which 
normally requires a combination of three or more high-resolution chromatographic 
steps. This purification protocol is designed with great care as it usually forms the 
basis of subsequent pilot and process scale purification systems. The purified product 
is then subject to a range of tests that are aimed at characterising it fully. Once these 
characteristics have been defined, they form part of the basis of quality control (QC) 
identity tests routinely performed on the product during commercial manufacture.
Regulatory authority to commence clinical trials in humans is subject to successful 
pharmacological and toxicological tests being carried out on animals. Such pre- 
clinical studies can take three years to complete and cost from $2 million to $30 
million (Walsh, 1998). Safety evaluation in acute studies would normally include 
two different animal species and for chronic toxicity, one species can be sufficient if 
the two species initially studied have comparable toxicity profiles (Febbraro, 2002). 
The range of major tests undertaken on a potential new drug candidate during the 
pre-clinical phase are (Walsh, 1998):
• Pharmacokinetic profile
• Pharmacodynamic profile
• Bioequivalence and bioavailability
• Acute toxicity
• Chronic toxicity
• Reproductive toxicity and teratogenicity
• Mutagenicity
• Carcinogenicity
• Immunotoxicity
• Local tolerance
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The above tests are used to identify any effect on major systems like the 
cardiovascular, respiratory, renal and central nervous systems. The exact range of 
tests that regulatory authorities suggest should be undertaken for biopharmaceutical 
substances remains flexible (Walsh, 1998). Normally only a subgroup of the standard 
tests for chemical-based drugs is considered appropriate. In addition tests for 
mutagenicity and carcinogenicity are not likely required for most biopharmaceutical 
substances. The drug is normally patented by the developing company once it has 
been characterised and perhaps early clinical work is under way in order to ensure it 
receives maximal commercial benefit from the discovery (Walsh, 1998). If the pre- 
clinical testing yields favourable results and the developers are confident about the 
therapeutic and economical value of the drug candidate, it is taken into the clinical 
development phase. This is described next.
2.3.2.3 Clinical trials
The clinical trials are the most expensive and lengthiest process of the drug 
development pathway. The trials are conducted in increasing size and complexity to 
first determine the toxicity, dosage and then the efficacy in humans. In order to get 
approval to market the product, the company has to convince the regulators that it is 
safe and has a higher efficacy than current therapies in use. Satisfying these broad 
aims usually requires an ordered program of clinical trials, each with its own specific 
objectives. To conduct clinical testing in the United States, a manufacturer must first 
file an investigational new drug application (IND) with the FDA. Once drug 
developers believe that they have enough data gathered of safety and efficacy, they 
will compile the results of their tests in an application to regulatory authorities for 
approval. In the United States, manufacturers submit a biological license application 
(BLA) to the FDA for review and approval.
a) Phase I clinical trials
The Phase I clinical trials are conducted in healthy humans to confirm the safety of 
the new drug candidate and to gather information regarding absorption, distribution, 
metabolic effects and excretion. Approximately 20 -  30 healthy volunteers are 
recruited for the first phase trials. The results from Phase I trials are used to design 
well-controlled, scientifically valid Phase II trials. Material for Phase I are 
manufactured in a lab or a multi purpose pilot plant.
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b) Phase II clinical trials
The Phase II trials are conducted in 200 -  300 subjects who have the targeted disease 
or condition and are designed to further assess the common short-term side effects of 
the drug and establish preliminary data on efficacy. This normally takes up to two 
years. Phase II material is made either in a multi purpose pilot plant or in a small 
pilot plant.
c) Phase III clinical trials
The final phase of clinical trials is used to firmly establish the efficacy and uncover 
side effects that occur infrequently. Several thousand patients are used at this stage 
with many centres being used and the results are used as an adequate basis for 
extrapolating the results to the general population and as information in the product 
label. The Phase III trials can take up to three years in duration. Here, an acceptable 
level of efficacy is defined before the commencement of the trial. This has to be 
done, as the drug may not have its desired therapeutic effect on all the patients. For 
example it may be decided that the drug has to be efficacious in 25% of the patients, 
so as to be judged efficient. Therefore if the observed incidence is below this set 
minimum, the trials can be terminated with the drug being judged unsuccessful
d) Post marketing surveillance
Finally, post-marketing safety surveillance is carried out to assess the long-term 
effects of drug and could result in drugs being taken out of the market. Immune 
Globulin Intravenous (Human), Gammar-P I.V., 10 gm
(Aventis Behring L.L.C) was recalled by the FDA in April 2004 
(http://www.fda.gov/cber/recalls). Approximately 10 biological products are recalled 
every year by the FDA. Parker and Lahr (1999) cite the increasing complexity of 
product design, manufacturing process, product liability and the stringent regulation 
process as a reason for the recall of drugs. The authors explore different recall 
strategies and outline steps by which a firm can minimise damage due to a recall.
With clinical trials being the longest stage of the drug development process, many 
suggestions have been made on how the efficiency of the clinical trials can be 
improved (Marks and Power, 2002; Norris, 2001). The authors suggest the use of 
information technology for the recruitment process and data mining for uncovering
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patterns or systematic relationships between large amounts of data. To conclude a 
summary of the description of the clinical trials is presented in Table 2.3.
Table 2.3 Summary of clinical trials
Trial Evaluation undertaken and usual number of Average
Phase patients duration (years)
Phase I Safety testing in healthy human volunteers (20- 
80)
1
Phase II Efficacy and safety testing in a small number of 
patients (100-300)
2
Phase III Large-scale efficacy and safety testing in 
substantial numbers of patients (1000-3000)
3
Phase IV Post-marketing safety surveillance undertaken for 
some drugs which are administered over a 
particularly long periods of time (number of 
patients vary)
Several years
2.3.2.4. Process design and product development
Once the clinical development of a drug candidate commences, the product and 
process development work has to be pursued. The most efficacious and safest drug 
will not bring in revenue until the process to manufacture it is developed and 
approved. The product development concerns the characterisation as described in 
Section 2.2 and the formulation work. A suitable process to manufacture the material 
for the clinical trials and the market has to be developed on time. The cost of 
developing and implementing new process technology often approach and sometimes 
greatly exceed the cost of product development (Pisano and Wheelwright, 1995). 
Bioprocess development is essentially a multi-disciplinary task involving 
microbiology, biochemical engineering, biochemistry, virology, and molecular 
biology.
The regulations demand that the process used to manufacture the material for the 
Phase III clinical trials has to be subsequently used for the manufacture of the 
material for the market. Therefore the manufacturing process has to be developed by 
the beginning of the Phase III clinical trials. In biotechnology, new molecules are so
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complex to manufacture that developing basic process technology often determines 
the lead times for commencing human clinical testing. In addition, low-yielding 
processes often make it impossible for a company to produce enough material to 
supply all the necessary clinical trials in a timely fashion and can lead to delaying the 
clinical trials and the commercial launch of the product. Innovative process 
technologies are an under-exploited way for organisations to protect and extend the 
proprietary position of their product (Pisano and Wheelwright, 1995). A summary of 
the different activities involved in process development and the key outcomes are 
summarised in Table 2.4.
T a b le  2 .4  Key activities and outcomes involved in bioprocess development (adapted 
from a presentation at a MBI course at University College London by Hari Pujar, 
Merck)
Process development activities Key outcomes
Designing process conceptually Integrates fermentation,
Developing key analytical assays purification and assay
Developing process at lab scale development
Process science Supplying bulks for downstream
Engineering scale-up development
Determining process sensitivities Manufacture of clinical supplies
Process intensification Documentation for each transfer
Specifying equipment requirements Factory start-up
Defining manufacturing operating conditions Product licensure
Defining process validation parameters
Process engineers have long recognised that when a project is started at the 
laboratory scale, industrial systems must also be considered. The high importance of 
process development has resulted in novel methods being pursued to reduce the time 
to market of biopharmaceuticals (Titchener-Hooker et al., 2001). With gains in the 
efficiency in electronic data management, the clinical trials are speeding up, 
increasing the pressure on the process development work (Norris, 2001). The same 
author states that having a clear business-process development definition, a multi­
functional project team and the deployment of information technology solutions (e.g.
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simulation) as key areas to that need to be addressed in order to avoid delays due to 
process development.
Table 2.5 Methods of reducing bioprocess development times and increasing process 
quality (Titchener-Hooker et al., 2001)
Ultra scale-down to examine key bioprocess parameters 
Systematic bioprocess selection including use of accumulated knowledge 
Bioprocess modelling to complement scale-down and check design options 
Scale-down of whole bioprocess for per-pilot process guidance 
Analytical information in real-time to achieve addressable bioprocessing 
Bioprocess decisional tools to enable the consequences of both business and 
process choices on project success to be assessed
2.3.2.5 Product manufacture
Once sufficient yields have been achieved through the process development work, 
the manufacturing of materials takes place. The transfer of new biotechnological 
processes from research and development to manufacturing is always fraught with 
difficulties (Gerson et al., 1998). The authors state that increased success in the 
transfer of new processes from development to manufacturing can markedly increase 
the number of new drugs and vaccines brought to market, reduce the time to market 
and increase the profitable lifetime of the product. The uncertainty surrounding 
product approvals, the long lead times and the high cost of getting a facility 
functional have made biopharmaceutical manufacture a formidably challenging task 
(Brastow and Rice, 2003). Biologies are manufactured from biological sources such 
as mammalian-derived cells or bacterial hosts in a process that is much more 
expensive, complex and time consuming than the manufacture of chemical 
compounds. Typically the cost of goods varies from US$ 500 -  5000 per gram 
(personal communication, Richard Francis, Protherics, London, UK). Enbrel 
(Amgen, California, USA) and Herceptin (Genentech, USA) have sales values in 
excess of US$ 4000 per gram (Curling, 2000).
The manufacture of biopharmaceuticals is a highly regulated and rigorously 
controlled process. In order to gain a licence for the manufacture of material, the 
sponsoring company must demonstrate to the regulatory authority that not only is the
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product itself is safe and effective, but that all aspects of the proposed manufacturing 
process comply with the highest safety and quality standards. The principles 
underlining such standards are summarised in publications, which detail good 
manufacturing practices (GMP). Muller et al. (1996) provides an overview of 
regulations with special regards to GMP of biopharmaceuticals in different countries. 
The authors discuss the regulatory procedures with regard to each different stage of 
manufacturing.
Biopharmaceutical manufacture comprises the upstream process of protein 
expression and the downstream process of purification. A typical campaign for a 
single batch in a mammalian cell based process would last 7 - 8  weeks, with shorter 
time periods for products derived from Ecoli or yeast fermentation. Biologicals are 
distinguishable from their chemically synthesised counterparts with respect to their 
manufacturing process and the impact on the product quality and safety. The quality 
of biologicals is defined by the chosen production and manufacturing process. Minor 
changes in the manufacturing process can affect the quality of the drug. Regulations 
demand that depending on the complexity of the change to the manufacturing 
process such alterations have to be followed up with new clinical trials or 
pharmacokinetic studies, to prove the consistency of the product. Delays in the time 
to market are often due to deficiencies in manufacturing rather than to the scientific 
or clinical sections in the biotechnology industry (Fisher & Pascucci, 1996).
Since changes to the FDA regulations in 1996, biological products can be produced 
at any facility and are not confined to a single licensed facility. Therefore purpose- 
built facilities do not have to be built prior to product approval and early commercial 
production can take place in a contract manufacturing facility. Such outsourcing to 
contract manufacturers has become increasingly popular with both large 
pharmaceutical companies and the biotech community in particular (Byrom, 2000) 
and is currently growing at a rate of 20% per year (Savage, 2000). In 2002, over 30% 
of the manufacturing capacity was held by contract manufacturing organisations 
(Ginsberg et al., 2003).
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Building a facility with a capacity of 100, 000 L could cost US$ 200 -  400 million 
and take up to 5 years to be fully operational (Ginsberg et al, 2003). The issue of 
having manufacturing capacity to meet the demand of the new drugs coming into the 
market is an issue of much discussion within the industry today (Molowa, 2001; 
Molowa, 2002; Ginsberg et al., 2003). In 2000 -  01 several sources reported that the 
biotechnology industry was suffering from a severe shortage of manufacturing 
capacity for recombinant protein therapeutics, especially monoclonal antibodies (e.g. 
Byrom, 2000; Molowa, 2001). However more recent reports suggest that 
manufacturing capacity will not become a bottleneck (Ginsberg et al., 2003; 
Grimster, 2003; Sinclair, 2003). The manufacturing capacity in 2002 was estimated 
by Ginsberg et al. (2003) to be 413 000 litres worldwide.
In planning manufacturing capacity, estimates have to be made in advance about the 
demand in order to avoid losses due to not being able to meet the demand of the 
market. Given the number of products in clinical development and the growth of the 
market for the products currently in the market, it is projected that 940 000 litres of 
mammalian cell culture-based manufacturing will be needed by 2005/2006 (Ginsberg 
et al., 2003). The ability to meet the above manufacturing demand will determine 
whether the new biopharmaceuticals that make it to the market will be able to justify 
their economic value. Ginsberg et al. (2003) provides a breakdown of the 
manufacturing capacity being added at different companies and using these values, 
concludes that the capacity to meet this demand in 2005 does exist (Tables 2.6 and 
2.7).
Table 2.6 Current and forecasted biological manufacturing capacity (Ginsberg et al., 
2003)
Contractors Current volume (L)
Additional 
volume (L)
Total
volume (L)
Boehringer-Ingelheim 90,000 90,000 180,000
DSM Biologics/Catalytica 8,100 8,100
Lonza 14,500 43,500 58,000
Other 9,800 9,800
Contractors Subtotal 122,400 133,500 255,900
Drug/Biotech Companies
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Abbott/BASF/Knoll 3,500 48,000 51,500
Abgenix 32,000 32,000
Aventis 2,000 5,000 7,000
American Home 100,000 100,000
Products/Immunex
Amgen 80,000 80,000 160,000
Avecia 9,000 3,000 12,000
Biogen 12,000 180,000 192,000
BioMarin 1,010 1,010
Bristol-Myers-Squibb 10,000 10,000
Chiron 10,000 10,000
Chugai Pharmaceuticals 15,000 15,000
Genentech 96,000 96,000 192,000
Genzyme 1,000 10,000 11,000
GlaxoSmithKline 5,000 5,000
Human Genome Sciences 2,000 40,000 42,000
ICOS 3,850 3,850
IDEC 2,000 90,000 92,000
Imclone 30,000 30,000
J&J/Centocor 10,000 20,000 30,000
Medarax 1,961 29,412 31,373
Medlmmune 5,000 5,000
Protein Design Labs 750 22,000 22,750
Roche 20,000 20,000
Xoma 4,000 4,000 8,000
Other 12,000 12,000
Drug/Biotech subtotal 291,071 804,412 1,095,483
Total industry capacity 413,471 937,912 1351,383
53
BIO PH A RM A C EU TICA L DRUG DEVELO PM EN T PRO CESS
Table 2.7 Future monoclonal antibody manufacturing capacity requirement estimates 
(Ginsberg et al., 2003)
2000 2005/2006
Sales of antibodies on market (US$M) 2637 5304
New antibodies launched in 2001 - 2005 21
Average estimated sales of new antibodies (US$M) 300
Total new antibody sales (USSM) 6300
Total antibody sales (US$M) 11604
Estimated quantity sold (kg) 500 2200
Capacity required (1) 98,039 431,415
Sales of proteins on market (US$M) 10701 21523
New proteins launched in 2001 -  2005 19
Average estimated sales of new proteins 300
Total new protein sales 5700
Total proteins sales 27223
Estimated quantity sold (kg) 45 114
Capacity required (I) 200,000 940,221
Total required capacity (1) 298,039 940,221
Industry capacity (1) (Table 2.8) 413,471 1,351,383
Having described the different activities that make up the drug development process, 
the costs and risks involved will be discussed next.
2.4  B u sin e ss  o f  b io p h a r m a c e u t ic a l  d r u g  d e v e l o p m e n t
As described in Section 2.4, the development of biopharmaceuticals is a lengthy and 
complex process that is both expensive and risky. The objective of this section is to 
discuss the time lengths and costs involved with drug development and to review the 
attempts made at quantifying the risk. The cost of bringing more complex drugs to 
market is increasing impacting both the drug development pipeline and return on 
investment for emerging and long established drug development companies (Foo et 
al., 2001). In the year 2002, globally, biotechnology companies employed 
approximately 190 000 personnel and made a total revenue of over $41 billion (Ernst 
and Young, 2003).
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2.4.1 Time to market
Time to market is a key driver in the business of drug development. For a product 
that is estimated at bringing in annual revenue of $350 million, about a $1 million is 
lost for each day it is delayed in entering the market. The development times for 
biopharmaceuticals have always been shorter than for classical chemical entities 
(Gosse et al., 1996). The tremendous rewards available when a product is introduced 
to the market have added pressure on companies to shorten the time to market. 
Therefore the time to market remains a subject of much discussion and research 
within the pharmaceutical community.
Several studies have been undertaken to research the time to market of 
pharmaceuticals. DiMasi et al. (2003), in a detailed study of 68 randomly selected 
new drugs calculated the average time to market. The authors concluded that the 
average time to market (from start of clinical testing to market) was on average 90.3 
months, which was less than the 98.9 months from a previous study by the same 
researchers (DiMasi et al., 1991). However the majority of the drugs studied were 
new chemical entities and only 6 were biopharmaceuticals (4 recombinant proteins 
and 2 monoclonal antibodies). The reason for the shortening in the time has been 
attributed to the much shorter approval times in the mid to late 1990s that were 
associated with the implementation of the Prescription Drug Use Fee Act of 1992.
These accelerated process methods apply to drugs that are for life threatening 
diseases that do not have adequate therapies currently in use, for example AIDS and 
cancer. The European Medicine Evaluation Agency (EMEA) offers a centralised 
process whereby a new drug can obtain approval for market for the entire European 
Union through one application, but does not have a clearly defined class for products 
for faster review.
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Figure 2.3 The change in development time for pharmaceuticals over the last four 
decades for the different activities. This shows that the durations have been on the 
increase (Burrill and Company 2004b).
Gosse and Manocchia (1996) provide the earliest record of time to market for 
biopharmaceuticals. The first 29 biopharmaceuticals approved in the US (1980-1994) 
were examined to breakdown the phase lengths o f clinical and review stages. The 
average development time was calculated as 61 months and the average values for 
different therapeutic categories were presented. The authors conclude that the mean 
time for development for biological entities (61 months) is 38.9 months shorter than 
the mean development time for new chemical entities approved during the same time 
phase. The authors suggest two reasons for this observation. The first is that these 
compounds being biological entities, they have specific pharmacologic profiles and 
defined physiological mechanisms. The second reason is that this set o f biological 
entities had recombinant proteins, which had purified non-recombinant protein 
counterparts in therapeutic use by the general population, therefore had clinical data 
available enabling faster clinical development.
In a follow up study, Reichert (2000) provides the data for 26 biopharmaceuticals 
approved between 1995 and 1999 with a comparison of the mean phase lengths by 
product category, review status, orphan-drug designation and therapeutic indication.
1960s 1970s 1980s 1990s
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Reichert (2000) concludes that the variation observed in the approval phase lengths 
is due to the review status (standard or priority) and not a result of therapeutic 
indication or product category. These are compared to the values of Gosse and 
Manocchia (1996). Reichert (2000) concludes that the mean approval phase for 
biopharmaceuticals has shortened from the 1980 -  1994 period to 1995 -  1999, while 
the mean clinical development phase has increased. The reason cited for the 
reduction of the approval phase is the same identified by DiMasi et al. (2003); the 
introduction of the Prescription Drug Use Fee Act of 1992 and the Food and Drug 
Administration Modernisation Act of 1997. The increase in the clinical phase is 
attributed to several reasons. They being the additional complexity of the disease 
interventions, the advancement of the technology used to manufacture and 
characterise the biopharmaceuticals and the high standards being established by the 
FDA.
The same reasons are suggested by Reichert and Paquette (2003) for the increase in 
the time length for clinical phase of recombinant proteins. Reichert and Paquette 
(2003) presented data on the time length of the clinical phases of recombinant 
proteins based on the year of clinical initiation and FDA approval. A total of 271 
recombinant proteins in development and in the market were used for this study. 
Reichert (2003) analyses clinical development and approval data for 554 therapeutics 
(504 small molecules, 40 recombinant proteins and 10 MABs) approved from 1980 -  
2001 in order to assess the effects of the regulation changes cited earlier. The author 
provides a breakdown of the therapeutic categories as well as the year of approval for 
the drugs investigated for easy comparison. The author states that the trends indicate 
that the effect of these regulation changes was to shorten the time to market from mid 
to late 1990s. However, the gains have not been sustained during the early 2000s.
While the approval phase has shortened the clinical development phase has increased 
and the reasons suggested are the same as Reichert (2000). Reichert and Healy 
(2001) compare the approval times of the EMEA in Europe and the FDA in the US 
of 27 biopharmaceuticals within the period of 1995 - 1999. The authors conclude that 
the approval time for all products was 13% faster in the EU compared to the US 
(10.6 vs. 12.2 months). This is despite the EMEA not having a prioritisation scheme 
for approval of therapies for life threatening diseases like the FDA.
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Foo et al. (2001) using information available in the public domain published the time 
lengths of 25 biopharmaceuticals that had made it to the market (Figure 2.4). The 
time to market was defined as the estimated year of cloning till the date of approval. 
Foo et al. (2001) observed that there was no clear correlation between the time to 
market and the type or function of the drug. The authors identify the supply of 
material for pre-clinical and clinical trials as a critical issue that affects time to 
market and suggests that the planning for the production of material must occur 
before the efficacy of the product is established.
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Figure 2.4 Time to market versus year of market approval for marketed 
biopharmaceuticals (adapted from Foo et al., 2001). The figure indicates a wide 
variation of the development time and the average time for the 24 products is 7.8 
years, which is close to the 7.5 years deduced by DiMasi et al. (2003).
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Regulatory hurdles have been cited as a reason for increasing drug development time 
lengths (Foo et al., 2001; Wechsler, 2002). However Zemmel and Booth (2004) state 
that while the regulations have got tougher, it has not affected the time lengths 
(Figure 2.5).
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Figure 2.5 FDA’s NDA approval rates during the past 15 years, where 70 -  80% of 
all of the NDAs submitted have been approved. The number of annual submissions 
and approvals were relatively constant and the data show that there has not been a 
significant increase in the approval time due to the FDA activities.
2.4.2 Cost of biopharmaceutical drug development
The importance of empirical analysis of the cost of drug development is highlighted 
by DiMasi et al. (1991). The authors raise four important reasons for doing so. First, 
knowledge of R&D costs is important for analysing issues such as the returns on 
R&D investment. Second, the cost of a new drug has direct bearing on the 
organisational structure of innovation in pharmaceuticals. Third, R&D costs also 
influence the pattern of international resource allocation. Finally, the cost of R&D 
has become an important issue in its own right in the recent policy deliberations 
involving regulatory requirements and the economic performance of the 
pharmaceutical industry.
59
BIO PH A RM A C EU TICA L DRUG D EVELO PM EN T PRO CESS
The cost of producing new drugs, both chemical and biological, has been on the 
increase over the years (Stonebraker, 2002). The higher attrition rates during the 
development phase mean the drugs that do make it to the market have to pay for the 
drugs that fail. Research and development costs have grown 13% every year since 
1970, a fifty-fold increase (Booth and Zemmel, 2004). During the same time period, 
the number of investigational new drug candidates and new drug applications has 
remained constant. In the 1950s, the norm for pharmaceutical companies was to 
invest ~5% of sales revenue in R&D; by 1980 this had risen to ~9%, and by 2002 the 
industry average was 16%, with some firms spending well over 20% (Booth and 
Zemmel, 2004).
Several studies have been conducted to estimate the total cost of taking a drug from 
discovery to market launch. DiMasi et al. (1991) presented one of the most 
comprehensive studies and was conducted mainly on new chemical entities (93 
randomly selected drugs from 12 pharmaceutical companies). The authors estimated 
the pre-tax cost of an approved drug to be US$ 231 million (1987 dollars). Myers 
and Howe (1997) estimated the value of US$ 297 million (1994 dollars) for 
developing and launching a drug and this takes the cost of failed drugs into 
consideration, but the manufacturing and marketing costs are not included. The 
breakdown of these costs into different stages is presented in Table 2.8. While 
DiMasi et al. (1991) used data from companies, Myers and Howe (1997) used a 
financial model of the drug development process to estimate their values.
In a follow up study, DiMasi et a l (2003) calculated the cost to be US$ 802 million 
(2000 dollars) and took into account the cost of failed drugs in the portfolio. The pre- 
clinical cost was estimated at US$ 335 million and the clinical development cost at 
US$ 467 million. The breakdown of the costs to different stages is presented in Table 
2.9. This is the most comprehensive study of this nature that is available in literature. 
Again it is based mostly on chemical entities. Stewart et al. (2001) provides a 
breakdown of the cost of clinical trials for biopharmaceuticals, with average cost per 
subject, but does not provide the cost of process development, manufacturing and 
marketing. The reason for increase in the development costs of pharmaceuticals have 
been attributed to the increase in clinical trials cost due to more test per patients and 
more patients per trial being used (Booth and Zemmel, 2004).
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Table 2.8 Cost (1994 dollars) per approved drug by R&D phase in US$ millions 
(Myers and Howe, 1997)
Discovery Pre-clinical Phase 
testing I
Phase Phase FDA 
II III Approval
Myers and 16.71 64.28 11.63
Howe
(1997)
20.20 28.34 4.39
DiMasi et 81.9 11.63 
al. (1991)
20.20 28.31
Table 2.9 Average clinical period capitalised 
investigational compounds (DiMasi et al., 2003)
cost (2000 US dollars) for
Phase Capitalised expected phase cost (US$ million)
I 30.5
II 29.5
III 37.4
Long-term animal 3.0
2.4.3 Risk in drug development
The pressure on R&D is such that on the one hand, the pipeline is required to 
produce a large number of innovative products in a short time; on the other hand, 
new products need to be more innovative than in the past (Chiesa, 1996). Due to the 
highly regulated nature of the industry the probability of failure is high and this 
attrition has been cited as reason for the loss in productivity in the pharmaceutical 
industry (Booth and Zemmel, 2004). Grabowski and Vernon (1994) investigated the 
development of new pharmaceuticals (chemical entities) and concluded that seven 
out of ten marketed products do not recoup their original investment.
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Drug candidates could fail at any point of the development process or even after it 
has been launched in the market. The latter would be a failure in a commercial sense, 
where the investment made on the drug is not being recovered. Sager (2001) points 
out that the marketplace itself is comprised of multiple tiers of demand channels: 
from pharmaceutical manufacturers to drug wholesalers, from pharmacy retailers to 
physicians, from patients and patient advocacy groups to managed care 
organisations. The introduction of new therapeutic product often depends upon a 
carefully balanced sales and marketing campaign leveraged through all these 
potential channels. The failure during clinical development could be due to the fact 
that the drug is not presenting enough evidence to support the efficacy levels or the 
toxicity being too high. The inability to develop a manufacturing process that would 
enable the drug to be manufactured economically is another reason for failure. The 
collapse of a drug development program at a late stage will incur losses running into 
millions of dollars. Given that development costs are very high and continuously 
grow, killing projects at early stages is increasingly critical (Chiesa, 1996).
Many attempts have been made to assess the risk that is present in the drug 
development process (Struck, 1994; Gosse et al., 1996; Reichert, 2001; DiMasi et 
al., 2003). One method of quantifying the risk is to compute the phase transition 
probability, which refers to the likelihood that an investigational drug will progress 
in testing from one phase to the next. The overall clinical approval success rate is the 
probability that a compound that enters the clinical development will eventually 
make it to the market. Struck (1994) presented phase transition probabilities for 
biopharmaceuticals and were based on information gathered from the public domain. 
Nicholson (1994) published the probability of reaching a market from different 
phases and these were based on discussions made with industrial personnel. Gosse et 
al. (1996) presented the phase transition probabilities for recombinant proteins and 
therapeutic monoclonal antibodies in clinical trials between 1980 and 1994. The data 
gathered for this study was sourced from the European Medicines Evaluations 
Agency (EMEA) and the US biopharmaceuticals database, both of which are 
maintained by the Tufts Center for the Study of Drug Development (Tufts CSDD). 
The authors concluded that recombinant proteins and new chemical entities had 
similar failure rates for the time period 1980 -  1989. DiMasi et al. (2003) calculated 
the phase transition probabilities for new drugs in different stages of development
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(Table 2.10). As these data are based on new chemical entities they do not truly 
represent the nature of biopharmaceuticals. However DiMasi et al. (2003) remains 
the most comprehensive study that has been undertaken. Booth and Zemmel (2004) 
suggest that biologies have had 70% higher clinical survival rates than small 
molecules.
Table 2.10 Phase transition probabilities for new drugs in development (DiMasi et 
al., 2003)
Phase Probability of entering Phase (%)
Phase I 100.0
Phase II 71.0
Phase III 31.4
Long-term Animal Studies 31.4
There are two other publications of research that were conducted on the failure rates 
of biopharmaceuticals. Reichert (2001) published the phase transition probabilities 
for monoclonal antibodies (MABs) using data collected on 182 MABs which were in 
the market and at different stages of clinical development (Table 2.11). The source 
for this data was again the databases maintained by Tufts CSDD.
Table 2.11 Phase transition probabilities for monoclonal antibodies (Reichert, 2001)
Monoclonal 
antibody type
Phase I to 
II (%)
Phase II to 
III (%)
Phase III to 
Review (%)
Review to 
Approval (%)
Murine Mabs 77 52 45 33
Chimeric Mabs 86 40 80 100
Humanized Mabs 84 72 75 100
Average 82.3 54.7 66.7 77.7
In a later and more detailed study Reichert and Pavlou, (2004) published the overall 
success rate of monoclonal antibodies (Table 2.12) but did not revise the phase 
transition probabilities for MABs. Reichert and Paquette (2003) presented the overall 
and phase transition probabilities for recombinant proteins (Table 2.13). The 
probabilities regarding recombinant proteins were based on 271 rDNA therapeutics 
that entered clinical study during 1980 -  2002 and are divided into the different
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therapeutic categories. This is the most comprehensive study done on 
biopharmaceuticals that is available in literature currently. In all of the studies 
mentioned above, the authors conclude that in time with more data being available 
the probabilities will change and be more valid.
Table 2.12 Overall success rates for MABs (Reichert and Pavlou, 2004)
MAB type Overall success rate (%)
Murine Mabs 4.5
Chimeric Mabs 26
Humanized Mabs 18
Human 14
Table 2.13 Probabilities for clinical and U.S. review phase transitions for therapeutic 
recombinant proteins (Reichert and Paquette, 2003)
Recombinant protein
PI to 
PII 
(%)
PII to 
PIII
(%)
PIII to US 
review 
(%)
US review to 
approval 
(% )
Anti-infective (n = 27) 69 53 86 83
Antineoplastic (n = 36) 90 41 57 100
Wound/bum healing (n = 14) 86 70 75 100
CV/Haemostasis (n = 45) 90 69 71 100
Blood cell deficiency (n = 23) 83 79 50 100
Immunological (n = 34) 93 67 78 100
Enzyme replacement (n = 16) 93 56 100 100
Endocrine (n = 52) 87 94 79 100
All products (n = 271) 89 69 65 97
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2.4.4 Rewards in biopharmaceutical drug development
The rewards when a drug candidate succeeds in getting into the market are 
significant. A blockbuster drug on average would return over a US $1 billion per 
year during its peak sales. In turn this money could be invested back in the other 
drugs in the portfolio. Blockbusters alone contributed almost 50% of the total 
revenues of Pfizer, AstraZeneca, Eli Lilly and Schering-Plough in the year 2000 
(McNamara, 2002). This provides an understanding of the high rewards that await a 
successful drug in the market.
Protein-based therapeutics generated more than US$13.3 billion of sales in 2000, 
which was an increase of 23% from US$10.9 billion in 1999 (Ginsberg et al., 2002). 
The revenue from biological products worldwide had increased to US$ 41 billion in 
the year 2002 (Ernst & Young, 2003). Table 2.15 lists the sales generated by 24 
major protein therapeutics in the year 2003. The FDA in 2002 approved 9 biologies 
within the US, and in 2003 a total of 14 biologies received approval for market 
launch. Table 2.14 lists a set of drugs and that are expected to be generating high 
revenue in the future (Burrill and Company, 2004b).
Table 2.14 Biopharmaceuticals that are expected to generate high revenue in the 
future (Burrill and Company, 2004b)
Drug Company Indication Peak potential ($M)
Genaissance Genta/Aventis Melanoma 200-500
Cinacalet Amgen/NPS Hyperparathyroidism 300 -  500
Anidulafimgin Vicuron Fungal infections 200-300
Symlin Amylin Type II diabetes 200-300
Exenatide Amylin/Eli Lilly Type II diabetes 500-1000
Gilead Viread/Emtriva HIV 5 0 0 - 1000
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Table 2.15 Highest revenue generating therapeutics of 2003 (Burrill and Company, 
2004b)
Drug 2003 Sales (US$M) Company Disease
Epogen 2435 Amgen Anaemia
Rituxan 1982 Genentech and Biogen- 
IDEC
Non-Hodgkin
lymphoma
Aranesp 1544 Amgen Anaemia
Enbrel 1300 Amgen and Wyth Arthritis
Neupogen 1267 Amgen Neutropenia
Neulasta 1256 Amgen Neutropenia
Avonex 1168 Biogen Multiple sclerosis
Synagis 849 Medimmune Infectious disease
Rebif 819 Serono Multiple sclerosis
Cerezyme 739 Genzyme Gaucher disease
Viread 567 Gilead HIV
Gonal-f 526 Serono Infertility
Herceptin 425 Genentech Breast cancer
Growth
hormone
322 Genentech Growth hormone 
deficiency
Provigil 290 Cephalon Excessive daytime 
sleepiness
Renagel 282 Genzyme End stage renal 
disease
Actiq 237 Cephalon Breakthrough 
cancer pain
Fluvirin 219 Chiron Influenza
AmBisome 198 Gilead Infectious disease
Betaseron 189 Chiron Multiple sclerosis
Integrilin 184 Millennium Acute coronary 
syndrome
TOBI 172 Chiron Cystic fibrosis
Saizen 152 Serono Growth hormone 
deficiency
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2.5 T h e  f u t u r e  o f  b io p h a r m a c e u t ic a l  d r u g  d e v e l o p m e n t
2.5.1 Biogenerics
The biopharmaceutical market has come along way since 1982 when the first 
biopharmaceutical product, recombinant human insulin, was launched. As patent 
protection expires for the first wave of biopharmaceutical products, the potential 
marketplace for generic substitutes looms large. Biogenerics offer a multi-billion 
dollar marketplace which has yet to be exploited (Polastro, 2004). Biogenerics are 
essentially similar to the original product and involve an active substance with an 
expired patent. There is little or no sales promotion involved with biogenerics and 
they could be approved through a simplified abbreviated registration process. To be 
first on the generics market, patent windows need to be identified and utilised during 
the development strategy in order to avoid infringement battles 
(Maleck and Pollano, 2001). A good example of this is the Merck-Amgen EPO 
dispute in the 90s, which eventually allowed Merck to develop EPO because of a 
smart patent avoidance strategy. At least 8 of the highest selling biopharmaceuticals 
have generic versions being developed currently (Burrill and Company, 2004b). 
Assuming a similar penetration to that of the traditional drugs, the market for 
biogenerics has been estimated at USS 2 billion (Maleck and Pollano, 2001).
However there are many barriers that have to be overcome if the biogenerics market 
is to realise its said potential. The main barrier is from the regulatory authorities. As 
the manufacturing process and the expression cell system are unique to each product, 
the authorities would require clinical trials to be performed for the biogenerics. Still 
the cost would be lower due to fewer failure rates and less research during 
development. Of the US$ 803 million it costs to develop the average drug, only 
about five to 10 per cent of those costs will be incurred by a re-developer (BCG 
Focus, 2001). Other challenges that biogenerics has to overcome include the 
requirement of a high level of specialised skills and competencies; the willingness to 
dedicate long-term financing; and extensive planning - something not commonly 
found in the somewhat short-sighted generics industry (Maleck and Pollano, 2001). 
Given the value of the biopharmaceuticals, the original companies would use 
multiple patents of the product as well as the process to protect their portfolio.
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2.5.2 New opportunities
Sequencing the human genome has been described as the single most important 
event in the history of human health care and has provided enormous opportunities. 
Leveraging the 40,000 -  72,000 genes that have the greatest potential will serve as 
the foundation for developing personalised medicines and fundamentally change the 
way new biopharmaceuticals are identified and developed. Pharmacogenomics is the 
science of developing a customised and personalised medicine (Sager, 2001). 
According to some estimates the human genome has around 3,000 drugable targets 
(Booth and Zemmel, 2004). The vast amount of knowledge about genes, proteins and 
the biology of disease that has been created by the sequencing of the genes are 
thought to be so much that the ability to meaningfully use this data is not possible at 
the moment (Sager, 2001). Therefore it has been suggested that information 
regarding genes, proteins mRNA, ADMET and clinical trials must be linked across 
platforms and broadly utilised (Genetic Engineering News, Dec 2001). It can be said 
that the strategic issue facing drug discovery is not the availability of genome data, it 
is the ability to transform the data into information with biological and therapeutic 
significance. Booth and Zemmel (2004) agree stating that if these genomic targets 
are not properly scrutinised early, companies could end up with high failure rates 
down the development pathway and increased losses.
Using a combination of embryonic stem-cell technology and retroviral therapy, it 
may soon be possible to design new functions in aging or diseased organs, to grow 
new cells, tissues and organs from scratch (Sager, 2001). Further in the future, there 
could be alternatives to conventional protein production; for instance, 
pharmacologists will use the protein as a template for rational, small chemical drug 
design (Greener, 2001).
The age factor is playing an important role, with a higher percentage of the 
population being in the 60 -  90 age group it is estimated that there are over 200 drugs 
(both chemical and biological) being developed for age related diseases. Other areas 
of the market where more companies are concentrating their research are obesity, 
Alzheimer’s, antibiotic resistance and wellness. The last category of wellness refers 
to preventative cure. Another area that is being pursued is ‘feel-good’ drugs, for 
example, male pattern baldness and wrinkle removing.
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2.5.3 Transgenic expression systems
One of the challenges created by the biotechnology revolution is the development 
methods for the economical production of highly purified proteins at large scale. 
Transgenic animals could emerge as an important source of therapeutic proteins, 
probably in another decade (Greener, 2001). These transgenic animals are expected 
to acquire a large slice of the protein market. The ethical issues concerning the use of 
transgenic animals are supposed to be overcome due to the fact that they are being 
used for therapeutic uses and not as a source of food. Watler (2001) provides a 
comprehensive comparison of the cost and capacity of transgenic and cell culture 
production systems. The author states that 25 -  30% savings could be made on the 
cost of goods (COG) using transgenic systems as opposed to a bioreactor. However 
in this study the additional facility, regulatory and development costs were not 
accounted for. When the capacities are taken into consideration, it is claimed that the 
transgenic systems are capable of producing high quantities (multi-tonne capacities), 
but the feasibility of field/farm GMP operations have not been fully demonstrated.
Dove (2002) provides a comparison of the raw materials cost of different expression 
systems with the benefits of the use of transgenic animals being highlighted. Again, 
the costs are very low compared to the mammalian cells ($2 compared to $150). 
Hood et al. (2002) presents another comparison which agrees with the above values. 
Pollock et al. (1999) provides a description of the use of transgenic milk as method 
of production of recombinant antibodies and argues that it is possible to achieve 
high-level expression of active recombinant immunoglobulins and immunoglobulin- 
fusions in the milk of transgenic animals. The author points out the scale-up 
flexibility and low costs (increasing or decreasing the herd) compared to more 
traditional cell culture facilities. The feasibility of using different animal species 
(mouse, rabbit, goat etc...) for the production of milk is presented with the 
comparison of reproductive age, average yield etc...
Protein production in plants is a means of resolving the dilemma of mammalian cell 
manufacturing capacity. The number and types of antibodies expressed in plants has 
increased steadily since the first reports of this accomplishment in the 1980s, 
illustrating the versatility of plants as a production system for antibodies (Hood et al., 
2002). The authors compare the process of manufacturing in different systems (CHO
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cells and transgenic animals) to manufacturing in plants and conclude that the 
advantages of using transgenic plants are capital cost savings, ability to scale up or 
down depending upon the market demand, freedom from human pathogens and 
savings on cost of goods. The next section provides a brief overview of the 
organisational changes that are made in order to minimise the risk and maximise 
rewards by companies involved in drug development and manufacturing.
2.5.4 Strategic partnering
Many organisational changes are being made in the industry in order to increase the 
productivity of the companies and minimise the effects of risk in drug development. 
By partnering with a company that knows the market, understands the regulatory 
requirements a start-up biotechnology company can reduce its risks and minimise 
adding heavy overheads (Humphrey, 1996). Worldwide there were 600 publicly 
traded biotech companies in 2002, which made a combined loss of more than 
US$ 12 billion (Ernst and Young, 2004). Becoming a fully functional pharmaceutical 
company for example in the mould of Amgen and Genentech, for a small start-up 
company is still a possibility, but risky and expensive (Ernst and Young, 2004). 
Given this uncertain environment, many companies, both large and small, seek to 
form strategic alliances.
The strategic decisions available take many forms. In licensing refers to adding a 
new drug candidate from outside to a company’s product portfolio. This could be 
done to increase the therapeutic areas a company has in its portfolio as well as a back 
up for drugs that can fail. Other deals could involve strategic partnering, where the 
development of products are shared in order to make available better resources for 
research and development as well as manufacturing for a product. In the year 2003, 
five such deals were arranged for Phase I products, each valued at over US$ 100 
million (Burrill and Company, 2004b). Mergers refer to companies merging to form 
a larger company in order to expand the product portfolio as well as the resource 
base. Acquisitions are made by larger companies in order to expand their product 
portfolio. In the US all such deals are regulated by the federal trade commission 
(FTC). Table 2.16 provides a list of the mergers and acquisitions that took place in 
the year 2003.
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Table 2.16 The main mergers and acquisition deals that took place during 2003 
(Burrill and Company, 2004b)
Companies involved Value of the deal (US$ million)
Johnson and Johnson/Scios 2400
Roche/Igen 1400
Pfizer/Esperion 1300
Roche/Di setronic 1200
Chiron/Powdeij ect 879
Novartis/Idenix 612
2 .6  C o n c l u s io n s
This chapter has described the process of biopharmaceutical drug development, 
which is a lengthy and costly one. The different activities that are involved in taking 
a drug from discovery into the market have been discussed. The cost of drug 
development has seen an increase over the years, culminating in pharmaceutical 
companies increasing the amount of money spent in research and development. The 
number of biopharmaceuticals in the market has been increasing steadily and these 
generate high revenues to the developers.
The state of manufacturing currently in the industry has been reviewed. There is 
much capacity being built around the world with products in the pipeline to utilise 
the new capacities. The risk and the uncertainty present in the process of drug 
development have been explored. Quantifying the risks helps decision-making. 
Attempts to quantify these risks have been discussed in Chapter 1. The next chapter 
describes the conceptual framework and the implementation of a prototype tool to 
model the drug development process in order to aid decision-making in managing the 
drug development and new drug candidate selection.
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C h a p t e r  3
D e s ig n  a n d  im p l e m e n t a t io n  o f
THE TOOL
3.1 I n t r o d u c t io n
As indicated in the preceding chapters, the high uncertainty in drug development has 
initiated many attempts to contain costs, reduce the time to market and reduce the 
losses due to failure of drugs at different stages in the development process. In this 
chapter a conceptual framework to model the process of biopharmaceutical drug 
development and manage the product portfolio is presented. This is then followed by 
a description of the implementation of the framework into a decision-making 
software tool.
This chapter is divided into eleven main sections. Section 3.2 provides a description 
of the biopharmaceutical drug development domain that is addressed by the 
framework/tool. The scope of the framework is indicated in Section 3.3. In Section 
3.4, the modelling approach taken is described. In the next two sections the key 
features and parameters are summarised. In Section 3.7 the different software 
platforms are assessed briefly for the implementation of the framework. A tool 
overview in Section 3.8 is followed by a detailed description of the components in 
Section 3.9. The approach to modelling uncertainties in the tool is described in 
Section 3.10. Finally a summary is provided in Section 3.11.
3.2  D o m a in  d e s c r ip t io n
The key features of drug development and portfolio management are identified in 
this section. As the cost of research and development of new drugs is on the rise, 
simulation tools can be used to capture the tasks, resources, business issues and 
uncertainties involved in drug development and thus compare different portfolio 
management strategies.
72
DESIGN AND IMPLEMENTATION OF THE TOOL
IND Application 
to the FDA
NDA Application 
to the FDA
Discovery & 
Pre-Clincal 
Development
Phase I Phase II Phase III
Regulatory
Review
■Clinical Development*
Figure 3.1 The process of drug development, which is comprised of a set of 
sequential well-defined phases that increase in complexity.
Figure 3.1 presents the main phases involved in taking a drug into the market. For 
each of these phases there are a range of activities that are carried out requiring 
extensive levels of resources. In the pre-clinical phase a large number of molecules 
are extensively screened for potential drug candidates. Once a molecule has been 
identified as having both the potential to cure a disease as well as generate revenue, it 
is taken into clinical development where it is subjected to a series of tests to ensure it 
is both safe and effective in achieving its claimed therapeutic effect(s).
During Phase I, initial process development is carried out to produce the material in 
small (gram) quantities. The process and product development work at this phase 
also concentrate on the establishment of new analytical methods. Given the high 
uncertainty at this initial stage, minimum process development is carried to get a 
reproducible process in order to reduce losses in case of early product failure. 
However, any significant deviations from the initial protocol to generate material at a 
later stage could invalidate earlier results. Manufacture at Phase I is usually carried 
out at lab-scale or pilot-scale. Clinical trials are conducted in 20 -  80 healthy 
volunteers to identify toxic effects, if any. This Phase on average would take 1 -  2 
years.
Drug candidates that are deemed safe would then proceed to Phase II, where further 
process and product development is carried out, building on the work done earlier. 
The manufacture of material for these clinical trials and other development work is 
carried out at pilot plant scale. The clinical trials are tailored to confirm the stated
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efficacy of the drug. This involves approximately 100 -  300 patient volunteers. 
Phase II would take 1 .5 -2  years on average.
Phase III is the longest and costliest phase. Process development work is 
concentrated on ramping up the production from pilot-plant scale to large scale. The 
clinical trials will involve 1000 -  3000 patient volunteers. Therefore the 
manufacturing has to be carried out at large scale. The aim of these clinical trials is to 
confirm effectiveness in a larger sample and to identify minor adverse reactions from 
long-term use. Phase III would take on average 2 - 3  years for completion. The 
equipment, facility and the assays all need to be fully validated at this stage.
Failure of the drug candidate could occur at any stage of the development process. 
The inability to develop an economically feasible process, low yields and titres are 
reasons for failure related to process development. Batch failure due to 
contamination could result in manufacturing delays. The drug’s low efficacy level 
and any adverse side effects could cause the drug to be abandoned after clinical 
trials.
If the results from the Phase III clinical trials are deemed successful, a new drug 
application (NDA) is filed with the FDA for final approval. Once the FDA approval 
is granted, the drug is then marketed. At each step, resources have to be allocated for 
successful completion of the phase and decisions have to be made as to whether the 
drug candidate is carried forward, held back for a time period or dropped from the 
portfolio. The resource level of the company and its strategy will also decide the 
number and the type of drugs being held within its portfolio.
For process development, a cross functional team would have to be employed. The 
manufacturing strategy for each phase of the development cycle has to be set in order 
to have material ready initially for pre-clinical/clinical trials and then for the market. 
This would involve making decisions about where to invest, in production facilities 
or to find appropriate contract manufacturers. Since changes to the FDA regulations 
in 1996, biological products can be produced at any facility and is not confined to a 
single licensed facility. Therefore purpose-built facilities do not have to be built prior 
to product approval and early commercial production can take place in a contract
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facility. Clinical trials have to be planned ahead with clear objectives. They form the 
costliest aspect of drug development. Given the high level of risk and uncertainty, 
planning the development work and the resource allocation have to be carried out to 
minimise the effect of any failure of drugs. A computer-aided tool capable of 
capturing the risk and the rewards of different strategies can help provide a rational 
basis for confident decision-making in biopharmaceutical drug development 
planning and portfolio management.
3 .3  S c o p e  o f  f r a m e w o r k
Defining the scope of the modelling effort was a key initial step required to focus 
simulation efforts and to ensure the breadth of the analysis was not too wide that it 
became too complex to handle. As stated earlier, the purpose of the simulation tool is 
to assess the impact of different strategies on a portfolio of biopharmaceutical drugs 
proceeding through development. More specifically, the scope of the modelling 
framework was defined as follows:
• To simulate the development of new biopharmaceuticals
The tool should be able to model the process of a drug being taken through all the 
development phases and, if successful, its performance in the market. This should 
enable the user to calculate the cost and the time to market of developing a particular 
drug.
• To prototype different management strategies before implementing in real life. 
Given the number of critical decisions that has to be made during the development 
stages of a drug, the tool has to be able to be used to test each of these new decisions 
prior to implementation. For example, given the limited levels of resources, both 
human and capital, available for drug development, different allocation patterns 
could be tried out in order to decide the best strategy for allocating resources.
• To conduct risk and profitability analysis
The risk in drug development can be quantified so as to compare different strategies. 
For example, comparing the value and risk associated with different drug portfolios.
In summary, the tool will provide the basis for a better decision-making strategy. 
What follows in the next section is a description of the approach adopted to model 
the process of biopharmaceutical drug development.
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3.4 M o d e l l in g  a p p r o a c h
A structured model of the biopharmaceutical development pathway was used in order 
to facilitate rapid modelling of the impact that business and process decisions made 
during the management of biopharmaceutical product development have on the 
portfolio profitability and risk. Figure 3.2 provides a simplified schematic of the 
proposed model.
USER INTERFACE for inputs and outputs
DATABASE 
Cost Attributes Time Attributes etc...
t
RESOURCES
Capital
In-House Capacity
Personnel
Contract
Manufacturing
Capacity
Contract Reseach 
Organisation
Phase 1 Phase 3 MarfcetPhase 2
Level 4
Level 3
ManufactureDevelopment Clinical Trial
DRUG
PORTFOLIO TASKS
Drug 1 
Drug 2 
Drug 3
Level 1 Biopharmaceutical 
Development Portfolio
♦ i► i
Level 2 Drug 1 Drug 2 Drug 3
Figure 3.2 Simplified schematic of the main components of the proposed 
framework.
The framework seeks to integrate various aspects, including resource management 
and the development and manufacturing activities required for clinical trials as each 
relate to strategic decision-making. The model structure was arranged in a 
hierarchical manner to represent the key tasks of the biopharmaceutical drug 
development process through a series of levels increasing in complexity (Figure 3.3). 
The hierarchical structure enables the user to prototype a management strategy at the 
required level of detail, for example high level for executive decision-making and 
lower level for process decision-making. In addition it enables to simulate a series of 
‘what - i f  scenarios’ rapidly. It also allows the user to access a breakdown of the 
model outputs. Therefore the costs and durations of specific tasks (e.g. cost and 
duration of clinical trials of Phase I) are available for analysis or comparison.
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The hierarchical task representation also provided the flexibility to extend the task 
tree further without compromising tool functionality. With more information, each 
level activity could be broken down into sub-tasks that generated more accurate 
values for key parameters. This type of modelling framework is attractive in that it 
reflects the organisational structure of a drug company with longer term strategic 
planning at a corporate level and campaign planning at a development level. This 
makes for more efficient models requiring less maintenance and of greater accuracy. 
A similar approach has recently been employed to model the manufacture of 
biopharmaceuticals (Farid et al., 2000; Farid, 2001; Farid et al., 2001; Lim et al., 
2004; Mustafa et al., 2004). A hierarchical solution approach was also proposed by 
Levis and Papageorgiou (2004) for multi-site capacity planning under uncertainty in 
the pharmaceutical industry.
The framework comprises the tasks involved in taking a drug to the market (e.g. 
development work, manufacture, clinical trials) and the resources required to carry 
out each task (e.g. capital, in-house capacity, personnel, contract manufacturing 
capacity). At the top-most level of the tasks the portfolio of drugs is modelled, which 
then breaks down into the projects handling individual drug candidates. At a greater 
level of detail the three phases of development and the market features are modelled 
for each drug. As depicted in Figure 3.2, the model includes the development 
process, manufacture and clinical trials associated with each phase. At the next level, 
the activities that make up the above different tasks are modelled. Each activity will 
have different inputs of time and cost. For example, the development phase would 
consist of the number of people working on a drug candidate, the yields achieved and 
the time spent in process development. Under the manufacturing tasks, production 
facilities and contract manufacturers are modelled. For each of these activities a 
series of decision points were defined and relevant attributes assigned.
The framework captures the interaction between the drug development tasks and the 
resources required for each drug in the portfolio. The resources are connected to all 
the tasks in the model, which in turn enables the activities to draw on the resources 
on the basis of availability. Resources are entities that are consumed or used by 
activities either in order for the activity to be completed or as a consequence of the 
activity being completed.
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Figure 3.3 Hierarchical representation of the biopharmaceutical drug development pathway. This approach allows new levels of detail to be 
added as required by the simulation.
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In addition, the attributes are stored in a database that the user can access. Default 
values for task durations and costs, as well as probability of failure are provided as 
part of the knowledge repository. The outputs of the model are exported into the 
database and saved during the simulation.
The model is flexible in order for simulations of alternative strategies to be 
investigated at all levels of decision-making. This involves the ability to model 
decision-making, evaluating alternatives for both stochastic and deterministic 
processes at different levels of detail. A robust modelling framework will reconcile 
the different metrics computed at different levels of the modelling hierarchy.
All the outputs from each level would add up through the hierarchical level through 
the use of common parameters running through all the levels, namely cost and time. 
However, useful outputs will be generated, summarised and presented from the lower 
levels as well, for example the human resource utilisation profiles for process 
development staff for Phase I. A summary of the typical outputs from each level is 
shown in Table 3.1.
3.5 K e y  f e a t u r e s
To satisfy both process development and business applications, each level defined 
the drug development process in terms of the tasks, the resources available and the 
drug candidates that proceed on the development pathway. Outside these core 
knowledge requirements existed characteristics that are more specific to each 
individual application. For process applications, examples include manufacturing 
data. Business applications require cost data and knowledge of resource utilisation 
and availability. The developed framework allows the user to investigate different 
production strategies in terms of the cost of development, time to market, resource 
use and profitability indicators such as net present value of the portfolio of projects. 
A systematic approach was used to map out the interaction between the different 
drug development activities.
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Table 3.1 Summary of typical outputs from each level of the proposed framework
Level Outputs
Portfolio Number of drugs
Portfolio cost
Net present value (NPV)
Project Total development cost of a drug 
Time to market for a drug 
NPV of a drug
Phase Duration of each Phase 
Cost of each Phase
Task Cost of process development, 
manufacturing and clinical trials 
Duration of process development, 
manufacturing and clinical trials 
Resources utilisation profiles
3.5.1 Tasks
Each block in Figure 3.2 represents an activity or task performing operations that 
generally consume resources and may also produce resources for use by later tasks. 
A task could be broken down into subtasks as required. Therefore a task block could 
represent a collection of activities at a high-level or a single activity at lower level as 
indicated in Figure 3.3. The information available and the desired outputs of the 
analysis determined the level of detail adopted to represent a task. As a minimum, 
each task was characterised by its duration.
The framework was designed to run tasks both concurrently and sequentially in 
multiple plans to allow the modelling of portfolios, since the development pathway 
for many drugs can be considered. Precedence relationships for the tasks were set, 
which meant that one task could not begin until another was completed. For example, 
the clinical trials could not be started till the required quantities were manufactured. 
The possibility of tasks overlapping was allowed where possible. The functionality to
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represent alternative sequences of tasks, which maybe executed based on decisions, 
for example alternative manufacturing routes, was made available.
3.5.2 Resources
The drug development process requires a wide variety of resources. These include 
both renewable (e.g. personnel and facilities) and non-renewable (e.g. capital) 
resources. During a simulation the model calculates the need for and then request 
resources. The availability of resources acted as a constraint for the different tasks. 
The ability to outsource some of the developmental activities was incorporated. For 
example if the internal manufacturing facilities (resources) were not available, the 
ability to contract out was included. The ability to model flexibly resources along 
with their respective usage pattern is a key requirement in most simulation 
applications. The framework had the capability to monitor the availability, usage and 
replenishment of resources that are consumed by tasks.
During a simulation, the tasks in the drug development process request resources. 
The production or consumption of material or the status of a resource could define 
the availability of these resources. Resources therefore act as constraints on the 
process. If the resource was unavailable, the task could be delayed. An example of a 
resource category whose status restricted its use is personnel; the personnel could be 
busy with the development work of one drug and therefore the drug candidates 
following would have to be held back until the personnel needed became available. 
Another feature that was incorporated was the temporary availability of resources. 
For example, the shift patterns of personnel could be defined, where staff would be 
available only for a given period of time each day.
3 .6  K e y  p a r a m e t e r s
All the features described in the modelling approach had input and output 
parameters, or attributes. The following measures were considered critical for 
assessing the capabilities and limitations of alternative drug development strategies: 
cost, time to market, risk and net present value of the portfolio. These are closely 
interrelated.
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3.6.1 Cost
Costs include the capital expenditures and investments that would accumulate when 
a company undertakes the development of a new drug candidate. Capital costs would 
include the cost of building facilities for carrying out research and development, 
manufacturing for clinical trials and the market itself. Manufacturing costs for 
material manufactured for clinical trials were accounted on a cost per batch basis 
(personnel communication, Rebecca Paulraj, Lonza Biologies, Slough, UK, Peter 
Ketelaar, DSM Biologies). This included all the material costs as well as operating 
costs. In costing for the manufacture of material for the market, the cost of goods per 
gram was used, as is the case in the industry (Farid et al., 2001; Lim et al., 2004). 
Other costs include process development and clinical trials and marketing. These 
were collected through literature (DiMasi et al., 2003; Stewart et al., 2001) and 
through conversations with industrial experts (personal communication, Rebecca 
Paulraj; Steve Froud, Lonza Biologies, Slough, UK; Peter Ketelaar, DSM Biologies).
3.6.2 Time
The duration of each task was either given as an input or was computed based on the 
inputs or distributions entered. These durations were summed to calculate the time to 
market for the product. This enabled the different parameters that affect the time to 
market to be investigated further. The duration of a task was affected by resource 
constraints that could delay tasks until resources became available. Monitoring 
activities over time also permitted the generation of resource utilisation profiles. 
These could be used to assess whether modifications to operations would help to 
reduce bottlenecks in the drug development process. The global time unit of the 
framework was set to weeks, which allowed tasks to be modelled at a detailed level. 
At the top most strategic level the outputs were in years.
3.6.3 Profitability indicator
To quantify the success of drug development and compare different strategies an 
output of the simulation process is required. The net present value (NPV) was used 
as the main indicator of profitability in the process of drug development. The NPV 
refers to the present value of an investment's future net cash flows less the initial 
investment (Peters and Timmerhaus, 1991). The NPV calculated by the model is 
useful in comparing different management strategies or drug candidates in a
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portfolio. The steps involved in the NPV calculation and the assumptions are 
presented in Chapter 4.
3 .7  A s s e s s in g  s o f t w a r e  p l a t f o r m s  f o r  im p l e m e n t a t io n  
Once the conceptual framework was developed, the next stage involved selecting a 
suitable software platform to translate the framework into a computer-aided tool. As 
the key process and business features (e.g. tasks, costs and uncertainties) of the drug 
development process were identified, the requirements for the software platform to 
be used were specified. Past work at the Advanced Centre for Biochemical 
Engineering, University College London (UCL), had focused on using ReThink, a 
graphical application that runs in G2 (Gensym Corporation, Cambridge, 
Massachusetts, USA), an object-oriented programming environment (Farid, 2001; 
Karri et al., 2001). Key advantages of ReThink were the useful pre-built features that 
enable extension and customisation for process re-engineering. Such a package 
facilitates rapid prototyping for process development in a modular and hierarchical 
fashion by describing the manufacturing activities at various levels of abstraction. 
However, one of the key disadvantages was found to be that the package is extremely 
programming-intensive.
The suitability of many software platforms for a similar type of simulation work was 
investigated extensively by Farid (2001). The required capabilities of the modelling 
language were divided into two categories, “declarative and procedural knowledge”, 
representation capabilities and “dynamic behaviour” capabilities (Farid, 2001). The 
declarative and the procedural knowledge refer to the properties and functions of a 
task in the drug development process. For example, the process and product 
development task’s properties include its cost, duration and an output of the yield 
achieved. The dynamic behaviour capabilities relate to time-dependent operations 
that the language must be able to perform so as to visualise the process logistics and 
analyse its performance. An example of information that must be updated in “real 
time” is resource availability, since this affects the allocation of resources to tasks 
over time. This is important for tasks competing for specific resources since the tasks 
can become delayed by the non-availability of a resource. Table 3.2 summarises the 
requirements for the software language.
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Table 3.2 Requirement specifications for the tool (adapted from Farid, 2001)
Requirement type Specification
Representation of Tasks and their characteristics
declarative and Resources and their characteristics -  resources include
procedural capital, facilities and personnel
knowledge Drug candidate flow and its characteristics
Relationships between tasks, resources and material flow
Sequences of tasks
Resource requirements for each task
Calculation procedures for material production
Variables for the calculation procedures
Time
Hierarchical views of the tasks
Risk/uncertainty: stochastic variables defined using 
probability distributions
Dynamic Dynamic simulation of task sequences
simulation Dynamic allocation of resources to tasks 
Dynamic invocation of procedures to compute resource 
utilisation statistics 
Monte Carlo simulation
Single-threaded, multi threaded and parallel processing
Flexible Graphical user-interface
development Modular
environment Extensible
Extend (Imagine That Inc., San Jose, USA) is a visual, interactive Window-based 
simulation package that is tailored for a broad range of industries. Models are 
constructed graphically by dragging and dropping blocks from library windows onto 
the model worksheet. Data can be entered directly into block dialogs, interactively 
using controls or read from files as the simulation runs. The block development 
environment includes a fully featured, compiled, ModL language that allows 
simulation modellers to add custom functionality. This toolkit combines 
sophisticated statistical analysis with specialised blocks for processing, batching,
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transportation etc to provide a wide variety of modelling opportunities. It offers 
unlimited hierarchical decomposition and contains features to streamline operations, 
document procedures, identify bottlenecks and answer questions about capacity, 
productivity, utilisation etc. Extend Industry Suite v5, an extension of basic Extend, 
provides an integrated database system, which is necessary for the storage of 
modelling data.
Extend Industry Suite v5 was found to be the most appropriate software package and 
was chosen as the simulation package for the implementation of the decision-support 
tool. The “drag and drop” feature provides a user-friendly interface. ModL is a 
relatively easy programming language to learn and program due to its similarity with 
the C language. Extend has a customisable graphical and animated interface that 
provides a clear visualisation of the steps in the simulation run. This graphical tool 
offers an unlimited hierarchical decomposition to build complex systems. Microsoft 
Excel was chosen to provide the database interface, as it is transparent to most users 
and is compatible with Extend Industry Suite v5.
3 .8  T o o l  o v e r v ie w
Having developed the conceptual framework and selected the software platform, the 
research carried out to develop the prototype tool is described. In developing the tool 
the challenge was to represent the declarative and procedural knowledge required in 
a sufficiently robust manner, so as to enhance the efficiency, maintainability and 
reusability of the application. All work was implemented in Extend Industry Suite v5 
and Microsoft Excel. Since all-necessary building blocks specific to 
biopharmaceutical drug development are not part of the basic blocks, a number had 
to be custom built.
The system definitions comprise all the declarative and procedural knowledge for 
modelling manufacturing operations. The declarative knowledge consists of all the 
objects, such as tasks and resources, and their class definitions describing their 
properties. The procedural knowledge enables programmatic control over an 
application and takes the form of procedures, methods and rules.
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The steps to translate the framework into a software tool are as follows:
• Identify the tasks and resources in the development domain
• Create blocks for each task and resources
• Within each task and resource block, provide the procedural information to:
o Set attributes 
o Perform calculations 
o Assign resources 
o Export output data to database 
o Simulate durations
• Create database in Excel spreadsheet for input and output data
• Establish connection between Extend and the database
The graphical user interface simplifies rapid prototyping of specific cases since it is 
highly interactive and provides visualisation of the various drug development levels.
3 .9  T o o l  s t r u c t u r e
This section describes the main components that were created to model the process 
of drug development. A graphical user interface is used to represent the activities and 
resources of the development process. The tool was designed to comprise of four 
main components (Figure 3.2). They being, the activities in the drug development 
pathway, the market, resources and the database. Within the tool, each drug is 
modelled as an item. Once a simulation is started, a drug candidate that is taken into 
clinical development is taken through the drug development pathway and into the 
market beginning with Phase I. The resources needed for this process are made 
available through the resource component of the tool.
Once a drug is in the market component, the activities that take place when a drug 
enters the market (e.g. sales, manufacture of material and market competition) are 
simulated. The different attributes and data needed for this simulation process are 
imported into the modelling blocks from the database. The data that is generated 
within the tool are then exported into the user interface where further calculations 
can be performed in order to analyse this data. Next, each of the separate components 
of the tool is described in detail.
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Figure 3.4 Hierarchical structure of the drug development pathway model. By 
simply clicking on each level, the level below can be accessed. The blocks that are 
used to simulate the activities of the clinical trials are presented in detail. Changes to 
the values of the attributes during a simulation can be carried out by clicking on the 
particular block.
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3.9.1 Drug candidate
When a drug is generated at the beginning of the simulation, a name in the form of a 
number is set as an attribute. This allows the tool to recognise the drug candidate at 
any point of the simulation. As the drug proceeds through the different sections of 
the development pathway and the market, the attributes are assigned. These attributes 
could be inputs to the tool or calculated by the model itself.
3.9.2 Drug development pathway component
This component of the tool refers to the different tasks and activities involved in the 
process of drug development. As explained in the beginning of this chapter, the drug 
development process was separated into process development, manufacture of 
material for clinical trials and the clinical trials (Figure 3.3).
Each of these tasks was modelled separately with process development being the first 
task that a drug went through when it entered that phase. Once suitable yields were 
achieved, the manufacture of material was simulated. Finally, for each phase, the 
clinical trials were modelled. Part of the manufacturing and the clinical trials were 
modelled to take place in parallel to each other, so that once suitable quantities were 
manufactured, the clinical trials could begin. The pathway was built in a hierarchical 
manner, with increasing levels of detail. The attributes associated with the drug 
within the drug development pathway component were drug-specific and those 
associated with the company were company specific. The next section describes each 
of the sections that make up the pathway component.
3.9.2.1 Process development
A major, and costly, part of product development is the establishment of new 
manufacturing processes and analytical methods (Gregersen, 1995). Early planning 
of process development activities and the appropriate allocation of resources to the 
stage of clinical development are key to cost management and meeting clinical trials 
demands on time. These process development activities were modelled in order to 
prototype different management and resource allocation strategies.
As the drug candidate enters the process and product development activities the 
attributes in Table 3.3 are assigned (Figure 3.5). These are estimations based on
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similar drugs that have been developed. If such data is not available a set of default 
data can be used. Alternatively, a range of values with a probability distribution 
could be assigned.
Table 3.3 Attributes assigned at the process and product development stage 
Attributes set for each drug candidate
Number of personnel required for development work 
Duration of process development 
Estimated cost of development 
Target yields
The number of personnel refers to the managers as well as scientists, process 
development engineers and all other staff. The work carried out during process 
development has been described in Chapter 2. Once the attributes have been set, the 
process development work is simulated. The number of personnel required is drawn 
in from the resource pool that contains the process development personnel. Next, the 
drug is held within a block for the duration of the process development work. If the 
number of personnel required is not available, the drug candidate will be held back 
till the number become available. This waiting time is measured and added onto the 
total time for development.
The outputs of process development are the total cost and duration of development. 
These data outputs are then exported to the database. Here, the user will have access 
to a breakdown of the process development data. The outputs from process 
development sections from each phase are presented in Table 3.4. The facility in 
which the process development is carried out was modelled as part of the resource 
component of the tool and is described separately. The description above is the same 
for Phase I, II and III. In Phase III, the probability of failure due to economic or 
technical reasons is included. The simplified schematic in Figure 3.6 provides a 
summary of the activities taking place within the process development activities.
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Table 3.4 Outputs from the process development activity 
Output 
Waiting time 
Total development time 
Total cost of process development
Set A (5)
From
Database
/
\
\
\
\
\
\
Set Attribute Block (5)
Drug Name:
Attribute Name:
Personnel
Cost per Person
Duration
Yield
Efficiency
Value:
30
10000
0.8
30
Figure 3.5 Schematic of a ‘Set Attribute’ block for the process development section. 
The inputs from the database are imported by ‘Receive Data’ blocks, which apply the 
values to the attributes directly. The drug name attribute is used to identify and 
distinguish between the different drugs.
3.9.2.2 Manufacture
The aim of this part of the tool was to capture the business aspect of the 
manufacturing process in order to simulate different manufacturing strategies such as 
outsourcing vs. in-house manufacture. Biopharmaceutical manufacture takes place in 
batch or semi-continuous mode. The level of detail was limited in order to capture 
the strategically important cost and risk changes in manufacturing activities of drug 
candidates for clinical trials.
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Drug Candidate
Number of Personnel
Cost per Person
Estimated Cost of 
Process Development
Estimated Duration of 
Process Development
Hold Drug Candidate for Duration of 
Development ,
Allocate
Resources
Perform Calculations
Set Attribute Block
Total Cost of Process 
and Product 
Development
Total Time Taken
Proceed to 
Manufacture
Figure 3.6 The simplified schematic of the process development modelling section 
of the tool. Basic blocks from Extend were used to build a model of the process 
development activities.
Once the process development work has been completed the drug candidate will 
move into manufacturing the material for clinical trials. The facilities for 
manufacturing were modelled in a flexible manner, in order to change the resources
91
DESIGN AND IMPLEMENTATION OF THE TOOL
for each different simulation. These facilities will be described in further detail in the 
section concerning the resource component of the tool (Section 3.9.4).
The manufacturing process was modelled in two basic stages, the upstream process 
of protein expression and the downstream process of purification. Once the capacity 
of the manufacturing facilities (e.g. reactor volume) is defined, the process yields and 
recovery efficiency attributes from the process and product development section are 
used to calculate the number of batches and the time for the manufacturing 
campaign. The availability of the manufacturing personnel and the facilities, both 
upstream and downstream are used as resource constraints for the manufacturing 
process. As with the process development, as the drug candidate enters the 
manufacturing stage, attributes specific for manufacturing are assigned (Table 3.5).
Table 3.5 Attributes assigned for the simulation of the manufacturing process 
Attributes assigned to the drug candidate
Manufacturing personnel required 
Cost per person
Estimated quantity of drug to be manufactured 
Upstream campaign time 
Downstream campaign time 
Yield
Turnaround time for the facility 
Batch cost
Contract negotiation time (for contract manufacturing)
Once the attributes have been set, the drug candidate would move onto the 
manufacturing block. The manufacturing could be either in-house or contracted out 
depending on the simulation settings. The default strategy within the tool was set to 
outsource a drug candidate if the internal facilities were occupied with a different 
drug. The user has the option of setting the strategy and the level of resources, for 
example the size of the fermentor or the number of down stream processing facilities 
available. The tool would then perform the simulations and calculations required. 
The capability for batch failure and manufacturing delays to occur was incorporated. 
The outputs for the manufacturing stage are shown in Table 3.6.
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Table 3.6 Outputs from the manufacturing stage of the pathway component 
Output
Number of batches produced 
Waiting time 
Total manufacturing time 
Total cost of manufacture
As in the process development stage, the data generated are exported to the Excel 
spreadsheet database for further analysis. If there is a shortage of resources, the 
waiting time of the drug is measured separately and is included in the total 
manufacturing time. The drug candidate is then held on within a block for the 
duration of the manufacture in order to simulate the manufacturing period. This 
allows the effect of changing resource levels on manufacturing time to be 
investigated. The manufacturing stage is modelled in this same manner for all three 
phases.
3.9.2.3 Clinical trials
Once the quantity of material to start the clinical trials has been manufactured the 
drug development process would move onto the clinical trials. As the drug candidate 
enters the clinical trials the attributes for clinical trial are assigned initially (Table
3.7). The drug then moves on to simulate the process of clinical trials and calculate 
the outputs for the stage.
Table 3.7 Attributes assigned for the simulation of the clinical trials 
Attributes assigned to the drug candidate
Number of personnel needed for managing the clinical trials
Number of patients per trial
Cost per patient
Clinical trial time
Contracted clinical trial time
Contract cost per patient
Probability of failure at the particular clinical trial
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The cost per patient refers to all the expenses involved for the full duration of the 
clinical trial. This value depends on the disease for which the therapy is being 
developed, for example, a cancer therapy will need a wide range of tests be 
performed to monitor the drug’s efficacy, while a high blood pressure drug would 
require far less. The outputs generated for each clinical trial are presented below in 
Table 3.8. These values are then exported to the database to perform further analysis.
The option of performing the clinical trials in-house or contracted out was 
incorporated by having two different blocks. The user had the options of setting the 
strategy that was followed for doing the clinical trials in-house or contracted out. In 
the default setting within the tool it was set to contract out the drug in the instance 
where the internal resources (personnel) were occupied with a different clinical trial. 
If that setting is not applied, the drug candidate will continue to wait until the 
resources are made available and this waiting time will be measured and added onto 
the clinical trial time.
Table 3.8 Outputs generated from the clinical trial stage of the pathway component 
Outputs from the clinical trial stage 
Total cost of the clinical trial 
Total duration of the clinical trial
At the end of the clinical trials, the successful drug would pass onto the next phase or 
if the Phase III trials were completed, the drug would be launched into the market 
after the regulatory review period. The option of drug failure occurring due to the 
drug not meeting the expected efficacy and toxicity levels was simulated once the 
clinical trials were completed. Once a drug fails, the simulation of that particular 
drug will stop at that position, while the other drugs in the portfolio will continue 
along the pathway.
3.9.3 Market component of the tool
Drug candidates that complete the development successfully are launched into the 
market. The many activities that are involved in the sales effort of the drug that has 
been launched are simulated within this section of the tool. At the beginning of the 
market simulation, the specific attributes are assigned to the drug (Table 3.9).
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Table 3.9 Attributes assigned for the simulation of the market performance 
Attributes assigned 
Patent length of the drug (years)
Potential patient population 
Price per treatment 
Marketing cost factor 
Sales pattern 
Cost of goods
The cost of goods per gram was used to account for the manufacture of material for 
the market, as is the case in the industry (personal communication, Steve Froud, 
Lonza Biologies, Slough, UK). Once the development process is over, the patent 
time left in for the drug is calculated. During this time period, no similar drugs are 
simulated within the market. The option of applying different sales patterns was 
made available to the user and this included the possibility of introducing a 
competitive drug. The marketing cost factor refers to the percentage of the annual 
revenue reserved for marketing and administrative costs.
3.9.4 Resources component of the tool
Modelling the resources that individual tasks require was achieved by defining a 
resource pool, which represents a set of available resources and resource queue 
blocks, which associate a particular resource with a particular task in the simulation 
model. Access to the resources was made available to all the tasks in each level of 
the pathway component. The option of prioritising the allocation of resources was 
incorporated and allowed the user to decide whether to use it or not. Resource usage 
relationships were then defined for each task so that they could draw upon the 
associated resource pool to simulate the consumption and renewal of resources, 
simultaneously constraining the model.
The resources include the personnel, facilities and capital for drug development. 
Since Extend already had resource and resource queuing blocks, they were 
customised to be placed in the tool. The resource queuing block, within which drug 
candidates would await resources, had the ability to calculate the waiting time for
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resources and then allocate the resources as soon as they became available. The 
attributes of the resources were all set to be company specific attributes.
3.9.4.1 Personnel
The personnel were divided into different pools according to the tasks they were to 
perform. These categories being process development, manufacture of material, 
management of clinical trials and sales. When a task has to be performed, for e.g. 
process development work, the demanded number of personnel would be allocated to 
the drug candidate for the required time period and then returned to the pool after the 
task has been completed. Within a pool of one type (e.g. process development) there 
was no further breakdown of personnel into sub-categories, for example biochemical 
engineers, chemists etc. For each of the human resource pools the attributes assigned 
were number of people, cost per person and the availability.
3.9.4.2 Facilities
Facilities are required for process development work to be carried out as well as 
manufacturing of material. For simplicity and flexible operation the facilities were 
modelled using capacity, cost and availability attributes. For the manufacturing 
facility an associated fermentor capacity, cost of the facility and whether the facility 
was available for use or not at any given point of time was specified. The research 
facilities were associated with a cost. The cost and the depreciation of the facilities 
were taken into consideration when the overall costing of the drug development 
process was made. These are presented in Chapter 4. The ability to make additional 
investments in the facilities was incorporated into the tool. This allowed the user to 
model facility expansion during a simulation. A maintenance cost was assigned to 
the facilities for the time period when they were not in use.
3.9.4.3 Capital
The capital refers to the quantity of money available for all the activities. The capital 
pool is available to pay for the different tasks in the drug development process. Once 
the task has taken place, the request for payment would be made to the capital 
resource pool. The drug candidate would not be released until the capital was paid. 
Once a drug is launched into the market, the revenue generated is paid into the 
capital pool, enabling the company to perform further work on the drugs that are still
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in the development process and require capital. All capital requirements were set to 
be handled by one capital pool on a first-come-first-served basis. As with other 
resources, the option of setting priorities for allocation was set up in case the user 
required doing so. The capital resource pool can be updated at the beginning and at 
any point of the simulation.
3.9.5 Database component of the tool
The database was used to export inputs into the tool and store the outputs of the tool 
as well as perform further analysis work. A Microsoft Excel spreadsheet was used as 
the database. Data import and export blocks provided by Extend allow data to be 
transferred between the tool and Excel spreadsheets. Before each simulation the 
inputs for that particular simulation is entered into the Excel spreadsheet. As the 
simulation is progressing, the outputs generated are exported into the database.
3 .10  R e p r e s e n t in g  u n c e r t a in t ie s  in  p a r a m e t e r  v a l u e s  
As explained in Chapter 2, much uncertainty and risk is present in the process of 
developing as well as marketing a drug. Uncertainties in drug development are 
associated with factors such as yields, costs, durations, clinical success, price and 
patient population. Traditional project appraisals tend to be deterministic where 
uncertainties are not dealt with explicitly. By incorporating the effects of risk, the 
functionality of the tool was enhanced as it enabled the certainty associated with 
output measures to be expressed. Once the key uncertainties are identified, 
probability distributions can be assigned in order to reflect the risk of a proposed 
strategy. Historical data and expert opinion was used to identify suitable 
distributions. Monte Carlo simulation technique is used to determine resulting 
frequency distributions of the output measures.
Extend allows a wide variety of distributions, both continuous as well as discrete to 
be applied (Figure 3.7). For each of the distributions, arguments (e.g. mean and 
standard deviation for normal distribution) are set before the simulation starts. This 
allowed the possibility of setting the type of distribution that best described each 
parameter during simulation studies. For example, the sales pattern could be 
described using a normal distribution whereas the variation of the cost of process 
development could be specified using a triangular distribution. Probability
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descriptions of input variables and Monte Carlo sampling together provide a practical 
method of finding the distribution of the desired output given the various random and 
deterministic input variables (Farid et al., 2001; Coates and Kuhl, 2003).
Set A (1)
Random Number Generator Block
Distribution Normal
(1) Mean = 0.8 ^
(2) Std Deviation = 1
Empirical Table
Exponential
Integer, Uniform
Logarithmic
Lognormal
Real, Normal
Triangular
Weibull
More...
F igu re 3 .7  Schematic representation of the application of distribution probabilities to 
parameters. The distribution is applied via a ‘Set Attribute’ block.
3.11 C o n c l u sio n s
The research and programming decisions made in order to construct a prototype tool 
to model the process of drug development have been presented. The modelling 
approach developed and adopted in this thesis allows modellers to capture effectively 
both the risks and rewards in the process of biopharmaceutical drug development 
process. The process of building the simulation model allows better understanding of 
the process of drug development. During data gathering, the areas in which high 
uncertainty exists can easily be identified. This process brings together personnel 
from different areas of expertise such as process development, manufacturing, 
clinicians, accountants and all levels of management. The simulation results can then 
be used to build consensus amongst decision-makers.
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The framework allows alternative management strategies to be prototyped before 
being implemented in the process of drug development. The hierarchical framework 
is modular and extensible allowing further levels of detail to be added as required. 
Hence, users interested in obtaining an overview of the key performance metrics in 
the process may simply model the higher-level activities. Alternatively if a user 
requires modelling only the process development activities, then the simulations 
could be run using only that section of the tool. As with any applications package, 
the tool can evolve as new problem features become apparent. The next chapter 
describes the functionality of the prototype tool and the data that is been used as 
default data.
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O p e r a t io n  o f  t h e  t o o l
4.1 I n t r o d u c t io n
The previous chapter presented the design and implementation of the prototype tool 
to model the biopharmaceutical drug development process. This chapter describes 
the different ways in which the tool can be applied to assist decision-making in the 
process of drug development. The method of operating the tool and the default data 
used are also discussed. Given the level of uncertainty and risk in drug development, 
the ability to prototype different strategies for drug development will help to contain 
cost and minimise losses due to drug failure at different stages in the development 
pathway.
A tool such as the one developed in this thesis and that combines the 
biopharmaceutical drug development activities (e.g. process development, 
manufacturing and the clinical trials etc...) with the resource flows (e.g. cash, 
facilities, personnel etc...) has not been presented in the literature.
The ability to model and evaluate the impact of process and business options within a 
company could greatly enhance decision-making and improve the economics of new 
drug development (Karri et al., 2001). A typical example might be that the early 
planning of development tasks and the appropriate allocation of resources will help 
the company to identify resource bottlenecks and act upon them early.
The utility of the tool is first discussed in general in Section 4.2. Next, the steps 
involved in setting up a simulation and running it is discussed along with the key 
inputs and outputs of the tool (Section 4.3). This is followed by the description of the 
data that is being used for the case studies in this thesis in Section 4.4. The chapter 
ends with a set of conclusions in Section 4.5.
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4.2  T o o l  u t il it y
As described in Chapters 1 and 2, the process of drug development is a costly and 
lengthy one where failure may occur at any point. The developed tool has the blocks 
required to simulate the process of drug development at differing levels of detail. A 
tool such as this one could be utilised to explore the different strategies used in 
managing the development process of biopharmaceuticals. The main features of the 
tool include the ability to:
• Prototype the biopharmaceutical drug development process at strategic, tactical 
and operational levels;
• Identify the key parameters and business issues in the drug development process 
and model them;
• Evaluate the risk and reward of different strategies in the process of drug
development by simulation and measuring specific outputs from the model;
• Select the optimum portfolio for a small to medium-sized company, operating 
under a given level of resources.
The different strategies the simulation model is able to address are:
• Resource decisions -  e.g. how many process development staff should be
deployed and for how long for the process and product development activities to 
be completed;
• Scenario analysis -  e.g. what should be the best price for the drug and what level 
of patient population should be captured in order to break-even;
• What is the best manufacturing strategy -  e.g. should an investment be made on a 
facility for in-house production and if so when;
• Product portfolio selection -  e.g. for a given level of resources available to the 
company what are the products that should be taken in for clinical development.
In Chapter 5, the application of the tool to investigate resource allocation and 
scenario analysis is presented. Also included in the same chapter is a case study in 
which two different strategies regarding the manufacture of material is prototyped. 
Chapter 6 describes the application of the tool to select the optimal portfolio from a 
set of available drug candidates under resource constraints. The next section 
describes the steps involved in operating the tool.
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4.3  U s in g  t h e  p r o t o t y p e  t o o l
4.3.1 Simulation process
Whenever a simulation is run, the simulation clock advances with the completion of 
each task and the simulation model is animated to enable the user to view what is 
happening at any point in time. The executive block keeps track of the simulation 
time. The graphical user interface of the tool is shown in Figure 4.1 This functions as 
the main operating window of the tool. Attributes of the tasks and resources are 
initialised through the use of input blocks.
During a simulation run, the model is animated to enable the user to view the 
occurrence of events at any given point in time. Animation features enable the 
visualisation of the flow of items (for e.g. drug candidate) throughout the simulation 
run and aids in the de-bugging process for the developer. The use of discrete event 
modelling gives the capability to view the time-based behaviour of the system and 
makes it possible to track the values of time-dependent parameters such as cost and 
resource usage (Lim et al., 2004).
4.3.2 Decision points
The generic model was set up with a standard number of decision points along the 
drug development pathway. Each decision point provides an overview of the issues 
involved in a decision and the options available. When running simulations, the user 
had the option of making modifications according to the case study. Figures 4.3 to 
4.6 show the main decisions and the options available for a drug proceeding along 
the pathway.
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Figure 4.1 The graphical user interface. The executive block is located at the top left 
hand comer of the interface. The active blocks (for example the Pathway block for 
this simulation) are highlighted during the simulation.
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Figure 4.2 Layout of the blocks of the manufacturing options. The decision to 
manufacture the material in-house or contract out is made at the decision point.
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Figure 4.3 Main decision points and options for Phase I in the drug development 
pathway. Probability distributions assigned decide which of the values, x, y or z is 
selected for each simulation run.
104
OPERATION OF THE TOOL
START PHASE II
NO
YES
NO
YES
YES
ILINICAL TRIAL! 
IN-HOUSE? NO
YES
ABANDON
PROJECTNO
/ / P H A S E  l l \  
MANUFACTURE 
.IN-HOUSE?/
//P H A S E  II \  
MANUFACTURE 
\  ON TIME? /
DELAY IN 
MATERIAL 
DELIVERY?,
Clinical trials
SUCCESSFUL?
x MONTHS
NO-P DELAY
x MONTHS y MONTHS y MONTHS z MONTHS
PHASE II CLINICAL TRIALS
PHASE II CLINICAL 
TRIALS 
OUTSOURCE
PHASE II 
MANUFACTURE 
OF MATERIAL
PHASE II 
PROCESS & 
PRODUCT 
DEVELOPMENT
PHASE II 
MANUFACTURE 
OF MATERIAL 
OUTSOURCE
YES
PHASE I
Figure 4.4 Key decision points of Phase II in the drug development pathway. The 
user has the options of changing the number of options or the values (x, y and z) 
according to the case study. For a deterministic simulation, the default values entered 
will be used.
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Figure 4.5 Key decision points of Phase III in the drug development pathway. The 
decision regarding whether to build a facility is included in the options available as it 
is at this stage that this question has to be addressed by the decision-makers.
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Figure 4.6 Decision points in launching a drug in the market after successful 
completion of Phase III. By assigning probability distributions and running Monte 
Carlo simulations the uncertainty in the drug pricing and the market share captured 
was modelled.
4.3.3 Inputs and outputs of the model
The key inputs to and outputs from the tool are discussed below and summarised in 
Figure 4.7. As described in Chapter 3, an Excel spreadsheet was used to input data as 
well as collect the data generated by the tool and performs further analysis. Setting 
up a simulation of a drug development process involves specifying the resources of
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the company and the estimated attributes of the drug candidate. Factors and rates 
such as taxes that are to be used in calculating various profitability indicators (e.g. 
revenue, NPV) have then to be specified. When performing Monte Carlo simulations 
the probability distributions have to be defined. These could be selected from a 
default Extend file or be defined by the user. Next, the user has to define the strategy 
that is being applied. For example, the decision to manufacture the material in-house 
or to contract out has to be set accordingly (Figure 4.2).
After a particular case is set up the impact of different development strategies on the 
value of the portfolio of drugs can be assessed. The key outputs are the cost and time 
values of different tasks and the net present value (NPV) of the portfolio (Figure
4.7). All the data that is generated during a simulation are held in separate categories 
according to the point of origination. For example, the data regarding Phase I 
development is kept separate to Phase I manufacturing data. These values are then 
added to give totals for each activity (e.g. total development cost across the pathway) 
and phase (e.g. total manufacturing cost for Phase I). Calculations to perform further 
analysis on the outputs of the tool were carried out on the Excel spreadsheet 
receiving the initial information. Figures 4.8 and 4.9 present the user interface for the 
inputs and outputs of the model.
An example of one of the outputs of the application is the utilisation of the process 
development personnel over a selected period of time (Figure 4.10). These utilisation 
figures can be used to compare the demands on resources under different strategies 
or for different portfolios of drugs. This will lead to identifying strategies that 
maximise resource utilisation to improve productivity and reduce the time to market. 
One of the key outputs of the model was the net present value (NPV) of the portfolio 
for each year of operation. The calculation steps and the assumptions for the NPV 
calculation are presented in Section 4.4.2.
108
OPERATION OF THE TOOL
Company Resources
Resource Requirements by
Tasks
Estimated Data for 
Drug Candidates
Cost Data
M arket and O ther Financial 
Data
Strategy
Tool
M anufacturing Data
Resource Utilisation 
Profiles
Time to M arket
Cost of Drug 
Development
Portfolio NPV 
Risk Profile
Figure 4.7 Inputs to and outputs from the tool. The key inputs are the tasks, 
resources, costs and strategy. The key performance measures are cost, time to 
market, resource use profiles and portfolio NPV.
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Figure 4.8 View of the user interface to input estimated values of drug candidates, 
the company resources and market data. An Excel spreadsheet was used as the user 
interface for data input and output.
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F ig u r e  4 .9  View of the user interface for the outputs of the tool. The different 
outputs from the model are stored within different categories. Further analysis, for 
example, NPV calculations are carried out within the spreadsheet and the user can 
view these while the simulation is being carried out.
4 .4  D a t a  c o l l e c t i o n
Part of the work involved in preparing a tool for prototyping drug development is to 
collect data to populate the model and verify the outputs. Using default data to 
populate the model is a powerful feature of the software tool. This section describes 
process of data collection and presents the data that were used as estimates and 
default values in the case studies that were carried out to demonstrate the application 
of the tool in Chapters 5 and 6. The prototype tool described can be applied to 
simulate the development of any type of biopharmaceutical. The development 
process of monoclonal antibodies (MABs) was selected for the case studies presented 
in this thesis. Between 2001 and 2002, the value of the global therapeutic MAB 
market grew by 37% to USS 5.4 billion and to date, 17 therapeutic MABs have been 
approved by the US FDA with 132 more products currently in clinical development 
(Reichert and Pavlou, 2004). The global market is projected to increase to USS 16.7
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billion by the year 2008 with two major approval waves being expected during the 
next five years (Reichert and Pavlou, 2004).
A substantial amount of data was collected regarding monoclonal antibody 
development, manufacture and marketing. The key assumptions were mostly derived 
from literature and validated via discussions with industrial experts (Rebecca Paulraj, 
Steve Froud, Lonza Biologies, Slough, UK; Brendan Fish, Cambridge Antibody 
Technology, Cambridge, UK; Peter Ketelaar, DSM Biologies, Groningen, 
Netherlands; Dr. J Hettiarachchi, Pfizer, New York, USA; Dr. Bill Hornby, 
University College London, UK; R. Francis, Protherics, London, UK; A. Sinclair, 
Biopharm Services, Chesham, UK). While sensible inputs were sought, the prime 
target was to demonstrate the application of the tool to model the process of drug 
development.
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Figure 4.10 Example of a key output of the tool, resource utilisation profile. This 
particular example illustrates the number of people required during process 
development of a drug portfolio, where peaks and bottlenecks can be identified for 
resource allocation planning.
4.4.1 Input data for case studies
This section presents the data that has been used as inputs for case studies in 
Chapters 5 and 6. A six-drug candidate portfolio was assembled with the information
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gathered. A portfolio of three drug candidates is used in Chapter 5, while the full 
portfolio of six drug candidates is featured in the Chapter 6 case study. Any changes 
to the inputs made, such as assigning distributions in place of point estimations have 
been highlighted and described at the point of doing so within each of the case 
studies.
4.4.1.1 The portfolio
The drug portfolio consisted of six monoclonal antibodies, which were different to 
each other in type and therapeutic area (Tables 4.1 and 4.2). The drug-specific 
attributes for the 6 antibodies were based on historical data for commercial 
antibodies (Farid, 2001). These drugs have been modelled as breakthrough drugs in 
their respective therapeutic areas.
Table 4.1 Description of the drugs in the portfolio (Farid, 2001)
Drug Typical Typical price/ Typical Potential Potential
cumulative patient/ unit selling annual US annual US
dose/patieut treatment price market demand
(mg) ($) ($/g) (# patients) (kg)
A 30 1,690 56,300 309,600 9
B 5,740 33,350 5,800 12,800 73
C 1,050 7,590 7,200 54,000 57
D 3000 15,000 5,200 68,000 205
E 70 4,200 60,000 7,300 0.5
F 40 3,160 79,000 15,400 1
Table 4.2 Drug type and therapeutic category (Farid, 2001)
Drug MAB type Therapeutic area
A Chimeric Clot prevention in PTC A*
B Humanised Breast cancer
C Chimeric Crohn’s disease
D Chimeric B-cell non-Hodgkin's lymphoma
E Murine Organ transplant
F
*
Chimeric Organ transplant
tt~—------------------- ---- - ---------------------------------------------------------------------------------------------
PTC A - Percutaneous Transluminal Coronary Angioplasty
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4.4.1.2 Company
As described earlier the company that was used for this case study was modelled as a 
small to medium scale company that had its own defined level of resources and 
manufacturing facilities (Table 4.3).
Table 4.3 Company attributes modelled and their values
Attribute Value
Capital available ($) 900, 000, 000
Patent life (years) 20
Investment in facility ($) 13,000, 000
Personnel available for development work 60
Personnel available for manufacture 50
Personnel available for clinical trials 50
Cost per person per month ($) 10,000
Fermentation capacity (1) (L) 12,000L
Fermentation capacity (2) (L) 600L
Cost per batch (PI) ($) 2,000,000
Cost per batch (PII, PHI) ($) 1,500,000
Cost per gram (market production) (USS per gram) 1,500
Along with the above data the different tasks, resource requirements and the 
expected timelines for each of these drugs in the development process were then 
defined within the database. A cost of US$ 6.7 million was assigned to each drug to 
account for discovery and pre-clinical phases (Myers and Howe, 1997).
The costs of manufacturing (cost per batch and cost per gram) were estimated 
through discussions with industrial experts (personal communication Rebecca 
Paulraj; Steve Froud, Lonza Biologies, Slough, UK; Peter Ketelaar, DSM Biologies, 
Groningen, Netherlands). The investment for the facility was determined through a 
method suggested by an industrial expert (personal communication, Vaughan 
Thomas, SciTech Engineering, Guildford, UK).
Cost of facility (US$ million) = fermentation capacity (L)* 0.0017 + 10.79
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4.4.1.3 Process development
All three monoclonal antibodies were manufactured using a mammalian cell based 
process. The development work therefore would involve:
• Establishment of the cell line and characterisation.
• Process development and validation.
• Documentation etc...
The research and development personnel and the facilities have to be allocated to 
each candidate according to its demand. Where specific data was not available, 
default data was used and these were kept the same for all the drug candidates for the 
case study in Chapter 5. In the Chapter 6 different resource requirements were 
assigned to the six drug candidates. The manner in which these changes were applied 
is described in Chapter 6 and the data used is presented in Appendix 1.
Table 4.4 Resource requirements and time taken for process and product 
development for the three phases in drug development
Number of personnel Time taken Cost
required per drug (months) (USS million)
PI PII PHI PI PII PIII PI PII PHI
30 30 30 24 12 12 3 4 5
4.4.1.4 Manufacture of material for clinical trials
a) In-house manufacture
The resource requirement for the manufacture of the drugs within the portfolio is 
presented next. The production was modelled as a batch process. Again the data was 
changed for the Chapter 6 case study.
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Table 4.5 Manufacturing data for the three monoclonal antibodies during 
development phases
Drug Number of personnel Quantity required Mass per batch
required (g) (g/batch)*
PI PII PHI PI PII PHI PI PII PIII
A 30 30 30 10 300 1,000 96 300 630
B 30 30 30 300 650 4,000 192 600 1,260
C 30 30 30 10 300 2,500 96 300 630
D 30 30 30 50 470 450 96 300 630
E 30 30 30 1 5 19 96 300 630
F 30 30 30 5 8 15 96 300 630
The mass per batch values were based on the company using a fermentor with a 
capacity of 600 L for all the drugs except drug B. As drug 2 required products in 
higher quantities a fermenter of 1200 L capacity was used. The assumptions that 
were used to calculate the mass per batch are presented in Table 4.6.
Table 4.6 Assumptions for calculating the mass per batch for the three phases
Phase Titre (g/L) Yield (%)
P I 0.4 40
PII 1 50
PIII 1.5 60
b) Contract manufacturing organisation
The activities of the contract-manufacturing organisation (CMO) were modelled to 
allow the company to outsource some of the development work and the 
manufacturing of material for the clinical trials and the market. The cost and time 
data regarding the manufacturing of material through a CMO (Table 4.7) were 
compiled from literature (Nicholson and Latham, 1994; Seaver, 1995) and through 
discussions with industrialists (personal communication Rebecca Paulraj; Steve 
Froud, Lonza Biologies, Slough, UK; Peter Ketelaar, DSM Biologies, Groningen, 
Netherlands).
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Table 4.7 Attributes and values for the contract-manufacturing organisation
Attribute Value
Negotiation time (months) 3
Cost per batch (PI, PII, PIII) ($) 970,000
Cost per gram (market production) ($/gram) 2,700
Batch time (PI, PII, PIII) (months) 2
Development cost (PI) ($) 960,000
Development cost (PII) ($) 150,000
Development cost (PIII) ($) 150,000
4.4.1.5) Clinical trial inputs
a) In-house clinical trials
The estimates of the resource requirement for the clinical trials at each phase are 
presented next. Default data was used for the cost and the number of personnel 
needed to mange the clinical trials. The number of patients was collected from the 
public domain (e.g. http://www.gene.com/gene/pipeline/trialsA and a database 
maintained at UCL. Default values were used for the clinical trial length values, 
which were estimated from literature (DiMasi, 2003; Stewart et al., 2001) and 
validated through conversations with industrial experts (personal communication 
with Rebecca Paulraj, Steve Froud, Lonza Biologies, Slough, UK; Dr. J 
Hettiarachchi, Pfizer, New York, USA). An average value of 6.5 months was 
included in the Phase III clinical trials to account for the approval time (Reichert, 
2000).
Table 4.8 Clinical trial data used for the simulations
Drug Number of Number of patients Cost per patient
personnel ($/patient)
required
PI PII PIII PI PII PIII PI PII PIII
A 40 40 40 79 56 1,300 30,000 50,000 60,000
B 40 40 40 120 82 2,700 30,000 50,000 60,000
C 40 40 40 10 152 2,300 30,000 50,000 60,000
D 40 40 40 35 114 3200 30,000 50,000 60,000
E 40 40 40 8 33 1500 30,000 50,000 60,000
F 40 40 40 105 200 2000 30,000 50,000 60,000
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Table 4.9 Clinical trial durations
Clinical trial duration (months)
PI PII PIII
12 18 24
b) Contract research organisation
The activities of the contract research organisation (CRO) were modelled to allow 
the company to contract out the clinical trials if required. The costs include that of 
the physicians, the analysts and the tests needed to conduct the trials. These were 
compiled through literature (DiMasi et al., 2003) and discussions with industrial 
experts (Rebecca Paulraj, Lonza Biologies, Slough, UK; Dr. Bill Hornby, University 
College London, UK; Dr. J. Hettiarachchi, Pfizer, New York, USA). The durations 
were kept the same as the in-house values.
Table 4.10 Clinical trial cost estimations
Attribute Phase I Phase II Phase III
Cost per patient ($) 30,000 70,000 70,000
4.4.1.6) Failure at clinical trials
One of the biggest practical problems in applying decision analysis is that of 
estimating probabilities of success (Senn, 1998). The probability for failure at 
clinical trials was based on data published by Reichert (2001). The rates of failure 
due to technical reasons were changed according to the case study and these are 
presented within the sections that describe the respective case studies.
Table 4.11 Phase transition probabilities for MABs (Reichert, 2001)
Monoclonal 
antibody type
Phase I to 
II (%)
Phase II to 
III (%)
Phase III to 
Review (%)
Review to 
Approval (%)
Murine Mabs 77 52 45 33
Chimeric Mabs 86 40 80 100
Humanized Mabs 84 72 75 100
Average 82.3 54.7 66.7 77.7
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4.4.1.7 Market
Once the drug enters the market, the tool simulates its production for the market and 
the sales pattern. The patient population data shown in Table 4.1 was used to 
simulate the market data. The sales pattern shown in Figure 4.11 was applied to all 
six drugs as the default setting. The six drug candidates used in the case studies were 
modelled as breakthrough drugs in each of their therapeutic area. Stonebraker (2002) 
makes an estimation that a new therapeutic agent in a breakthrough market can 
command 70% -  95% of the market at its peak share. Therefore the peak share for 
the drugs when they made it to the market was set at 80% (Figure 4.11).
80
Market Share
(%)
2 6
Year in market
Figure 4.11 Sales pattern applied to each drug once in the market (Myers and Howe, 
1997; Stonebraker, 2002).
4.4.2 Net present value
One of the key outputs of the tool was the net present value (NPV) of the portfolio 
(Table 4.12). A depreciation rate of 11% was used for the NPV calculations (DiMasi 
et al., 2003). The tax was set at 33% and the discount factor (r) was set at 9% (Myers 
and Howe, 1997). At the end of each year the model will output the year’s expenses 
and revenues in order for the NPV calculation for that year to be performed. All 
expenses regarding building new facilities were taken into account when performing 
the NPV analysis. A pay back period of ten years was used for any loans taken for 
expanding facilities. The interest for the loans was based on the loan interest rates of 
the Bank of England and was set at 7%.
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Table 4.12 Steps for calculating the portfolio NPV for each year of operation
Year (t)
Category 0 1 2 . . . n
A. Total capital investment
B. Revenue
C. Running costs (without depreciation)
D. Profit (B-C)
E. Depreciation
F. Taxable profit (D-E)
G. Tax (33% of F)
H. Net cash flow (-A+B-C-G+E)
I. Discount factor ( — -— )
(1 + A
J. Annual present value (H*I)
n
K. Net present value ( ^  J , )
/ =  0
4.5  C o n c l u s io n s
This chapter has provided an overall discussion of the of the tool operation. The main 
uses of the tool and the way in which it can be used to assist in decision-making have 
been highlighted. Flow diagrams have been used to demonstrate the typical decision 
points that can be simulated in the process of drug development. Inputs into the 
model and the outputs from the tool have been summarised to provide an 
understanding of the capabilities of the tool. Much work has been put into collecting 
data that can be used as default data for the simulations. These have been presented 
along with other assumptions made.
The company-and drug-specific business and process characteristics all have been 
captured successfully and the resulting model is able to compute the time-to-market, 
cost, revenue and the risk, which all feature in the decision-making process. 
Simulating a portfolio of drugs and their development activities provide the 
management with the capacity to explore, in-silico, different strategies and to use the
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insight gained to make real-life decisions that would add value in both short and long 
term to the new product portfolio of the company. The application of the tool is 
demonstrated through two case studies in the next two chapters.
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C h a p t e r  5
A p p l ic a t io n  o f  t h e  t o o l  t o
EXPLORE ALTERNATIVE 
DEVELOPMENT STRATEGIES
5.1 In t r o d u c t io n
Drug development under uncertainty is a challenging task for any biopharmaceutical 
company. The development work and the manufacture of material for clinical trials 
have to be planned so as to maximise the use of finite resources and capacity and to 
avoid delays in time to market. This would help to get the drug(s) first into the 
market and maximise the returns on investment. The aim of this thesis section is to 
demonstrate the tool’s application during planning can help in deciding the 
development strategy for a portfolio of drugs. This tool can be utilised to help 
planning the allocation of resources and explore alternative strategies for executing 
the development work. The uncertainty and risk of failure is taken into consideration 
when applying the tool to aid decision-making. Several case studies will be used to 
illustrate the above applications.
Initially, in section 5.2 a brief description into the type of decisions that are made 
during drug development under uncertainty is presented, along with some examples 
from industry about the implications of these decisions. In Section 5.3 the 
background to the case studies is described which addresses the development of three 
monoclonal antibodies (MABs). In Section 5.4 a deterministic analysis of the 
problem is presented. The uncertainties in the problem are then identified using a 
sensitivity scouting analysis in Section 5.5. To demonstrate the decision-making 
objective of the model, a set of scenario analyses is carried out in Section 5.6. Finally 
in Section 5.7, Monte Carlo simulations are then used to imitate the randomness 
inherent in drug development. The case study involves deciding the best strategy for 
a small to medium size company considering whether to risk building a facility for
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the commercial manufacture of the antibodies and if so, when, or whether to rely on 
a contract manufacturer for material for the clinical trials as well as for the market.
5.2 P l a n n in g  a n d  m a n a g in g  b io p h a r m a c e u t ic a l  d r u g  d e v e l o p m e n t  
During the early stages of drug development, there is much uncertainty regarding 
almost every aspect of the development process. Strategic planning and efficient 
execution of drug development programmes are both desirable and necessary given 
the realities, economics, and regulatory requirements for approval of a drug or a 
biologic compound (Bernstein and Hamrell, 2000). Belated analyses of projects, 
which have been initiated without rational planning, could end up costs significantly 
exceeding anticipated revenues (Fisher and Pascucci, 1996). In the initial assessment 
of a new drug candidate, a series of estimates are made by experts in each field to 
predict its value to the portfolio (Johnson, 1998; Stonebraker, 2002). These range 
from predictions in dose levels to patient population captured by the drug and would 
also include estimations on cost and time scales. These forecasts are subject to 
uncertainty. Being better prepared to address these uncertainties will allow the 
company to deal with the risk that is present within a portfolio of new drug 
candidates.
The uncertainties could be technical or market related. Examples of technical 
uncertainty include dose levels and process efficiency. Market uncertainties relate to 
drug pricing and patient population share captured by the drug if and when it is 
launched. Given the varying resource requirements during the entire development 
process, it is vital to know in advance how much of these resources are required and 
when the need would arise. This would help to contain the cost of drug development, 
decrease time to market and minimise the negative impact of drug candidate failure.
Companies look to increase the value of portfolios in two ways (Keelin and Shew, 
2003). In the short term, the investor confidence has to be boosted, while in the long 
term the expected net present value of the product portfolio has to be increased. By 
having a fixed and clear strategy for the management of the portfolio, the 
stakeholder’s value is increased in the short term. Decisions regarding future work 
have to be geared to increase the portfolio NPV.
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There are numerous methods for taking uncertainty into consideration. Sensitivity 
analysis is often used to determine the behaviour of performance measure to ± x % 
changes in each uncertain factor and hence determine the stability of the base case. 
For more sophisticated problems, where it is possible to assign probability functions 
for uncertain factors, the Monte Carlo simulation technique is a practical way of 
determining the impact of project uncertainties. Monte Carlo simulation is an 
analytical technique in which a large number of simulations are run using random 
quantities for uncertain variables and looking at the distribution of results to infer 
which values are most likely.
Scenario analysis is a process of analysing possible future events by considering 
alternative possible outcomes (scenarios). The analysis is designed to allow 
improved decision-making by allowing more complete consideration of outcomes 
and their implications. For example, scenario analysis can be used as a tool for 
manufacturing capacity planning for fluctuations in dose levels. Two way sensitivity 
analysis using contour plots is used in this chapter for the scenario analysis.
The final part of the section of the case study in this chapter revolves around the 
decision whether to invest in a facility or not and if doing so, when it is best to make 
that investment. Having a robust manufacturing strategy will contribute to the 
company’s competitiveness (Demeter, 2003). Once a drug receives approval to be 
launched in the market, it is of vital importance to have sufficient manufacturing 
capacity to cater to the demand of the patient population. Not having this capacity 
would result in the loss of revenue. The best of example of this is Enbrel (rheumatoid 
arthritis, Amgen and Wyeth, USA), where the projected revenues for 2001 were in 
excess of US$ 1 billion (Grimster, 2003). However as the material was in short 
supply due to delays in the availability of the Rhode Island plant, the sales were only 
around US$ 750 million. This delay of material also resulted in the competitor 
product Remicade (Centocor, USA) gaining market share. The set up of the case 
study is presented next.
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5.3  C a se  s t u d y  b a c k g r o u n d
A hypothetical case study that examines the use of the tool to plan and manage the 
development of a biopharmaceutical drug portfolio is presented next. The example is 
based on a company that has three potential products, all monoclonal antibodies 
(MABs), in its portfolio that are ready to go into clinical development. Although all 
three drugs are MABs, they are of different therapeutic classes with differences in 
the doses and the market sizes. This allows the portfolio to be diverse and makes the 
decisions relevant and challenging. The company was modelled as a small to 
medium size organisation, which had finite resources and defined manufacturing 
capacity.
Initially a deterministic case was set up and validated to ensure the outputs were 
calculated correctly. The cost, time to market and the portfolio NPV for a portfolio of 
three drugs were computed. Using these values as the base case, a sensitivity analysis 
was then carried out to determine the key parameters that affect the net present value 
(NPV) of a portfolio of biopharmaceutical drugs in development. Once this had been 
done, a series of scenario analyses were carried out to demonstrate the use of the tool 
to capture the effects of uncertainties in drug development. Finally, the tool was used 
to test out three different strategies for the manufacture of material for clinical trials 
and the market.
5.4  In it ia l  d e t e r m in is t ic  a n a l y s is
This section describes the key features of the process of drug development. The 
output data from the simulation of the portfolio of three drugs are discussed. These 
results give an understanding of the capabilities of the tool in simulating alternative 
strategies during the process of clinical development of drug candidates.
5.4.1 Setting up the deterministic case
The software tool developed in Chapter 3 was used to model the process of 
developing three drug candidates from the start of Phase I to the market. As 
described in Chapter 3, each phase of development was broken down into the 
following activities: development, manufacture of material for clinical trials and the 
clinical trials. In addition, the performance of an approved drug in the market was
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simulated for the remainder of its patent life. The input data presented in Chapter 4 
was used for this case study. Only the first three drugs were used in the portfolio.
5.4.2 Deterministic results and discussion
5.4.2.1 Cost and time to market of drug development
Several simulations of drug development were carried out and the results are 
presented in this section. The cost and time to market are key factors in decision 
making in the process of drug development. The first set of results was generated to 
calculate the cost of the portfolio and the time to market for the three drugs in it for a 
set level of resources. The chance of failure and the uncertainties were not 
considered in the deterministic run. This was in order to establish the costs and time 
lengths involved in developing this set of drug candidates.
Out of the portfolio of three drugs simulated, the costs and time for a single drug are 
presented in Figure 5.1. The total cost to develop one drug was calculated by the 
model to be US$ 334.4 million (2002 US$). DiMasi et al. (2003) concluded in a 
detailed study that the cost of producing a drug to be US$ 404 million (2000 USS). 
However DiMasi et al. (2003) used mainly chemical entities for his study and the 
value presented is an average value. Therefore a direct comparison is not entirely 
correct. Also, the value calculated by the tool is for a specific drug and not an 
average value. Figure 5.1b shows the time taken for the development process. The 
longest phase is the third phase as it has the longest clinical trials involving over 
2000 patients. Reichert, 2000, calculated the average time to market value for a 
MAB developed during 1991 to 1999 to be 7 years (82 months). The value calculated 
by the tool, 7.8 years compares favourably with this value. The cost and time values 
depend on the type of drug and the therapeutic area (Reichert, 2000).
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Total Cost - US$ 334 Million Total Time - 7.80 Years
Phase I - 9% Phase I - 27%
jjiii^Phase II - 7%
Phase III -
Phase I I -  32%
Phase III - 84%
(a) (b)
Figure 5.1 Breakdown of the cost (5.1a) and time length (5.1b) of development of 
one drug. The Phase III is the costliest and the longest as it has the largest clinical 
trials, which involve several thousand patients to prove the efficacy and long-term 
safety of the new drug.
5.4.2.2 Resource usage
A common problem encountered by companies is how to deploy staff to ensure 
projects are completed on time. Figures 5.2a and 5.2b show how the overall demand 
on personnel increases with the size of the portfolio but also indicate points of low 
activity and high demands. Being able to predict bottlenecks and poor use of human 
resources on the basis of simulation results allows companies to plan ahead and to 
anticipate how business decisions will impact at this level. For example, when only 
one drug is in development there are periods (e.g. weeks 100 to 180) where the 
process development staff are not being used. The average utilisation for this 
simulation is 12 personnel per week. However when three drugs are being 
developed, the average utilisation increases to 36 personnel per week and during the 
weeks 0 to 100 the process development personnel usage is at its peak value. In this 
case, the peak demands on the process development staff act as a bottleneck as only 
two drugs can be developed at any time. Thus the management could take steps to 
either increase the personnel or reschedule the development work.
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Figure 5.2 Utilisation of process development staff for (a) 1 drug (b) 3 drugs within 
the portfolio. When a higher number of drugs are in the portfolio, the durations 
where all the personnel are being used can be noted and used to avoid bottlenecks.
Raising capital for drug development is a challenging task due to the uncertainty in 
the cost and the probability of failure at any time. Therefore the ability to estimate as 
accurately as possible the demand on capital in advance will aid in making better 
decisions. Figure 5.3 shows the anticipated capital flow over the first ten years of 
development for the portfolio. It provides the management the level of investment 
needed and the time the demands will occur. The spend profile shows that there is a 
large demand on the capital between weeks 300 and 450. This is due to the fact that 
all three drugs enter Phase III trials during that time interval and the first drug is 
launched at around week 480. Phase III clinical trials are the costliest and launching 
a drug involves a high investment in an exhaustive sales and promotional effort 
(Stonebraker, 2002).
Having such a demand on the capital is not the ideal strategy and the company can 
make an effort to plan the development in order to have a less demanding spend 
profile, where very large investments are needed in a short duration of time. This 
could involve licensing out a drug or acquiring a strategic partner. This type of 
output would provide valuable insight to decision-makers in order to avoid delays 
due to shortage of capital.
127
APPLICATION OF THE TOOL TO EXPLORE ALTERNATIVE DEVELOPMENT STRATEGIES
950
Capital Available 
(US$ million)
650
350
50
0 100 200 300 400 500
Time
(Weeks)
Figure 5.3 The predicted capital flow over the first ten years of the drug 
development process. Such data allows the management to anticipate the likely 
demand on capital and to plan ahead on fund raising.
5.5  I d e n t if ic a t io n  o f  k e y  u n c e r t a in t ie s
Although certain valuable conclusions can be made from a deterministic analysis, 
one cannot answer such questions as the likelihood of getting a particular drug to the 
market or of recovering the investments made during the development stages. Using 
a range of values, with their likely probabilities to estimate the future possibilities, 
rather than relying upon single-point forecasts, enhances the credibility of the 
analysis. Stochastic modelling with the Monte Carlo simulation technique was used 
to capture the degree of variability in the key influencing factors. Therefore to 
incorporate risk into the analysis, it was necessary at the outset to identify the 
variables that have the highest impact on the net present value (NPV) of the 
portfolio.
Each input was varied in turn while keeping the others constant. The % changes for 
each input are shown in Table 5.1 and were decided through literature (Stonebraker, 
2002) and by consulting industrial experts (personal communication Rebecca 
Paulraj, Steve Froud, Lonza Biologies, Slough, UK; Brendon Fish, Cambridge 
Antibody Technology, Cambridge, UK). The % change in NPV relative to the base 
case value was plotted on a Tornado diagram (Figure 5.4). This form of analysis will
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also aid in decision-making when allocating resources and planning the process of 
drug development.
Table 5.1 Percentage changes made to the different parameters from the base case 
values
Input Change to base case (%)
Market share ±50
Drug price set ±20
Time spent in process development ±50
Clinical trial time ±50
Personnel available for process development ±50
Presence of a competitor + 25
Mass per batch (In-House Production) ±50
Market manufacturing cost ±30
Product demand (Production Outsourced) +100/-50
Contract manufacturing time ±50
Product demand (In-House Production) +100/-50
The sensitivity analysis results depicted in Figure 5.4 indicate that the critical driver 
of the portfolio NPV is the size of the market captured. This is then followed by the 
price set for the drug. The results are in agreement with those by Stonebraker (2002) 
who assessed the value of a new drug candidate and concluded that the NPV was 
most sensitive to the peak product share and the price per treatment. As the time to 
market is directly influenced by the time the drugs spends in process development 
and clinical trials, these two become the next most sensitive factors in drug 
development. The faster the drug gets into the market, the more time it has to 
generate revenue before a competitor or a generic drug is introduced.
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Figure 5.4 Tornado diagram showing the sensitivity of the portfolio NPV to input 
parameters. The vertical axis intersects the horizontal axis at the base case value. The 
market share has the biggest impact on the portfolio NPV followed by the drug price.
The number of personnel available for development work acts as a constraint, 
holding back the drug until the number of personnel required is available for the 
development work to be done. Therefore the number of people affects the time to 
market value directly and is a key driver of the portfolio NPV. The number of 
personnel needed for manufacturing and clinical trials were not modelled as 
constraining factors, and therefore they do not appear in the Tornado diagram. The 
manufacturing tasks were modelled with the availability of the facility as a constraint 
and the clinical trials were always outsourced to a contract research organisation, as 
is frequently the case in industry today.
Delays in building new facilities, delays in the negotiation time and the presence of a 
competitor all have a negative effect on the NPV. Dose levels (product demand) and 
the yields do not appear to be a major factor influencing the NPV of the portfolio. 
Therefore small increases in the quantities that need to be produced do not affect the 
NPV. The relatively low cost and duration of manufacturing tasks compared to 
development work and clinical trials can be cited as a possible reason for this. The 
probabilities of failure due to technical reasons and at clinical trials are influential 
factors, but have not been included as their effects are more intuitive. Therefore all
% Change in NPV Relative to the Base Case
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these results were generated assuming there were no failures due to technical reasons 
or at clinical trials.
5.6 S c e n a r io  a n a l y s is
Following the sensitivity analysis, a series of simulations were performed to illustrate 
the application of the tool to perform scenario analysis. In each of these, two 
parameters were changed simultaneously so as to study the effect of a combination of 
inputs on the portfolio NPV. The next sections describe the areas of drug 
development explored in each scenario analysis and the impact on the value of the 
portfolio. Again, the percentage changes to the two inputs were decided by 
consulting industrial experts (personal communication, Rebecca Paulraj, Steve 
Froud, Lonza Biologies, Slough, UK; Brendon Fish, Cambridge Antibody 
Technology, Cambridge, UK; Phil Morton, Delta Biotechnology, Nottingham, UK).
5.6.1 Scenario analysis set up
5.6.1.1 Process efficiency vs. time spent in process development
Early planning of process development activities and the appropriate allocation of 
resources to each stage of a product’s clinical development can contribute 
substantially to the success of a new biopharmaceutical product and add value to the 
company (Byrom, 2000). One of the most challenging decisions that confront 
management is when to stop process development work and move forward into 
manufacturing for clinical trials.
The first scenario considered the time spent in process and product development and 
the improvements in yields achieved. The negative effects of process development 
delays can only be felt later if and when the drug gets into the market and fails to 
recover the money invested. The impact of varying the time spent in development 
(-75% to 50%) and the associated yields achieved (-75% to 50%), on the NPV was 
recorded. The results were plotted on a two-dimensional surface diagram to show 
how time in development and yields need to be balanced if an improved NPV is to be 
achieved.
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5.6.1.2 Product demand vs. manufacture time
The analysis was extended to include uncertainty in the estimated dose levels and the 
manufacturing time of product for clinical trials. The dose levels required would 
initially be estimated by clinicians and confirmed towards the end of Phase II clinical 
trials or even as late as Phase III trials. Therefore manufacturing activities have to be 
planned according to the estimated dose levels and patient numbers needed for 
clinical trials. The product demand also encompasses non-clinical uses such as 
quality control and stability samples.
Having the capacity to predict the effect of fluctuations in product demand 
throughout development provides valuable data for planning. Such a scenario also 
relates to the occurrence of manufacturing delays, which can take place for a variety 
of reasons, from facilities not being available to batch failure occurring. On a 
positive note, adoption of different production routes could result in shorter 
production cycles and increased manufacturing output. A series of simulations were 
carried out in which the product demand (-50% to 150%) and the manufacturing 
times (-25% to 75%) were varied, while keeping all other inputs constant. The effect 
of these changes on the NPV was recorded.
5.6.1.3 Drug pricing vs. market share
The drug price and the patient population captured are each crucial to achieving high 
revenues/profits and for the recovery of investments. Government regulations and 
restrictions limit a company’s ability to set the price for a new drug (Nicholson and 
Latham, 1994) and the presence of competitors means that a company needs a strong 
marketing strategy so as to capture a significant patient population and in order to 
make profits. Launching a new drug into the marketplace with the goal of achieving 
maximum penetration and exposure is an expensive advertising and public relations 
effort (Stonebraker, 2002). Therefore in the next scenario analysis, the drug price 
(±40%) and the market share (-75% to 25%) were varied to record the change in the 
portfolio NPV.
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5.6.2 Scenario analysis results
The results of the different scenario analyses detailed earlier are presented in contour 
plots, Figures 5.5 -  5.7, which explore key decisions in biopharmaceutical drug 
development.
5.6.2.1 Process efficiency vs. time spent in process development
NPV ($M)< 0
NPV ($M) 0 -1000 —  25 
A
NPV ($M) 1000 -2000
% Change in 
Time Spent in Development
-75 -50 -25 0 25 50
% Change in Yields 
Achieved
Figure 5.5 Portfolio NPV for variations in process development time and yields 
achieved. Points A, B, C and D refer to different options the management could 
deploy in planning process development work, with point A being the base case 
scenario.
Figure 5.5 illustrates the impact of variations in process development time and yields 
on the portfolio NPV. The point A marks the base case result. If the desired yields 
are not achieved by the anticipated deadlines or take longer to achieve, operation 
moves to the top left hand region of the figure and the NPV will eventually take 
negative values. Point B achieves the same NPV as A, but requires a less efficient 
process and hence less time spent in development. The resources saved by moving to 
point B can be applied to a different project. By moving to point C or D, the NPV 
will increase. In this case, the trade-off is between spending less time in 
development, resulting in either no efficiency gain (C) or an improved process (D). 
Point D gives the greatest improvement in NPV of the options considered.
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This level of insight into resource usage is not obvious at first, but very much an 
asset to decision-making when allocating resources and planning for development 
programs. The process development group can use this type of output from the tool 
to keep a check on the yields and the deadlines necessary to achieve them. If the 
management feels that the process development team is falling behind, they can take 
steps to allocate extra resources in order to keep to the schedules or implement other 
actions to redress the situation. This type of study can be used to quantify the value 
of spending time in improving process efficiency and trade this against any resulting 
reduction in the time to market for the drug.
5.6.2.2 Manufacturing time vs. Product demand
NPV 
NPV (M$) 350 -
NPV (M$) 450 • 550
100
gQ % Change in the 
Product Demand
-25 0 25 50 75
% Change in the Manufacture Time
Figure 5.6 Portfolio NPV for the variation in the quantity of material and 
manufacturing time. Changes in the product demand and the manufacturing time do 
not seem to bring about a wide change in the portfolio NPV. Point A refers to the 
base case scenario.
The NPV of the portfolio is not highly sensitive to the manufacturing time and the 
quantity of material as shown earlier in the Tornado diagram (Figure 5.4). Changes 
in NPV to variations in both the quantity of material that has to be produced as well 
as changes in manufacturing times are plotted in Figure 5.6. If the manufacturing 
time increases beyond 50% of the base case value (2 months campaign time), the 
portfolio NPV becomes quite sensitive to the manufacturing time and drops of up to
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US$100 million can be observed (point B). However an increase in the product 
demands does not influence the portfolio NPV as much as an increase in the 
manufacturing time (point C).
The above results would enable the management to feel confident about pursuing 
development work on a new drug candidate, which might have high uncertainty in 
the dose levels and plan for additional manufacturing capacity if required.
5.6.2.3 Drug pricing vs. market share
NPV ($M) 1000 - 2000
NPV
NPV ($M) 0-1000
-25 °^ ° Chan9e *n Market
Share
-40 -20 0 20 40
% Change in Price Per Treatment
Figure 5.7 Portfolio NPV for the variation of the patient population and the price per 
treatment of the drug candidate. Point A refers to the base case scenario.
The results of changing the price of the drug and the market share on the portfolio 
NPV are shown in Figure 5.7. As the process of drug development is driven by the 
profits achieved in the market, it is important to gauge the effects of such 
fluctuations. The portfolio consisted of a set of breakthrough drugs (A). Lower 
market capture and an inability to command a high price could shift the portfolio 
NPV to point B, resulting in a negative NPV. The above results could be used to plan 
the sales strategy and make judgement on which markets to launch the drug. If the 
company feels that there is too much competition or the drug is too expensive to get
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approval from the authorities, using this type of scenario analysis the project could 
be terminated at an early stage or be held back.
5.7 In - h o u s e  v s . c o n t r a c t  m a n u f a c t u r in g
The sensitivity analysis was used to identify the key uncertainties in Section 5.4. The 
major technical and market uncertainties were incorporated into the final case study 
presented in this chapter. This case illustrates the application of the tool to aid in 
decision-making in biopharmaceutical development under uncertainty. The outputs 
are depicted and an illustration of how such results from Monte Carlo simulations 
can be interpreted is provided.
5.7.1 Case study background
This example was based on a biopharmaceutical company with a pipeline of three 
monoclonal antibody candidates. The company is considering whether to risk 
building a facility for the commercial manufacture of the antibodies and if so, when 
to sanction construction, or whether to rely on a contract manufacturer throughout. 
The use of contract manufacturing organisations (CMOs) for the delivery of material 
can range from just process development work to the full manufacture of material 
and is a key feature of the biopharmaceutical industry (Byrom, 2000). The options in 
terms of outsourcing manufacture or building capacity for in-house manufacture 
must be weighed carefully and will in all events be constrained by the resources 
available.
The decision to build a cGMP facility takes considerable time and cost and risks 
having a facility lying idle if products fail at clinical trials (Langer, 2004). Opting for 
a contract manufacturer offers potential time savings, which can be critical to a 
drug’s market share and success. However, contract manufacturers are expensive and 
the company will have to relinquish control over the manufacture of material. The 
software tool was used to model and analyse the different options that were available 
for manufacturing of material for clinical trials and eventual sales.
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The three options considered were:
1. Build Early Option (Aggressive)
The facility is used for the production of material for the clinical trials and 
building a new plant starts when the first drug reaches the end of Phase II clinical 
trials. In this case the manufacturing plant will be ready to supply product(s) to 
the market upon approval. This is an aggressive and risky strategy.
2. Contract Manufacturing Option (Cautious)
The production of material for the clinical trials and the market is outsourced to a 
CMO. No building work is required. This is a cautious strategy, but does mean 
the company has less control over manufacturing.
3. Build Late Option (Conservative)
The material for the clinical trials is produced within the existing plant and a new 
facility is built once the first product successfully completes Phase III clinical 
trials. This would enable the company to start producing its first approved drug 
in-house by the third year into the market. While the facility for commercial 
production is being built a contract manufacturer is used for the first approved 
drug. It is a cautious strategy but one which results in more company control of 
manufacturing.
The three options were analysed in two different ways. The first was a deterministic 
approach where the uncertainty in the different parameters and the risk of failure of 
drugs were not taken into consideration. In the second approach, Monte Carlo 
simulations were used to capture the risk in each of the options. The aim of using 
these two approaches to analyse the three options was to highlight the impact of 
incorporating risk and uncertainty into the options. The following sections describe 
the data used for the case study and the probability distributions assigned to the key 
uncertainties.
5.7.2 Deterministic case set up
The input data presented in Chapter 4 were used for the deterministic study (Tables
4.1 to 4.10). It was assumed that whenever the manufacture of clinical trial material 
was outsourced, some of the research and development work was handled by the 
same contract manufacturing company. Drugs that completed the development work 
successfully then proceeded to the market where a set sales profile was applied.
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5.7.3 Monte Carlo set up
Next the chance of failure and distribution probabilities to the key parameters was 
assigned in order to perform Monte Carlo simulations. The phase transition 
probabilities for the MABs were kept the same for all three options (Table 4.11). 
However the probability of failure due to technical reasons was assumed to change 
depending on the option selected (Table 5.2). When a CMO was involved the 
probability of a drug failing due to technical reasons was assumed to be low 
reflecting the fact that there is experience and knowledge available to the company 
from the CMO regarding process and product development (personal 
communication, Richard Francis, Protherics, UK).
Table 5.2 Probability of failure due to technical reasons
Without a CMO With a CMO
Probability of failure due to technical 0.30 0.10
reasons
The key uncertainties identified in the sensitivity analysis study in Section 5.5 were 
assigned with probability distributions for this case study (Tables 5.3 and 5.4). These 
values were determined from literature sources and through discussions with 
industrial experts (personal communication, Rebecca Paulraj, Lonza Biologies, 
Slough, England).
Table 5.3 Parameters that were assigned with probability distributions
Build early option Contract manufacturing 
option
Build late option
Building cost Delays in contract Building cost
Building completion time negotiation Building completion
Price per treatment Delays in material time
Patient population delivery Price per treatment
Price per treatment Patient population
Patient population
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The facility, estimated at $200 million (Langer, 2004) was expected to be able to 
produce three monoclonal antibodies at 200 kg per year under cGMP condition and 
was expected to be completed in three years (personal communication, Steve Froud, 
Lonza Biologies, UK).
Table 5.4 Key parameters and their probability distributions
Parameter Possible values Probability
Negotiation time 3 months 50%
6 months 30%
12 months 20%
Delays in material delivery (CMO) 0 months 60%
3 months 30%
6 months 10%
Cost of facility US$ 200 million 60%
US$ 250 million 30%
US$ 180 million 10%
Time for completion of facility 3 years 90%
4 years 10%
Price per treatment 80% * Base case estimation 50%
Base case estimation 30%
120% * Base case estimation 20%
Market share 60%*Base case estimation 50%
Base case estimation 30%
110%*Base case estimation 20%
Making accurate predictions about market sizes for new products is notoriously 
difficult and estimating market share for a company’s own product is hard as there 
are a large number of influencing factors such as pricing, sales efforts and 
competitive moves (Brastow and Rice, 2003). Therefore wide distributions from the
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base case values were assigned to the price per treatment and the market share. The 
values and the probabilities assigned were decided upon much discussion with 
industrial experts (personal communication, Rebecca Paulraj, Steve Froud, Lonza 
Biologies, Slough, UK; Brendon Fish, Cambridge Antibody Technology, Cambridge, 
UK; Phil Morton, Delta Biotechnology, Nottingham, UK).
Once the major technical and commercial uncertainties were identified and 
incorporated into the analysis, it was possible to run Monte Carlo simulations to 
assess the impact on the portfolio NPV. The blocks that assign the probabilities to the 
parameters were activated within the tool for this purpose. Having validated the 
results of a single simulation in the deterministic analysis, 400 simulations were 
carried out for each option. At the end of each simulation, the inputs used and the 
outputs generated were saved. To determine the number of simulation runs required 
to reach convergence, running averages of the key output, the NPV were monitored 
until they levelled off. The next section discusses the results from the deterministic 
approach as well as the Monte Carlo simulations technique.
5.7.4 Results and discussion
5.7.4.1 Deterministic results
Figure 5.8 shows the results of the deterministic study that does not account for drug 
failures. The tool predicted that the option to build early, at the end of Phase II 
clinical trials, is the most attractive followed by the option to build after the product 
makes it to the market. The lower portfolio NPV associated with the build late option 
can be attributed to the high contract manufacturing costs in the first three years in 
the market and the high marketing costs involved in launching the product which 
combine to lower the profits made. However, the build late option is still marginally 
better than the contract manufacturing option (by 10%) due to the savings made by 
manufacturing in-house during development and once the commercial facility is 
built.
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Figure 5.8 The portfolio NPV for the three options without the uncertainty and risk 
incorporated. The aggressive option of building early has the highest portfolio net 
present value.
5.7.4.2 Monte Carlo results
Figure 5.9 shows the distribution of the portfolio NPV for the build early option. The 
distribution is skewed to the left, as most of the NPV values are negative due to 
losses made when drugs fail to reach the market. Figure 5.10 shows the frequency 
distribution of the portfolio NPV for all three options. This indicates that there is a 
wide spread of possible portfolio net present values in each, as well as a high degree 
of overlap. Each of the graphs shows at least two peaks. The first corresponds to the 
conditions where drugs fail and the second is due to the financial rewards achieved 
when drugs succeed in making it to the market. Blau et al. (2000) also reported the 
occurrence of two peaks for the distribution of NPV values for a portfolio of drugs. 
Ideally the distribution with higher NPV values and with the least dispersion of NPV 
values would be the preferred option. However, this is not clear from the Figure 5.10 
due to the multiple peaks and the overlap between the three options.
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Figure 5.9 The NPV distribution from the Monte Carlo simulations for the build 
early option. Majority of the portfolios have a negative NPV due to the drug 
candidates failing during the clinical trials.
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Figure 5.10 Frequency distribution of the expected portfolio NPV for the three 
options. The net present values for the three options show much overlap and each 
graph has at least two peaks.
From the frequency distributions in Figure 5.10, it is possible to calculate the mean 
(expected portfolio NPV) and standard deviation (risk) of each option and compare
142
APPLICATION OF THE TOOL TO EXPLORE ALTERNATIVE DEVELOPMENT STRATEGIES
them. The outputs generated by the Monte Carlo simulation technique are shown in 
Figure 5.11. Factoring in risk and the uncertainty reduces all the expected net present 
values (Figure 5.11) relative to the deterministic value (Figure 5.8) due to the fact 
that many drugs fail in clinical trials or for technical reasons. The option with the 
highest NPV and the lowest risk is preferred. The best option in terms of reward 
(expected NPV) is the build late option, which is building after at least one drug gets 
into market. However, the best option in terms of minimising risk is the contract 
manufacturing option.
Considering all three options, the expected NPV values are within ± US$ 20 million 
of each other and yet the risk values are between ± US$ 85 million and ± US$ 251 
million. This high degree of overlap between the options results in the t-test showing 
no significant difference between them in terms of the expected NPV (Table 5.5). 
Therefore the decision is most likely to be based on the risk involved with each 
option. The option of using a contract manufacturer is the least risky as there are no 
high investments in new facilities to be recovered. Also the contribution from the 
CMO in terms of knowledge and experience serves to lower the risk of failure due to 
technical reasons. The risks in this option, for example delays in negotiation and 
material delivery, do not appear to have a major effect.
The option of using a contract manufacturer is a cautious strategy. However, if the 
management is willing to tolerate a higher risk in order to get a higher expected 
portfolio NPV, the best option would be the build late option. While the risk is 
minimised by setting the minimum requirement of at least one drug into the market 
before building, the revenue increases relative to the contract manufacturing option, 
as it has control over the manufacturing of material after the first three years. The 
risk is still high as the revenue from just one drug is insufficient to recover the full 
investment on the facility. If the success of two drugs is set as the minimum 
requirement for starting to build, the risk involved with the option of building after 
the product gets into the market will be much lower. This decision is further justified 
by the fact that even if only one drug makes it to the market from this portfolio, other 
new drug candidates, which might follow (and have not been considered in this case 
study) could be produced in the same facility.
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Figure 5.11 The reward and risk associated with the three options, after the 
uncertainty and the risk involved have been factored in. The build late option has the 
highest expected portfolio NPV, while the build early option has the highest risk.
Table 5.5 Expected values and standard deviations for the three options
Performance
Measure
Statistic
Value
Build early Contract
Manufacturing
Build
late
NPV Mean 19 9 31
Standard deviation 251 85 168
t-statistic* N/A 0.53 -0.76
‘Indicates the statistical significance relative to the baseline build early option. An absolute value of 
greater than 1.645 is considered significant at the 5% level.
Accounting for failures and uncertainties knocks the build early option out of first 
place, highlighting the limitations of relying solely on deterministic results. The 
option of building early is the second best in terms of reward but has the highest risk. 
This is because in case none of the drugs making it to the market, the company is 
saddled with a high investment that cannot be recovered. However when two or all 
three drugs do make it to the market, the profits are substantial.
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5.8  C o n c l u s io n s
This chapter has highlighted that the tool can be used to model drug development 
tasks in a transparent manner that facilitates effective allocation of resources and the 
quantification of the risks and uncertainties. The chapter has provided the results for 
the simulation of a set of drugs that have proceeded through the development 
process. A comprehensive sensitivity analysis has been carried out to identify the 
important parameters in drug development. The tool has then been used to simulate 
and analyse different scenarios for development work, clinical trials and the market 
performance of drugs. The contour plots provide the ability to plan for a range of 
contingencies including uncertainties in manufacturing efficiencies, product demand 
and the market share captured.
A case study has been used to demonstrate the functionality of the tool to output the 
expected net present value (NPV) of a small drug portfolio under uncertainty for 
different manufacturing options. The effects of technical and market uncertainties on 
the question of whether to build or use a contract manufacture were analysed using 
Monte Carlo simulations. The simulation studies highlighted the benefits of 
incorporating uncertainties when ranking different strategies. Effective use of the 
simulation outcomes can lead to risk mitigation, more effective use of resources and 
improved overall economic performance. This provides an extra dimension to the 
decision-making process where decisions can be based on both the expected NPV 
and the likelihood reaching a critical NPV.
In this hypothetical case study, depending on the level of risk that the management is 
willing to tolerate, the decision would vary. A cautious strategy would be to contract 
out the manufacturing of materials. By contracting out the company can defer high 
investments in facilities. Whereas a management that would be risk taking would 
select the option of building a facility once a single product makes it to the market. 
The next chapter describes how the tool can be utilised to select the optimal portfolio 
under a given level of resources.
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C h a p t e r  6 
O p t im a l  p o r t f o l io  s e l e c t io n
6.1 I n t r o d u c t io n
One of the greatest challenges facing the biotech industry in the new century will be 
the process of selecting which new products to develop (Blau et al., 2000). The 
product pipelines of pharmaceutical companies are in a constant state of flux as new 
drug leads are identified and products reach the market or are discontinued during 
development because of safety or efficacy concerns (Rogers et al., 2002). The 
pharmaceutical companies are now under increasing market pressure from managed 
healthcare organisations, the entrance of branded competitor drugs and competition 
from expired-patent generic drugs (Rogers et al., 2003). The process of drug 
development is complicated by the fact that each project is subject to technical and 
market uncertainties. In the pharmaceutical industry, a firm needs to consider its 
entire product portfolio in the context of market and technical uncertainty, budgetary 
constraints and the desire to balance the portfolio across many drug type 
classifications (Blau et al., 2000; Sharpe and Keelin, 1998; Subramanian et al., 
2000). However, to date many R&D managers are not satisfied with the existing 
portfolio selection models (Cooper et al., 1997). As a result, the optimal management 
of the new product pipeline has emerged at the foremost of all strategic planning 
issues within such companies (Rogers et al., 2002).
Approaches to portfolio management differ, depending on whether the decision­
making process revolves around the prioritisation of the portfolio products or around 
the company’s strategic direction, which groups preferred products in terms of key 
properties (Soegaard, 2003). A review of all the product portfolio selection and 
management techniques was provided in Chapter 1. High quality decisions about 
determining long-term business strategy often require explicit analysis of 
uncertainty. Proponents of risk analysis argue that increased risk information 
improves management’s understanding of the nature of risks, helps identify the 
major threats to project profitability and reduces forecasting errors (Ho and Pike,
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1998). Understanding the array of possible outcomes and key sources of uncertainty 
provide management with a key tool to manage and balance the portfolio.
Effective portfolio analysis can identify the optimal portfolio in terms of value 
creation and its risk for any given set of constraints. The company’s business strategy 
is then applied through the selection of products for development. The previous 
chapter illustrated the use of the tool developed in this PhD to model alternative 
development strategies and to perform scenario analysis. In this chapter the tool is 
applied to quantify the risk and reward of different drug candidate portfolios to aid 
decision-making in product portfolio selection. Incorporating the ability to perform 
risk analysis on the product portfolio enhances the capability of the tool and adds 
quality to the decisions made using it. A combination of two traditional methods is 
proposed as an effective mechanism to capture the reward and risk present in a 
portfolio of biopharmaceutical drug products. The use of the tool to apply the method 
is demonstrated through a hypothetical case study.
This chapter is structured as follows. Section 6.2 provides a description of the 
proposed method to assess the risk and reward of different drug portfolios. An 
overview of how this is applied using the tool is presented. A case study is presented 
in Section 6.3 to demonstrate the application of the method using the tool in 
computing the value and risk of different portfolios under resource constraints. The 
chapter ends with a set of conclusions about assessing the value and risk of different 
product portfolios.
6.2  M e t h o d  d e s c r ip t io n
6.2.1 Introduction
An approach that combines two traditional methods is proposed as an effective 
mechanism to capture the risk and reward present in a portfolio of biopharmaceutical 
drug candidates. One way to make decisions about such a portfolio is to use the 
efficient frontier method derived by Harry Markowitz (1952, 1991). The portfolio 
theory was developed to select company shares and maintain an optimal share 
portfolio.
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This theory is based on three major precepts:
1 A theoretical rational investor -  Markowitz (1952, 1991) asserts that a 
rational investor is not indifferent to risk and will choose more value over less 
value, but will also prefer less risk to more risk;
2 There is more than one optimal portfolio -  it is sometimes possible to find a 
better expected return by tolerating more risk, but this may not be always be 
acceptable;
3 The portfolio as a whole is more optimal than its individual projects -  each 
project or investment must be considered in the context of what it contributes 
to the entire portfolio. For example an optimal portfolio of five investments 
does not always contain the five ‘best’ investments.
Based on this understanding, Markowitz (1952, 1991) defines a portfolio as being 
efficient if two conditions are met:
1 No other portfolio exists that has a greater expected return and a lower level 
of risk.
2 No other portfolio exists that has less risk and a higher expected return.
If one or both of these conditions are not true, a portfolio is said to be inefficient. 
When all portfolios are plotted on a graph of value vs. risk, the efficient portfolios 
appear on a line called the “efficient frontier”. There are no viable portfolios above 
this line (Figure 6.1). Once all the efficient portfolios are plotted, the company can 
make informed decisions regarding their portfolio selection, balancing acceptable 
risk with the highest possible return.
It is possible to locate this efficient frontier line using the approach described by 
Markowitz (1952, 1991). However an alternative method, using Monte Carlo 
simulations, provides a more convenient way to capture the features and 
complexities found in the field of biopharmaceutical drug development. This 
particular method has been suggested by McVean (2004) as a suitable approach to 
assessing different portfolios in the petroleum industry. Walls (2004) demonstrated 
through a case study the application of the efficient frontier method in oil exploration 
and production. Rogers et al. (2003) demonstrated an efficient frontier for the 
selection of a drug portfolio for a pharmaceutical company. However, no
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applications of the ‘efficient frontier’ approach could be fond in the literature in the 
field of biopharmaceutical portfolio selection. The Markowitz method is described 
next, followed by the application of the Monte Carlo method.
6.2.2 Markowitz approach
Markowitz outlines a mathematical technique for deriving the efficient frontier for 
selecting a portfolio of stocks (Markowitz, 1952; Markowitz, 1991). It should be 
noted that the description of the efficient frontier was originally formed around a 
discussion of securities investments, but it can, at least in principle, be applied to the 
biopharmaceutical product portfolio selection. As in many other 
analysis/optimisation techniques, the Markowitz method requires a high level of 
information to be collected for each project and for it to be converted into a format 
that could be used as there is in performing the actual analysis.
There are five steps that must be completed in order to determine the efficient 
frontier:
1. The expected value of each project under consideration is estimated.
2. The variance in the potential value (e.g. NPV) of each project is estimated as a 
measurement of risk.
3. The correlation between each project and every other project is estimated.
4. The constraints that limit which portfolios are acceptable are expressed in the 
form of simple linear equations.
5. Once all of this information has been collected, an analytical expression for the 
efficient frontier is determined.
A detailed description of this method is not appropriate for this discussion, however, 
the end result, after considerable linear algebra and matrix manipulation, is the 
efficient frontier line on a value vs. risk graph (Figure 6.1). Any point on this line has 
a corresponding equation that represents a portfolio of projects. Moving up the 
efficient frontier line, results in an increase in both value and risk (Figure 6.1).
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Value
R isk
Figure 6.1 The efficient frontier is a line that connects all the efficient portfolios. 
The portfolio at point A is less efficient to a portfolio at B, as it has more risk for the 
same value. The portfolio at point C provides more value for the same level of risk 
and is hence superior to all of the other solutions at A and B.
In order to perform Markowitz’ efficient frontier analysis, some key information 
must first be assembled, e.g. the expected NPV and the risk of each project. The 
manner in which this information is compiled is not always straightforward. 
Historical data, if available, can provide some indication to future performance. 
Comparison with similar projects may also yield appropriate information. Industry 
experts might be able to provide expert knowledge but by definition this is likely to 
be more subjective. By contrast the Monte Carlo method relies less on opinion. Of all 
the information required, the correlation between a project’s performance and that of 
other projects may be the most difficult to ascertain. The next section describes how 
the application of Monte Carlo simulations can be used to generate the efficient 
frontier of portfolios.
6.2.3 Monte Carlo method
Monte Carlo simulation is an analytical technique in which a large number of 
simulations are run using random values for uncertain variables. This yields a 
frequency distribution for each of the output parameters, from which the expected 
value and risk (standard deviation) can be calculated. In order to perform Monte 
Carlo simulations, it is first necessary to identify key uncertain inputs parameters 
using a sensitivity analysis. Then probability distributions must be applied to these 
key uncertainties. Subsequently, an appreciable number of Monte Carlo simulations
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must be performed to generate the expected value and risk for the individual projects 
(Figure 6.2).
Value
Risk
Figure 6.2 Using Monte Carlo simulations create a random collection of possible 
portfolios. The upper boundary created by the portfolio will form the ‘efficient 
frontier’.
6.2.4 Comparison of the methods
The traditional Markowitz approach uses variance as a measure of risk for the 
individual investment opportunities. The implicit assumption is that the risk profile 
for an opportunity is fully specified by its mean and variance. Essentially, all risk 
profiles are approximated by a normal distribution. In drug development, this is not 
always the most appropriate type of approximation. For example, the sales and drug 
pricing can have a skewed distribution and projects can be abandoned at any stage of 
development.
In the Monte Carlo method different types of distributions can be assigned to the 
parameters (Figure 6.3). For example, the probability distribution used to describe 
the price set for the drug will be different to that of the development cost. Different 
types of distributions (e.g. triangular, normal etc...) can be applied in order to 
capture the risk profile that describes the biopharmaceutical drug development 
process best. Literature and the opinion of industry experts can be used to identify 
the most appropriate distribution for each parameter. Stonebraker (2002) presents a 
method where the opinion of experts is used to help assigning distributions for the 
key parameters in drug development.
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Figure 6.3 Different probability distributions can be assigned to the significant 
uncertain variables. Monte Carlo simulations are then carried out until a confident 
risk profile is generated.
As part of the efficient frontier analysis, the correlation between the projects within a 
portfolio has to be established. As the projects are resourced from the same resource 
pools (both, renewable and non-renewable) the interaction between the projects will 
be captured. Having established the basics of the model, the application of the 
method utilising the tool is illustrated through a hypothetical case study.
6.3 C a se  s t u d y
6.3.1 Background
A hypothetical case study that computes the reward and risk in different portfolios of 
drug candidates will now be presented. The reward is measured as the expected NPV 
and the risk is taken as the standard deviation of the NPV distribution. The study is 
based on a company with six potential monoclonal antibodies that are ready for 
clinical development (Table 6.1). Given the finite level of resources available, the 
company is unable to take all six into clinical development. The objective of the case 
study is to provide decision-makers with an explicit view of the rewards and risks of 
different portfolios in order to decide which drugs the portfolio should consist of. 
These results are presented to demonstrate the type of analysis that can be carried out 
using the prototype tool.
The drug portfolio of six drug candidates presented in Chapter 4 was used for this 
case study. The drug characteristics are summarised in Table 6.1. In order to make 
the portfolio selection decisions more realistic and challenging, the set of drugs used 
was selected to contain characteristics that are quite different in all possible aspects
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of drug development (e.g. market, price, therapeutic area etc.). Next, differing levels 
of uncertainty were assigned to further diversify the potential products (Table 6.2). 
The drug portfolio selection problem was then carried out under three different 
resource levels as constraints in order to illustrate the range of options available to 
decision makers.
Table 6.1 Description of the drugs in the portfolio
Drug candidate
' 1 .......  *... ...
Market share MAB type Comments
A High Chimeric New drug
B Low Humanised New indication
C Medium Chimeric New drug
D Very high Chimeric Blockbuster
E Low Murine New drug
F Low Chimeric New drug
Market share = dose x price x patient population
Table 6.2 Level of uncertainty assigned to each drug candidate
Drug candidate Uncertainty
A Medium
B Very low
C Medium
D High
E Medium
F Low
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The next section describes the steps carried out to generate the efficient frontier for 
portfolio selection at different resource levels using Monte Carlo simulations.
6.3.1 Sensitivity analysis
The sensitivity analysis carried out in Chapter 5, (Figure 5.4) was used to identify the 
top seven inputs that impact on the portfolio NPV:
• Market share of drug
• Drug price per patient
• Development time
• Clinical trial time
• Mass per batch
• Delays in material delivery
• Manufacturing cost (COG)
Although the number of personnel for process development work was shown to be a 
significant factor in Figure 5.4, it is a company specific attribute and has been used 
as a resource constraint in this case study. The building delay and CMO negotiation 
time delay parameters result in a delay in manufacturing material for clinical trials 
and the market. Therefore both of these were included together as a simple factor 
‘Delays in material delivery’. By varying the market share, the effects of a 
competitor being present were accounted for.
6.3.2 Assigning distribution parameters
Probability distributions were assigned to the parameters that the portfolio NPV was 
most sensitive to (Table 6.3). The distributions were based on literature (Myers and 
Howe, 1997; Stonebraker, 2002) and discussions with experts from the industry 
(Rebecca Paulraj and Steve Froud, Lonza Biologies, Slough, UK; Brendan Fish, 
Cambridge Antibody Technology, Cambridge, UK). The probabilities were assigned 
to reflect the level of uncertainty attributable to the characteristics of the drugs in 
Table 6.2. For example, drug D was modelled as a project with high risk and reward 
was assigned a negatively skewed distribution for the development time to reflect the 
increased likelihood of delays. All the values used in this case study are presented in 
Appendix A.
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Table 6.3 Key parameters and type of distribution assigned
Parameter Probability distribution
Market share of drug
Normal distribution, five discrete values
Drug price per patient
Development time
Clinical trial time
Product yield Skewed distribution, three discrete values
Delays in material delivery
Manufacturing cost (COG)
The clinical trial failure rates on Table 4.11 were used for this case study. The chance 
of failure due to technical reasons was again set according to the uncertainty level 
assigned to the drug candidate with drugs with high risk having a higher chance of 
failure due to technical reasons (Table 6.4). As drug B was a new indication for an 
existing drug there was no technical uncertainty involved in that drug candidate.
Table 6.4 Probability of failure due to technical reasons
Drug candidate Probability of failure due to technical reasons at PIII (%)
A 20
B 0
C 10
D 30
E 5
F 15
6.3.3 Setting up the Monte Carlo simulations
The first simulation was carried out with all six drugs in the portfolio and no resource 
constraints being applied. This was performed in order to compare to the results from 
the resource-constrained simulations. Next, three resource levels of US$ 500, 750 
and 900 million were defined as constraints and simulations carried out for each to 
identify the number of drugs that could be supported in the portfolio at each of these 
levels (Table 6.5). The probability of failure for the drug candidate during 
development and all the other uncertainties were not applied during these
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(deterministic) simulations. The highest number of drugs progressing into the market 
under each resource level was taken as the number of drugs per portfolio for the rest 
of the case study. For example, at resource level of US$ 500 million, three drugs 
made it to the market. Therefore the number of drugs supported at that level was set 
as three. As six drug candidates were taken into consideration, there were 20 possible 
combinations at this resource level (Table 6.5).
Table 6.5 Resource levels and the number of drugs in the portfolio
Resource level 
(US$M)
Number of drugs per 
portfolio
Number of possible 
portfolios
Unconstrained 6 1
500 3 20
750 4 15
900 5 6
Once the number of drugs capable of being supported at each resource level had been 
identified, all the possible drug combinations (a total of 42) were generated and 
Monte Carlo simulations carried out for each drug combination. Appendix A 
provides the corresponding list of portfolios and their composition. To determine the 
number of simulation runs required to reach convergence, running averages of the 
results were monitored until they levelled off. For each of these portfolios, 380 
simulations were required to achieve convergence. The order in which the drug 
candidates were taken into clinical development was determined by the market value 
of each drug (estimated patient population x estimated price). The tool was 
programmed to start with the drug that had the highest market value and once all the 
drug candidates were in the development process, the resources were allocated on a 
first-come-first-served basis (Table 6.6).
Frequency distributions of the estimated performance measures were generated and 
various statistics computed to aid the decision-making process. The results were 
used to construct the efficient frontier as described earlier (Section 6.2) for each 
resource level.
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Table 6.6 The market value of the drugs and the ranking based on it
Drug candidate Market value (US$)
D 1,029,000,000
A 523,224,000
B 426,880,000
C 409,860,000
F 48,664,000
E 30,660,000
6.3.4 Results and discussion
6.3.4.1 Portfolio with all six drugs
The first set of results shown in Figures 6.4 and 6.5 provides an insight into the 
probability of making a profit from the portfolio of all six drugs without any resource 
constraints. In Figure 6.4, there are no instances where all six make it to the market. 
The most probable situation is getting just one drug into the market (30%) followed 
by two (22%). These probabilities are consistent with those of Reichert (2004). The 
author states for murine and humanised MABs the overall rate of success varies from 
14% to 26%. As the majority of the drugs fail, the one(s) that does make it to the 
market have to bear the cost of the failed drug(s).
Using the probabilities of failure used in the Monte Carlo simulations (Table 4.11) 
the number of drugs that fail for each one that does make it successfully to the 
market can be calculated. The cumulative rate of success for a MAB is 0.823 x 0.547 
x 0.667 x 0.777 = 0.233. Therefore the average number of failed MABs per 
successful MAB is 1/0.233 = 4.3. DiMasi et al. (2003) and Myers and Howe (1997) 
have taken a similar approach to accommodate the cost of failed drugs in calculating 
the cost of drug development. This means that each MAB that enters the market has 
to bear the cost for 4.3 failed MABs. This feature is demonstrated in the distribution 
of the expected NPV in Figure 6.5, where most of the portfolio NPV values turn out 
to be negative due to investment losses.
Figure 6.6 presents another output of the tool; the risk profile of the portfolio with six 
drugs. The probability of not making a profit (a negative NPV) for this particular
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portfolio is 58 %. On the positive side, the successful commercial launch of all six 
drugs brought in an expected NPV of over US$ 900 million. These results indicate 
the nature of the biopharmaceutical drug development process that is encountered by 
the industry and highlights the importance of making the right choices in selecting 
drug candidates for clinical development, using limited resources.
In reality resource constraints will be applied to drug candidate selection. The next 
section describes the results from the Monte Carlo simulations carried out under the 
influence of resource constraints to construct the efficient frontier.
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Figure 6.4 The number of drugs that make it to the market from a portfolio of six is 
presented. The highest probability is for just one drug to make it to the market and 
there are no instances where all six drugs have made it despite no resource 
constraints being applied.
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Figure 6.5 NPV distributions for the portfolio with all six drugs and an unlimited 
level of resources. There is a wide distribution of the NPV values and majority of the 
NPV values are negative
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Figure 6.6 Risk profile for the portfolio with all six drugs and unconstrained 
resource levels. The probability of making a negative NPV for this particular 
portfolio is 58%.
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6.3.4.2 Efficient frontier
a) Efficient frontier for US$500 million resource level
The expected NPV values and risks computed for each o f the portfolios for the US$ 
500 million resource level are presented in Figure 6.7. Portfolios with negative 
expected NPVs (7 out of 20) were excluded.
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Figure 6.7 Efficient frontier for US$ 500 million resource level. Portfolios 12, 13, 1 
and 2 form the ‘efficient frontier’ for this particular resource level.
As there are only 20 portfolios possible at this resource level, the number o f points 
on this efficient frontier diagram is limited. The reward (expected NPV) as well as 
the risk o f the simulated portfolios changes within a wide range according to the 
combination o f drugs held in the portfolio (Figure 6.7). Portfolios 13 and 14 have 
almost the same expected NPV, but portfolio 14 has a much higher level o f risk (US$ 
59 million greater). Therefore it is a safer option to have portfolio 13 in clinical 
development rather than 14. In this hypothetical case study, this would require the 
company to drop drugs D and E and bring in drugs C and F. Drugs D and E could be 
outsourced in order to diversify the risk taken by the company.
If changing the portfolio composition is not an option, other strategic moves could be 
applied. For example as the risk and reward o f a portfolio has been quantified, steps 
could be taken to add value and reduce risk. To add value other indications can be
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pursued. To reduce the risk, a higher number of tests could be carried out earlier in 
the development pathway, thereby reducing the chance of late stage failure. This type 
of explicit consideration of the alternative projects will help create a management 
strategy for the company that would add long-term value to the company portfolio 
(Keel in and Shew, 2003). These changes can then be added to the model and by 
carrying out simulations the movement of the portfolio relative to the efficient 
frontier can be observed.
Portfolios 1 and 15 have similar risk levels but portfolio 1 has an expected NPV that 
is US$ 57 million higher than portfolio 15 (Figure 6.7). Therefore for the same level 
of risk, portfolio 1 would offer much greater value and the company would benefit 
by maintaining portfolio 1 rather than 15. To effect these changes, the company may 
have to utilise a different management strategy.
The company will have to decide the level of risk they would want to operate under 
and the spread of risk in the portfolio prior to new candidate selection (Blau et al., 
2000). A risk-taking management could opt to pursue portfolio 2, but a risk-averse 
management could come further down the efficient frontier and settle for portfolio 1. 
The difference between these two portfolios is that drug C in portfolio number 1 is 
replaced by drug D (highly risky, potential blockbuster) in portfolio 2. This single 
change brings about an increase of the risk by US$ 59 million but the expected NPV 
rises by US$ 71 million. This type of insight is not obvious at the outset and would 
be an asset to decision-makers.
b) Efficient frontier at higher resource levels
The reward and risk distributions for the portfolios for USS 500 and 750 million 
resource levels of resources are presented in Figure 6.8. The results indicate that 
increasing the number of drugs in a portfolio by virtue of having a greater financial 
resource does not necessarily result in an increase in the expected NPV. This is 
because a higher number of drugs mean more capital has to be invested, which in 
turn increases the costs the portfolio has to recover to make profits. This is further 
confirmed by the yields of the portfolio containing all six drugs. This has an expected 
NPV of only USS 6 million and a risk of USS 260 million.
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As before the risk is reduced by an increase in the number of drugs. For example 
portfolio 2 is the highest in value under the US$ 500 million resource constraint and 
portfolio 36 is the highest under the US$ 900M constraint (Figures 6.8 and 6.9). 
While there is a drop in the expected NPV from portfolio 2 to 36 of USS 122M, there 
is also less risk (USS 26M) involved with portfolio 36 than 2. Risk-averse 
management may prefer portfolio 36, provided they can generate the additional 
resources, in order to spread the risk.
By considering just the market value (patient population x drug price), portfolio 21 
(Appendix 1) would be expected to be the highest yielding of the portfolios if 
USS 750 million of resources were made available. However, the results show that 
the expected NPV of portfolio 24 is USS 8 million higher than 21. This demonstrates 
the unreliability of static values to estimate the value of a project and the importance 
of factoring in uncertainty and risk into the portfolio evaluation. Adding drug C to 
portfolio three (which results in portfolio 22) increases the expected NPV by USS 26 
million and reduces the risk by USS 4 million. This type of information could be 
utilised by the management for raising required funds in order to increase the number 
of drugs in its portfolio.
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Figure 6.8 The risk and reward distributions for the portfolios for USS 500 and 750 
million resource levels. For comparison the portfolio with all six drugs have been 
included.
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The results also enable the effect of different drugs on the portfolio value and risk to 
be compared. For example, replacing drug E with F at a US$ 750 million resource 
level (portfolio 31 and 32) does not bring about a significant change in risk or 
reward. This allows the company to select the drugs strategically. For example a 
company may choose a drug in a new therapeutic area in order to gain confidence of 
investors and regulators or align with the core competencies of the company. In 
comparison to all the other portfolios, the portfolio with all six drugs has the lowest 
expected NPV and a medium level of risk. Therefore, even if the resources existed it 
would be strategically important to outsource some of the drugs in order to reduce 
the risk and increase the value.
Figure 6.9 presents the expected NPV and the associated risk for a USS 900 million 
level of resources. The strategy by which the value of the portfolio could be 
increased is demonstrated. By replacing drug F in portfolio 39 with C (portfolio 36) 
the value could be increased by USS 17 million and the risk reduced by USS 7 
million. Again, the portfolio of six drugs is quite far away from the efficient frontier. 
Finally, as an illustration of further analysis that can be carried out by the tool, the 
risk profiles for three selected portfolios are discussed.
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Figure 6.9 The efficient frontier for USS 900 million resource level. For comparison 
the portfolio with all six drugs has been included. With the increase in the number of 
drugs in the portfolio, the NPV has reduced.
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6.3.4.3 Portfolio risk profiles
The risk profiles for the portfolio with the highest expected NPV in each resource 
category are presented in Figure 6.10. The probability of losing money (negative 
NPV) due to the uncertainty or risk of failure for portfolio 2 is 28.2%. This is known 
as the “downside risk” of the portfolio (Stonebraker, 2002) and is the lowest of all 
the portfolios taken into consideration in Figure 6.10. With a higher number of drugs 
(portfolio 24 and 36) the probability of not making a profit is higher (45 and 50% 
respectively). These results help to compare further and distinguish between the 
portfolios. Stonebraker (2002) uses a risk profile for a single drug candidate to 
compare against the company benchmarking in deciding whether to proceed with 
development work or not with that particular candidate. For portfolio 2, the 
probability of making a positive NPV is 17 -  22% higher than portfolios 24 and 36 
respectively.
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Figure 6.10 Risk profiles for portfolio 2, 24 and 36. With the increase in the number
of drugs in the portfolio, the probability of making a negative NPV increases.
These outputs could be compared to internal standards to decide on whether to 
proceed with a project portfolio or not. Stonebraker (2002) states that Bayer 
Pharmaceuticals find a downside risk value of 20% to be low relative to similar 
projects. Portfolio 2 has an upside potential (a maximum NPV) of US$ 900 million.
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Taking all of the results into consideration, portfolio 2 appears the best for the 
company to start off with since, although it is risky, it provides high returns for a 
lower level of resources. The data gathered from the simulation can be used for 
further analyses, which can be used to understand the dynamics of drug 
development. Similar risk analysis can be carried out on a single drug candidate or 
concentrate on one phase for the full portfolio.
6.4  C o n c l u s io n s
To remain competitive companies must deploy their capital effectively and in ways 
that maximise returns and minimise risk (Walls, 2004). Decisions made on a project- 
by-project analysis and ignoring the diversification affects often yield sub-optimal 
results. This chapter has presented a method to compute the value of different 
portfolios while taking the uncertainty in the parameters of drug development into 
consideration. This was followed by the application of the tool to quantify the risk 
and reward of different drug portfolios in a biopharmaceutical company. The 
uncertainties in the R&D and the market have been captured in a single simulation.
Through this method, decision-makers will be able to identify clearly where the 
company portfolio is positioned with regard to risk-retum characteristics of 
alternative product portfolios and hence make appropriate investments based on 
limited resources. The flexibility of the tool to model different types of distributions 
allows uncertainty in drug development to be captured appropriately. When more 
information is available with the progress of development work, the simulations 
could be repeated. With the inputs having less uncertainty; by comparing the new 
position of the portfolio relative to the former position, informed decisions could be 
made about the portfolio composition and portfolio management strategy.
The goal of portfolio analysis is to enable senior management and teams to have 
better conversations about important decisions and not to provide the answer (Keelin 
and Shew, 2003). The type of results and analysis presented in this chapter will 
enable such dialogue to take place by quantifying the risk and reward within a 
portfolio.
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C h a p t e r  7
C o n c l u s io n s  a n d  f u t u r e  w o r k
7.1 In t r o d u c t io n
The ever-expanding field of biopharmaceuticals requires that companies add value to 
their organisation at all levels. The product pipelines of companies are in a constant 
state of flux, where new drugs are identified and existing drugs are either 
discontinued from development or launched into the market. The cost of 
biopharmaceutical drug development has been on the increase during the past several 
decades. This increase in costs, along with the pressures from managed healthcare 
organisations means that the companies are under pressure to manage strategically 
their research and development activities. The risk and uncertainty inherent in the 
drug development process provides further challenges in trying to take a drug from 
discovery into the market under a finite level of resources. Simulation tools can be 
used to enhance the decision-making process in managing the drug development 
process strategically. This chapter summarises the efforts made in this thesis to 
prototype such a tool to model the drug development activities. Future work that 
could advance the understanding of this topic is also discussed.
7.2 O v e r a l l  c o n c l u sio n s
The main focus of this thesis has been the design and implementation of a decision- 
support tool that captures the technical, operational and financial aspects of 
biopharmaceutical drug development, as well as incorporating the effects of risk. As 
an illustration, the tool was used to simulate the development of monoclonal 
antibodies, from discovery to commercialisation. The decision-making and 
management process of drug development were reviewed in Chapter 1 in order to 
understand the type of information required from such a tool and to identify the 
deficiencies of current methods. An investigation of the drug development process 
enabled the activities that are involved in biopharmaceutical drug development to be 
defined (Chapter 2). While the application of the tool was demonstrated through
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modelling the development of monoclonal antibodies, it is generic in its approach 
and could be used for modelling of any biopharmaceutical, for example, recombinant 
proteins.
The modelling approach adopted in this thesis allows modellers to address explicitly 
the technical and business aspects of biopharmaceutical drug development. The 
conceptual framework and the implementation process presented in Chapter 3 allow 
for different management strategies of development activities to be prototyped before 
implementation. Key indicators of profitability such as cost of development, time to 
market and net present value (NPV) of the portfolio of products are computed as aids 
to decision-making. A key point in this tool is that it aims to provide a frequency 
distribution showing the probability that a project’s NPV will exceed a certain level, 
rather than a simple point estimation. The resulting prototype tool combines 
interactive graphics, animation, risk analysis and dynamic simulation to create a 
flexible environment for modelling the drug development pathway.
The benefits of the hierarchical nature of the framework were highlighted; the 
framework confers maximum flexibility since it permits tasks to be modelled at 
different levels of detail, according to the aims of the user. Resource usage profiles 
generated by the tool for renewable as well as non-renewable resources help identify 
bottlenecks and periods of under-utilisation of resources. The ability to view the 
simulation process through a graphical user interface eases the debugging process. 
The costing takes into account the activities as well as resources such as facilities. 
The ability to assign distribution probabilities instead of point values allows the 
modelling of uncertainties. Risk of failure at different stages of the drug development 
pathway has been incorporated into the model, allowing Monte Carlo simulation 
technique to be carried out for risk analysis. Investment assessments could be based 
on both the expected outcome and the likelihood of achieving certain critical values. 
Industrial expert knowledge has been crucial in establishing a base case set of 
assumptions, specified as defaults values in the framework in a database to be used 
when populating the model for a simulation. These values and the simulation process 
were described in Chapter 4.
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The application of the tool for modelling the process of development of a portfolio of 
monoclonal antibodies was presented on Chapter 5. A sensitivity analysis was 
performed to identify the key parameters in drug development. This was used to set 
the probability distributions when performing risk analysis in the latter sections of 
the thesis. The sensitivity analysis was followed by a scenario analysis to observe the 
effect of changing just two specific input parameters while keeping all the others 
constant. The contour plots generated allows the decision-makers to understand the 
consequences of changes to these parameters due to the uncertainty present in drug 
development. A case study was then carried out to whether to build a manufacturing 
facility or to contract out the manufacture of material for clinical trials and the 
market. Assigning distribution parameters and performing Monte Carlo simulations 
took the uncertainty in drug development into account. Advice from industrial 
experts was used to verify the inputs and validate the outputs of the tool. The case 
study highlighted the importance of taking uncertainty into account when evaluating 
different options in planning drug development activities. Methods of presenting and 
analysing information generated by the simulations were suggested.
In Chapter 6, the application of the tool to compute the reward and risks of different 
product portfolios was demonstrated. A method to generate an efficient frontier of 
product portfolios through Monte Carlo simulations was suggested and implemented. 
The prototype tool was then used to perform the necessary simulations and construct 
the efficient frontier under the influence of different resource levels. This allowed 
different product portfolios to be compared on a risk-reward basis and informed 
decisions be made in new drug candidate selection. Risk profiles for different 
portfolios were generated to understand the risk faced by a company seeking to apply 
resources to develop a selected set of drug candidates. This type of information 
provides the management with an insight into the portfolio management problem in 
order to make informed decisions. In summary, the chapter demonstrated how 
simulations could be used to develop and manage a product portfolio.
The work in this thesis highlights the benefits of adopting an integrated approach to 
the process-business interface in biopharmaceutical manufacture. This has been 
realised through the design and application of a simulation tool. During and after 
data gathering, the layout of the simulation model serves as a platform for
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communication between different departments within a company such as process 
development, manufacturing, accounting and management. Such a model could 
therefore aid in understanding how a process really works. Effective use of the 
simulation results can be used to streamlining the company’s resources according to 
the demands. This will in turn lead to concentrated R&D efforts, more effective use 
of resources, faster time-to-market and improved returns on investment. The 
applicability of the model has been demonstrated through several case studies.
7.3  F u t u r e  w o r k
The framework and methods developed in this thesis contribute to the emerging field 
of computer-aided design tools that integrate process and business perspectives of 
biopharmaceutical manufacture. It also provides a base for further work; several such 
examples are discussed next.
In addition to the work presented in this thesis, parallel work (Lim et al., 2003; 
Mustafa et al., 2004) has concentrated on modelling the manufacturing process of 
biopharmaceuticals. Using a hierarchical approach, the manufacturing process has 
been modelled in detail. By integrating this detailed manufacturing model with that 
of biopharmaceutical drug development, the development process could be viewed 
from a more detailed manufacturing perspective. Such integration should allow the 
impact of manufacturing on the development process to be studied better.
An increase in the level of detail at which the drug development is modelled will 
help to add value to the data generated. The hierarchical structure allows new levels 
to be added to the model. A detailed model of the manufacturing process of 
development work can be added in order to achieve better results. The process of 
scheduling manufacturing and development tasks can be added in order to provide 
the optimal schedule for a selected portfolio of drugs. For ease of implementation, 
the clinical trials were modelled in a simple manner. For example, by adding the 
ability to model clinical trials being carried out at different locations, the challenges 
faced, such as logistics could be planned better.
The structure of the company could be modelled more explicitly, with a breakdown 
of the management and the other staff. This will allow a more detailed resource
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utilisation profile to be generated. However the increase in the level of detail will add 
to the size of the model and slowdown the simulation time. Therefore steps will have 
to be taken to quicken the simulation tasks along with the new additions to the tool.
One of the main challenges in developing this prototype tool has been to gather data 
to use as default values for inputs. Developing a database of such drug development 
data would help in any work to be carried out in the future. Data such as time 
lengths, costs and failure rates can be collected through literature, databases 
maintained by regulators such as USFDA and through discussions with industrial 
experts.
The real options method used to decide on the composition of the product portfolio is 
proving to be popular in the industry (Nichols, 1994; Doctor et al., 2001; Rogers et 
al., 2002; Rogers et al., 2003). In the option pricing theory, it is assumed that a 
project can be treated as a stock option and conceptually the project under evaluation 
is being treated as it were a separate company with a defined value of stock. Adding 
the capability to perform real options analysis to the tool will enhance the tool’s 
ability to help in decision-making.
The work in this thesis illustrates the benefits of risk analysis, using the Monte Carlo 
simulation technique. The effect of uncertainty in many parameters was 
demonstrated. However, there are other uncertainties in the development and 
commercialisation of biopharmaceuticals, such as transportation and storage of 
products. By adding the ability to model the impact of different locations for 
manufacturing and sales, the different economic conditions in locations, for example, 
Europe vs. USA, can be captured. This would also allow multi-site investment 
decisions, e.g. how much to be invested where, to be simulated. Generating sales and 
inventory planning profiles would broaden the scope of decision-making for this 
tool.
Regarding the modelling of activities, more rigorous and predictive models can be 
developed. More advanced mathematical methods to capture the activities and risks 
could be applied. For example, operations management literature could provide 
methods to model the efficiency of process development personnel and scheduling
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methods could be included to help planning manufacturing activities. The optimum 
methods of incorporating these more rigorous models into the tool need to be 
investigated. Increasing the optimisation capabilities of the tool is also suggested. 
The use of mathematical methods, such as mixed integer linear programming can be 
investigated. Incorporating multi criteria decision-making will also add value to the 
outputs of the tool.
The case studies presented in this thesis demonstrate the advantages of taking into 
account the technical, operational and financial consideration in drug development 
planning. Further simulation studies using the tool could test new strategies such as 
different clinical trial methods. Further, the mergers and acquisitions occurring in the 
industry today could be modelled to identify the possible advantages a company 
would have in pursuing such an option.
The software package used, Extend Industry Suite v5, was found to be appropriate 
for modelling the drug development process. The simulation times were kept to a 
reasonable value. However with additional components being added, the time length 
for a simulation could increase considerably and will pose a problem. The 
optimisation capabilities of Extend Industry Suite v5 was found to be inadequate as it 
allowed a limited number of parameters to be included.
In conclusion, the future work that has been outlined draws upon the framework and 
methods established in this thesis. The development of more sophisticated models 
and the opinion of industrial experts would improve the accuracy of prediction. The 
future will see tools such as the one described in this thesis be used more frequently 
in order to aid decision-making.
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Data for case study in Chapter 6
This section provides the information used for the case study in Chapter 6. The 
portfolio compositions are presented in Table A.l and the distribution parameters are 
outlined below.
Table A.1 Portfolio names and compositions
Portfolio name Drug candidates Portfolio name Drug candidates
1 ABC 22 ABCE
2 ABD 23 ABCF
3 ABE 24 ABDE
4 ABF 25 ABDF
5 ACD 26 ABEF
6 ACE 27 ACDE
7 ACF 28 ACDF
8 ADE 29 ACEF
9 ADF 30 ADEF
10 AEF 31 BCDE
11 BCD 32 BCDF
12 BCE 33 BCEF
13 BCF 34 BDEF
14 BDE 35 CDEF
15 BDF 36 ABCDE
16 BEF 37 ABCDF
17 CDE 38 ABCEF
18 CDF 39 ABDEF
19 CEF 40 ACDEF
20 DEF 41 BCDEF
21 ABCD 42 (full portfolio) ABCDEF
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Table A.2 Distributions assigned to the drug candidates for the market share value
Drug candidate Number of annual patients Probability (%)
A 185,760 10
247,680 30
309,600 40
371,520 20
433,440 10
B 7,680 5
10,240 10
12,800 70
15,360 10
17,920 5
C 34,400 10
43,200 30
54,000 40
64,800 20
75,600 10
D 41,160 15
54,880 20
68,600 30
82,320 20
96,040 15
E 4,380 10
5,840 30
7,300 40
8,760 20
10,220 10
F 9,240 10
12,320 20
15,400 50
18,480 20
21560 10
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Table A.3 Probability distributions assigned to the drug price for each drug 
candidate
Drug candidate Price per patient per treatment (US$) Probability (%)
A 1,014 10
1,352 30
1,690 40
2,028 20
2,366 10
B 43,800 5
58,400 10
73,000 70
87,600 10
102,200 5
C 4,554 10
6,072 30
7,590 40
9,102 20
10,626 10
D 9,000 15
12,000 20
15,000 30
18,000 20
21,000 15
E 2,520 10
3,360 30
4,200 40
5,040 20
5,880 10
F 1,896 10
2,528 20
3,160 50
3,792 20
4,424 10
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Table A.4 Distributions assigned to the drug candidates for the development time 
value
Drug candidate Development time for PI, PII and PHI 
(months)
Probability
(% )
A 12, 6 ,6 20
15,9 ,9 50
24, 18, 18 30
B 0, 0 ,6 15
0, 0 ,9 80
0, 0, 18 05
C 12, 9 ,9 20
18, 12, 12 50
24, 18, 18 30
D 12, 12, 12 20
18, 18, 18 40
24, 24, 24 40
E 9, 9,9 20
12, 12, 12 50
15, 15, 15 30
F 12, 12, 12 10
18, 12, 12 70
24, 18, 18 20
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Table A.5 Distributions assigned to the drug candidates for the clinical trial time 
value
Drug candidate Development time for PI, PII and PIII 
(months)
Probability
(% )
A 9, 12, 18 20
12, 18, 24 50
18, 24, 30 30
B 9, 12, 18 15
12, 18, 24 80
18, 24, 30 05
C 9, 12, 18 20
12, 18, 24 50
18, 24, 30 30
D 9, 12, 18 20
12, 18,24 40
18, 24, 30 40
E 9, 12, 18 20
12, 18, 24 50
18, 24,30 30
F 9, 12, 18 10
12, 18, 24 70
18, 24, 30 20
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Table A.6 Distributions assigned to the drug candidates for the product yield
Drug candidate Yields for PI, PII and PIII (g/batch) Probability (% )
A 150, 450, 945 20
100, 300, 630 50
50, 150,315 30
B 150, 450, 945 15
100,300, 630 80
50, 150,315 05
C 150, 450, 945 20
100,300, 630 50
50, 150,315 30
D 150, 450, 945 20
100, 300, 630 40
50, 150,315 40
E 150, 450, 945 20
100,300, 630 50
50, 150,315 30
F 150, 450, 945 10
100, 300, 630 70
50, 150,315 20
192
APPENDIX A
Table A.7 Distributions assigned 
manufacturing material
to the drug candidates for the delays in
Drug candidate Delays for PI, PII and PIII (months) Probability (%)
A 3 ,3 ,3 20
0, 0 ,0 50
6, 6, 6 30
B 3 ,3 ,3 15
0, 0 ,0 80
6, 6, 6 05
C 3, 3 ,3 20
0, 0 ,0 50
6, 6, 6 30
D 3 ,3 ,3 20
0, 0 ,0 40
6, 6 ,6 40
E 3 ,3 ,3 20
0, 0 ,0 50
6, 6 ,6 30
F 3 ,3 ,3 10
0, 0 ,0 70
6, 6, 6 20
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Table A.8 Distributions assigned to the drug candidates for the changes in cost of 
goods value for the production of the material for the market
Drug candidate Cost of goods (US$/gram) Probability (%)
A 1,200 20
1,500 50
1,800 30
B 720 15
900 80
1,080 05
C 800 20
1,000 50
1,200 30
D 600 20
750 40
900 40
E 1,440 20
1,800 50
2,160 30
F 1,280 10
1,600 70
1,920 20
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